



05-19-10

IFW DAE

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jones et al.

Serial No.: 10/644,256

Filed: August 20, 2003

For: EFFICIENT PRODUCTION OF IgA
IN RECOMBINANT MAMMALIAN
CELLS

Examiner: M. Joike

Group Art Unit: 1636

Attorney Docket No.: 2578-6077US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EM417189575US

Date of Deposit with USPS: May 17, 2010

Person making Deposit: Grady C. Evans

PETITION UNDER 37 C.F.R. §§ 1.78(a)(3), 1.78(a)(6), AND 1.55(c) FOR ACCEPTANCE
OF UNINTENTIONALLY DELAYED PRIORITY CLAIMS

Mail Stop Legal PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In response to the Decision on Renewed Petition, received on March 9, 2010, the applicants respectfully renew their petition under 37 C.F.R. § 1.78(a)(3); 37 C.F.R. § 1.78(a)(6); and 37 C.F.R. § 1.55(c) for the acceptance of their unintentionally delayed priority claims.

Factual Background:

On November 16, 2006, the applicants submitted an initial request for the acceptance of an unintentionally delayed priority claim in the context of a response to an Office Action dated August 23, 2006. The request was accompanied by the requisite fee under 37 C.F.R. § 1.17(t).

10644256

05/20/2010 EEKUBAY1 00000010 201469

01 FC:1454 1410.00 DA

The request was subsequently denied in an Office Action dated February 28, 2007. Thereafter, the applicants submitted a formal Petition for Acceptance of an Unintentionally Delayed Priority Claim on June 14, 2007. This Petition was dismissed in a Decision dated September 30, 2008. Subsequently, the applicants filed a Renewed Petition on November 24, 2008. This Renewed Petition was dismissed on July 7, 2009.

On August 21, 2009, the applicants filed a further renewed Petition under 37 C.F.R. § 1.78(a)(6) for Acceptance of Unintentionally Delayed Priority Claims. The renewed Petition was directed to the addition of two sets of priority claims. The first set of priority claims concerned domestic priority claims under 35 U.S.C. §§ 120 and 365(c), directed to two international applications, together with associated priority claims to a US provisional application under 35 U.S.C. § 119(e). The second set of priority claims were directed to a domestic priority claim to an international application under 35 U.S.C. §§ 120 and 365(c), together with an associated priority claim to a foreign application under 35 U.S.C. § 119(a)-(d).

Applicants' Petition was dismissed in a Decision dated March 9, 2010. In his Decision, the Legal Examiner determined, pursuant to 37 C.F.R. §§ 1.178(a)(3) and 1.78(a)(6), the following with respect to the first set of priority claims, namely:

1. The Petition was filed after November 29, 2000, and therefore the Petition was properly submitted after the time periods specified in 37 C.F.R. §§ 1.78(a)(2)(ii) and 1.78(a)(2)(i), and therefore the Petition was a proper petition under 37 C.F.R. §§ 1.78(a)(3) and 1.78(a)(6).
2. The surcharge required by 37 C.F.R. § 1.17(t) was timely submitted;
3. The Statement that the entire delay between the date the claim was due under 37 C.F.R. §§ 1.78(a)(2)(ii) and 1.78(a)(5)(ii) and the date the claim was filed was unintentional was properly submitted.

With respect to the final requirement under 37 C.F.R. 1.78, namely that the applicants provide the reference required by 35 U.S.C. §§ 120 and 119(e), and 37 C.F.R. §§ 1.78(a)(2)(i) and 1.78(a)(5)(i), to the prior filed application, the Legal Examiner determined that the applicants

had submitted an acceptable reference with respect to the claim of priority under 35 U.S.C. §§ 120 and 365(c) to international application PCT/EP2003/007690, and through that international application under 35 U.S.C. § 119(e) to U.S. provisional application 60/397,066. It follows that with respect to the priority claim directed to PCT/EP2003/007690 and U.S. provisional application 60/397,066., the Legal Examiner determined that the Petition had met all of the statutory requirements for an acceptance of the priority claim.

With respect to the final requirement of providing the reference to the domestic priority claim under 35 U.S.C. §§ 120 and 365(c) with respect to international application PCT/EP03/50201, and through that international application under 35 U.S.C. § 119(e) to U.S. provisional application 60/397,066, the Legal Examiner determined that the applicants had failed to submit a proper reference. Specifically, the Legal Examiner noted that international application PCT/EP03/50201 was not published by the International Bureau (IB), and therefore it was not possible, given the present record, to ascertain whether the instant application was filed during the pendency of international application PCT/EP03/50201. In reaching his decision, the Legal Examiner cited MPEP § 1895.01 and its requirement that the applicants certify that the international application was not withdrawn or considered withdrawn prior to the filing date of the national application which claimed the benefit under 35 U.S.C. §§ 120 and 365(c).

In his Decision, the Legal Examiner indicated that should the applicants wish to renew their petition, the applicants would be required to provide a copy of PCT/EP03/50201 together with a certification and documentary support confirming that international application PCT/EP03/50201 was not withdrawn prior to the filing date of the instant application. Furthermore, the Legal Examiner indicated that the applicants would also need to establish that PCT/EP03/50201 named at least one inventor in common with the instant application. As a final requirement, the Legal Examiner further required that the applicants provide a substitute amendment containing a proper reference to the prior-filed international applications and the provisional application.

Regarding the second set of priority claims, *i.e.* the priority claim directed to PCT/EP03/50201 and its associated claim to foreign priority claim under 35 U.S.C. § 119(a)-(d) to EP application 02077953.4, the Legal Examiner first determined that the proper basis of applicants' petition was 35 U.S.C. § 365(b) instead of 35 U.S.C. § 365(c). The Legal Examiner

further concluded that such a petition, in order to be granted, must meet the provisions of 37 C.F.R. § 1.55(c). In analyzing the second set of priority claims under 37 C.F.R. § 1.55(c), the Legal Examiner determined as follows:

1. The instant application was filed after November 29, 2000, and therefore the Petition was properly submitted after the time periods specified in 37 C.F.R. § 1.55(c) and therefore the Petition was a proper petition under 37 C.F.R. § 1.55(c).
2. Applicants' priority claim, as identified in the Declaration filed on November 20, 2006, in the instant application, had properly identified the prior foreign application for which priority was claimed by application number, country and filing date.
3. The surcharge required by 37 C.F.R. § 1.17(t) was timely paid.
4. The Statement that the entire delay, between the date the claim was due under 37 C.F.R. § 1.55(a)(1) and the date the claim was filed, was unintentional was properly submitted.

With respect to the final requirement, namely that the nonprovisional application must be filed within 12 months of the filing date of the referenced foreign application, *i.e.* the filing date of EP application 02077953.4, the Legal Examiner determined that the applicants had failed to meet their obligation. Specifically, the Legal Examiner determined that the filing date of the instant application, namely August 20, 2003, was not within 12 months of the July 18, 2002, filing date of EP application 02077953.4. In reaching his decision, the Legal Examiner noted that notwithstanding his determination, this final requirement would be satisfied in a renewed petition if applicants could successfully add a claim of domestic priority to prior filed international application PCT/EP2003/007690 or international application PCT/EP03/50201, since the filing date of the EP application 02077953.4 would then be within 12 months of the filing date of either of these two international applications.

Applicants' Renewed Petition Regarding the Priority Claim to PCT/EP2003/007690 and the Accompanying Priority Claim to U.S. Provisional 60/397,066:

Pursuant to 37 C.F.R. § 1.78(a)(3) and 37 C.F.R. § 1.78(a)(6), applicants hereby renew their petition to be afforded, under 35 U.S.C. § 120, a claim of domestic priority to PCT International Patent Application No. PCT/EP2003/007690, and through this international application a claim of domestic priority under 35 U.S.C. §§ 119(e) and 365(c) to U.S. Provisional application 60/397,066. In support of this petition applicants submit as follows:

1. Applicants' application was filed on August 20, 2003, and was therefore filed after November 29, 2000. Accordingly, the applicants' claims are submitted after the expiration of the periods specified in 37 C.F.R. §§ 1.78(a)(2)(ii) and 1.78(a)(5)(ii). It follows there from that the instant petition is proper under 37 C.F.R. §§ 1.78(a)(3) and 1.78(a)(6).
2. The references to the prior filed applications, required by 35 U.S.C. §§ 120 and 119(e) and 37 C.F.R. §§ 1.78(a)(2)(i) and 1.78(a)(5)(i), are properly set forth in the Amendment to the specification of the application which is being filed simultaneously herewith. A copy of the Amendment is attached hereto as Exhibit A. The applicants respectfully submit that the Amendment properly identifies International Patent Application No. PCT/EP2003/007690 and its continuation-in-part relationship to the instant application. Furthermore, the Amendment also properly identifies U.S. Provisional application 60/397,066 and the 35 U.S.C. § 119(e) claim of priority to that provisional application through International Patent Application No. PCT/EP2003/007690. In view of the submission of this Amendment, the applicants submit that the reference requirements under 35 U.S.C. §§ 119(e), 120, and 365(c) and 37 C.F.R. §§ 1.78(a)(3) and 1.78(a)(6) have been satisfied.

3. The surcharge required under 37 C.F.R. § 1.17(t) was previously submitted in conjunction with applicants' prior request dated November 16, 2006.
4. Applicants hereby state that the entire delay between the date the claim was due under 37 C.F.R. §§ 1.78(a)(2)(ii) and 1.78(a)(5)(ii) and the date that the claim was filed was unintentional.

In view of the prior indications of the Legal Examiner, the applicants respectfully submit that the above petition for the acceptance of a priority claim to International Patent Application No. PCT/EP2003/007690, and through this international application, the priority claim to U.S. Provisional application 60/397,066, should now be in acceptable form. Reconsideration of the petition with respect to these priority claims is therefore requested.

Applicants' Renewed Petition Regarding the Priority Claim to PCT/EP2003/50201 and the Accompanying Priority Claim to U.S. Provisional 60/397,066:

Pursuant to 37 C.F.R. § 1.78(a)(3) and 37 C.F.R. § 1.78(a)(6), the applicants hereby renew their petition to be afforded, under 35 U.S.C. § 120, a claim of domestic priority to PCT International Patent Application No. PCT/EP2003/50201, and through this international application, a claim of domestic priority under 35 U.S.C. §§ 119(e) and 365(c) to U.S. Provisional application 60/397,066. In support of this petition, the applicants submit as follows:

1. Applicants' application was filed on August 20, 2003, and was accordingly filed after November 29, 2000. Therefore, the applicants' claims are submitted after the expiration of the periods specified in 37 C.F.R. §§ 1.78(a)(2)(ii) and 1.78(a)(5)(ii). It follows that the instant petition is proper under 37 C.F.R. §§ 1.78(a)(3) and 1.78(a)(6).
2. The references to the prior filed applications, required by 35 U.S.C. §§ 120 and 119(e) and 37 C.F.R. §§ 1.78(a)(2)(i) and 1.78(a)(5)(i), are properly set forth in the

Amendment to the specification of the application which is being filed simultaneously herewith. As noted previously, a copy of the Amendment is attached hereto as Exhibit A. The applicants respectfully submit that the Amendment properly identifies International Patent Application No. PCT/EP2003/50201 and its continuation-in-part relationship to the instant application. Furthermore, the Amendment also properly identifies U.S. Provisional application 60/397,066 and the claim of priority to that provisional application under 35 U.S.C. §§ 119(e) and 365(c) through International Patent Application No. PCT/EP2003/50201.

In his prior decision, the Legal Examiner had indicated that a proper reference to International Patent Application No. PCT/EP2003/50201 and U.S. Provisional application 60/397,066 would require the applicants, under the provisions of MPEP § 1895.01, to certify that International Patent Application No. PCT/EP2003/50201 was pending as of the filing date of the instant application; *i.e.* that the international application was pending on August 20, 2003. Responsive to the Legal Examiner's request, the applicants hereby affirmatively certify that International Patent Application No. PCT/EP2003/50201 was a validly pending application on August 20, 2003. In support of their certification, the applicants attach hereto as Exhibit B an as-filed copy of International Patent Application No. PCT/EP2003/50201, certified by the European Patent Office (EPO). The EPO was the International Receiving Office for International Patent Application No. PCT/EP2003/50201. A review of the certified copy will verify that the application was filed on May 27, 2003, with the EPO. Further confirmation of this filing is submitted herewith in the form of a Receipt of Electronic Submission, attached hereto as Exhibit C.

With regard to the pendency of International Patent Application No. PCT/EP2003/50201, as noted on the Receipt of Electronic Submission, this application was initially filed without the payment of a filing fee. On August 4, 2003, the EPO issued an Invitation to Pay Prescribed Fees Together with a Late Payment Fee under the provisions of PCT Rule 16bis. A copy of this Invitation is attached hereto as Exhibit D. This Invitation provided a one month period, *i.e.* until September 4, 2003, for the

applicants to pay the requested filing fees. Applicants did not submit the requested filing fees prior to the deadline. On September 23, 2003, the EPO formally issued a Notification That International Application Considered To Be Withdrawn pursuant to PCT Article 14(1) or (3) and Rule 29.1 or 92.4(g)(i). A copy of this Notification is attached hereto as Exhibit E. The issuance of this Notification acknowledged the withdrawal of this application effective September 23, 2010.

As documented by the attached Exhibits B-D, International Patent Application No. PCT/EP2003/50201 was validly filed on May 27, 2003 and after review by the EPO PCT Receiving Office was accorded an international filing date. Moreover, International Patent Application No. PCT/EP2003/50201 was pending from its date of filing until September 23, 2003, when it was formally withdrawn by the European Patent Office. The instant application was filed during the one month period provided to the applicants under PCT Rule 16bis to pay the filing fee in International Patent Application No. PCT/EP2003/50201. It follows that International Patent Application No. PCT/EP2003/50201 was validly pending on August 20, 2003, when the instant application was filed. In this regard, the applicants respectfully direct the Legal Examiner's attention to paragraph 6.009 of the PCT User's Guide.

With regard to the Legal Examiner's requirement that applicants confirm that at least one inventor is commonly named on both the instant application and International Application No. PCT/EP03/50201, the Legal Examiner may note from the frontpiece of the certified copy of the as filed application that at least one inventor, namely Abraham Bout, is named in both International Patent Application No. PCT/EP2003/50201 and the instant application.

In view of the showing that International Patent Application No. PCT/EP2003/50201 was pending on the filing date of the instant application, and further given the identification of a common inventor on both international application no. PCT/EP03/50201 and the instant application, the applicants respectfully submit that the requirement of a reference to the prior filed applications as required by 35 U.S.C. §§ 120 and 119(e) and 37 C.F.R. §§ 1.78(a)(2)(i) and 1.78(a)(5)(i) has now been satisfied for purposes of the present petition.

3. The surcharge required under 37 C.F.R. § 1.17(t) was previously submitted in conjunction with applicants' prior Petition dated November 16, 2006.
4. Applicants hereby state that the entire delay between the date the claim was due under 37 C.F.R. §§ 1.78(a)(2)(ii) and 1.78(a)(5)(ii) and the date that the claim was filed was unintentional.

In view of the prior indications of the Legal Examiner, together with the facts set forth above, the applicants respectfully submit that the petition for the acceptance of a priority claim under 35 U.S.C. §§ 120 and 365(c) to International Patent Application No. PCT/EP2003/50201, and through this international application under 35 U.S.C. § 119(e) to U.S. Provisional application 60/397,066, should now be in acceptable form. Reconsideration of the petition with respect to these priority claims is therefore requested.

Applicants' Petition Regarding the Priority Claim to PCT/EP2003/50201 and the Accompanying Priority Claim to EP02077953.4:

Pursuant to 37 C.F.R. § 1.78(a)(3) and 37 C.F.R. § 1.78(a)(6), the applicants hereby renew their petition to be afforded, under 35 U.S.C. §§ 120 and 365(a), a claim of domestic priority to PCT International Patent Application No. PCT/EP2003/50201, and through this international application, pursuant to 37 C.F.R. § 1.55(c) and under 35 U.S.C. §§ 119(a)-(d) and 365(b), a claim of foreign priority to EP02077953.4. Applicants respectfully submit that the showing above with regard to the claim for domestic priority of PCT/EP2003/50201 adequately establishes the basis of the applicants' claim to that domestic priority. With regard to applicants' petition under 37 C.F.R. § 1.55(c) for a foreign priority claim under 35 U.S.C. §§ 119(a)-(d) and 365(b) as to EP02077953.4, the applicants submit as follows:

1. Applicants' application was filed on August 20, 2003, and was accordingly filed after November 29, 2000. Therefore, the applicants' claims are submitted after the

expiration of the periods specified in 37 C.F.R. § 1.55(c). It follows that the instant petition is proper under 37 C.F.R. § 1.55(c).

2. The reference to EP02077953.4, the prior filed foreign application for which priority is claimed, has been properly made by identifying the application number, country and filing date of that application in the Declaration filed on November 20, 2006, in the instant application.
3. The surcharge required under 37 C.F.R. § 1.17(t) was previously submitted in conjunction with applicants' prior Petition dated November 16, 2006.
4. Applicants hereby state that the entire delay between the date the claim was due under 37 C.F.R. §§ 1.78(a)(2)(ii) and 1.78(a)(5)(ii) and the date that the claim was filed was unintentional.
5. The application, through which the present foreign priority claim is made, namely International Patent Application No. PCT/EP2003/50201, was filed within 12 months of the filing date of EP02077953.4. International Patent Application No. PCT/EP2003/50201 was filed on May 27, 2003. EP 02077953.4 was filed less than eleven months earlier on July 18, 2002. It follows that International Patent Application No. PCT/EP2003/50201 was filed within 12 months of the filing date of EP02077953.4.

In view of the prior indications of the Legal Examiner that a valid foreign priority claim to EP02077953.4 would exist provided that a proper domestic priority claim was established for International Patent Application No. PCT/EP2003/50201, further given the applicants' showing that such a domestic priority claim is factually and legally supported, and finally given the showing above that the instant Petition satisfies the conditions of 37 C.F.R. § 1.55(c), the applicants respectfully submit that the foreign priority claim under 35 U.S.C. §§ 119(a)-(d) and 365(b) to EP02077953.4 should now be in acceptable form. Reconsideration of the petition with

respect to this priority claim is therefore requested.


Authorization to Charge Deposit Account

Applicants note that, pursuant to 37 C.F.R. § 1.78(a)(3), the required surcharge set forth in § 1.17(t) was submitted in conjunction with the communication filed November 16, 2006. However, any fee required but not submitted with this communication may be charged to deposit account no. 20-1469.

CONCLUSION

Acceptance of the applicants' claim of domestic priority under 35 U.S.C. §§ 120 and 365(c) to PCT International Patent Application No. PCT/EP2003/007690 and International Patent Application No. PCT/EP03/50201 is requested. Acceptance of the applicants' claim to domestic priority under 35 U.S.C. §§ 119(e) and 365(c) to United States Provisional Application Serial No. 60/397,066, and their claim of foreign priority under 35 U.S.C. § 119(a)-(d) to European Patent Application No. 02077953.4 are also respectfully requested. If questions remain after consideration of the foregoing, or if the Office should determine that there are additional issues which might be resolved by telephone conference, the Office is kindly requested to contact the applicant's attorney at the address or telephone number given herein.

Respectfully submitted,



Alexander T. Stein, Ph.D.
Registration No. 66,296
Attorney for Applicants
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Enclosures: Exhibit A: Amendment
Exhibit B: Certified copy of PCT International Patent Application No. PCT/EP03/50201;
Exhibit C: Receipt of Electronic Submission (PCT/EP03/50201);
Exhibit D: Invitation to Pay Prescribed Fees (PCT/EP03/50201); and
Exhibit E: Notification that International Application Considered to be Withdrawn (PCT/EP03/50201)

Date: May 17, 2010
ATS/ats



COPY
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jones et al.

Serial No.: 10/644,256

Filed: August 20, 2003

For: EFFICIENT PRODUCTION OF IgA
IN RECOMBINANT MAMMALIAN
CELLS

Examiner: M. Joike

Group Art Unit: 1636

Attorney Docket No.: 2578-6077US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EM417189947US

Date of Deposit with USPS: May 17, 2010

Person making Deposit: Grady C. Evans

AMENDMENT UNDER 37 C.F.R. § 1.116

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Responsive to the Final Office Action of March 15, 2010, please amend the referenced patent application as follows:

Amendments to the Specification appear on page 2 of this paper;

Amendments to the Claims are set forth in the listing of the claims that begins on page 3 of this paper; and

Remarks start at page 7 of this paper.

IN THE SPECIFICATION:

Please amend paragraph [0001] as follows:

[0001] This application is a continuation-in-part of U. S. Patent Application Serial No. 09/549,463, filed April 14, 2000, now U.S. Patent 6,855,544 B1, the contents of the entirety of which is incorporated herein by this reference, which US Application Serial No. 09/549,463 application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Serial No. 60/129,452, filed April 15, 1999. The instant This-application is also a continuation-in-part of co-pending PCT International Patent Application No. PCT/EP2003/007690, filed on July 15, 2003, designating the United States of America, and published, in English, as International Publication No. WO 2004/009618A2 ~~WO-2004/009618 A2~~ on January 29, 2004, which International Patent Application claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/397,066, filed July 18, 2002. The instant application is also a continuation-in-part of co-pending International Patent Application No. PCT/EP03/50201, filed May 27, 2003, designating the United States of America, which International Patent Application claims the benefit under 35 U.S.C. § 365(b) to European Patent Application No. 02077953.4, filed July 18, 2002, and further claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application No. 60/397,066, filed July 18, 2002. ~~of PCT International Patent Application No. PCT/EP03/50201, filed May 27, 2003, European Patent Application No. 02077953.4, filed July 18, 2002, and United States Provisional Patent Application Serial No. 60/397,066, filed July 18, 2002.~~

IN THE CLAIMS:

Claims 2-5, 13, and 21 were previously canceled. Claim 9 is canceled herein. Claims 1, 8, and 10 have been amended herein. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of the Claims:

1. (Currently amended) A cell expressing E1A and E1B proteins of an adenovirus, said cell comprising recombinant nucleic acid comprising a selectable marker, said recombinant nucleic acid further encoding an IgA molecule in expressible format, wherein said cell is derived from a human embryonic retinoblast cell as deposited under ECACC number 96022940 by stable transfection of said human embryonic retinoblast cell with the recombinant nucleic acid encoding the IgA molecule in expressible format, ~~wherein stable transfection may be determined by selecting those transfected human embryonic retinoblast cells capable of surviving growth in a media selective for the presence of the selectable marker for a predetermined amount of time wherein said cell, when seeded at 0.5×10^6 cells/well and cultured in 6-well tissue culture plates at 37 °C in DMEM with 10%.~~

2.-5. (Canceled).

6. (Original) The cell of claim 1, wherein said cell comprises between one and twenty copies of said recombinant nucleic acid encoding the IgA molecule.

7. (Original) The cell of claim 1, wherein said IgA molecule is a human IgA molecule.

8. (Currently amended) A cell expressing E1A and E1B proteins of an adenovirus, said cell comprising a selectable marker, said recombinant nucleic acid further comprising recombinant nucleic acid encoding an IgA molecule in expressible format, wherein said cell is derived from a human embryonic retinoblast cell as deposited under ECACC number 96022940 by stable transfection of said human embryonic retinoblast cell with the recombinant nucleic acid encoding the IgA molecule in expressible format, and wherein said IgA molecule has a constant region comprising amino acids 137 to 489 of SEQ ID NO:3, wherein stable transfection may be determined by selecting those transfected human embryonic retinoblast cells capable of surviving growth in a media selective for the presence of the selectable marker ~~for a predetermined amount of time~~.

9. (Canceled).

10. (Currently amended) The cell of ~~claim 9~~ claim 1, wherein said cell, when seeded at 0.5×10^6 cells/well and cultured in 6-well tissue culture plates at 37°C in DMEM with 10% serum under an atmosphere containing 10% CO₂, produces at least 20 pg IgA/seeded cell/day.

11. (Previously presented) The cell of claim 10, wherein said cell, when seeded at 0.5×10^6 cells/well and cultured in 6-well tissue culture plates at 37°C in DMEM with 10% serum under an atmosphere containing 10% CO₂, produces at least 40 pg IgA/seeded cell/day.

12. (Withdrawn) A method for recombinant production of an IgA molecule, said method comprising:

culturing a cell of claim 1, and

expressing said recombinant nucleic acid encoding an IgA molecule,

thus producing an IgA molecule.

13. (Canceled).

14. (Withdrawn) The method according to claim 12, wherein said cell has from one to twenty copies of said recombinant nucleic acid encoding the IgA molecule.

15. (Withdrawn) The method according to claim 12, wherein said IgA molecule is a human IgA molecule.

16. (Withdrawn) The method according to claim 12, wherein said IgA molecule has a constant region comprising amino acids 137 to 489 of SEQ ID NO:3.

17. (Withdrawn) The method according to claim 12, wherein said cell is seeded at 0.5×10^6 cells/well and cultured in 6-well tissue culture plates at 37°C in DMEM with 10% serum under an atmosphere containing 10% CO₂, thus producing at least 5 pg IgA/seeded cell/day.

18. (Withdrawn) The method according to claim 12, wherein said cell is seeded at 0.5×10^6 cells/well and cultured in 6-well tissue culture plates at 37°C in DMEM with 10% serum under an atmosphere containing 10% CO₂, thus producing at least 20 pg IgA/seeded cell/day.

19. (Withdrawn) The method according to claim 12, wherein said cell is seeded at 0.5×10^6 cells/well and cultured in 6-well tissue culture plates at 37°C in DMEM with 10% serum under an atmosphere containing 10% CO₂, thus producing at least 40 pg IgA/seeded cell/day.

20. (Withdrawn) A process for recombinantly producing a human IgA molecule, said process comprising:

culturing the cell of claim 1, wherein said cell comprises recombinant nucleic acid encoding a human IgA molecule in expressible format, and
expressing said recombinant nucleic acid encoding an IgA,
thus producing a human IgA molecule.

21. (Canceled).

22. (Previously presented) A cell expressing E1A and E1B proteins of an adenovirus, said cell comprising recombinant nucleic acid encoding an IgA molecule in expressible format, wherein said cell is derived from a human embryonic retinoblast cell as deposited under ECACC number 96022940 by transfection of said human embryonic retinoblast cell with the recombinant nucleic acid encoding the IgA molecule in expressible format, wherein the cell expresses E1A and E1B proteins of an adenovirus after 3 weeks in culture.

23. (Previously presented) A cell expressing E1A and E1B proteins of an adenovirus, said cell comprising between one and about 20 copies of recombinant nucleic acid encoding an IgA molecule in expressible format, wherein said cell is derived from a human embryonic retinoblast cell as deposited under ECACC number 96022940 by transfection of said human embryonic retinoblast cell with the recombinant nucleic acid encoding the IgA molecule in expressible format, wherein the nucleic acid encoding an IgA molecule is not amplified within the cell.

REMARKS

The Office Action of March 4, 2010, has been received and reviewed. Claims 1, 2, 6 through 11, 15 through 17, 21 through 25 and 31 stand rejected. This application is to be amended as previously set forth. All claim cancellations and amendments are made without prejudice or disclaimer. Basis for the amendments can be found throughout the application; for example, in the previously presented claims and in the Specification at, *e.g.*, **Examples I and II**. No new matter has been presented. Reconsideration is respectfully requested.

Entry of Amendments

Pursuant to 37 C.F.R. § 1.116, applicant respectfully submits that the amendments presented herein should be entered, as the amendments are made to expedite prosecution and are believed to place the application in condition for allowance or remove issues for appeal; for example, they remove bases of rejection by the Office, and incorporate allowable subject matter into the independent claims. A substitute amendment to the Specification has been provided pursuant to the request made in the Decision on Renewed Petition of March 9, 2010 (at page 2, paragraphs 3 and 5).

Priority

The present application continues to claim priority to U.S. Patent Application Serial No. 09/549,463, filed April 14, 2000, now U.S. Patent 6,855,544 B1; U.S. Provisional Patent Application Serial No. 60/129,452, filed April 15, 1999; PCT International Patent Application No. PCT/EP2003/007690, filed July 15, 2003, designating the United States of America, and published, in English, as International Publication No. WO 2004/009618A2 on January 29, 2004; U.S. Provisional Application No. 60/397,066, filed July 18, 2002; co-pending International Patent Application No. PCT/EP03/50201, filed May 27, 2003, designating the United States of America; European Patent Application No. 02077953.4, filed July 18, 2002; and U.S. Provisional Application No. 60/397,066, filed July 18, 2002.

The Office has noted that the applicants must file a petition for acceptance of unintentionally delayed priority claims in order for the present application's priority claims to be

entered. Final Office Action, at pages 2-3. Applicants have filed such a petition in the Office concurrently with the present Amendment, a courtesy copy of which is provided herewith.

Objection to the Specification

The Specification stands objected to as containing priority references to PCT International Application Nos. PCT/EP03/007690 and PCT/EP03/50201, European Patent Application No. 02077953.4, and U.S. Provisional Patent Application Serial No. 60/397,066, which priority claims have not been granted. Final Office Action, at page 2. Applicants duly note the objection, and respectfully submit that the objection will become moot when the concurrently-submitted petition for amended priority rights under 37 C.F.R. §§ 1.78(a)(3), 1.78(a)(6), and 1.55(c) is granted. Applicants have submitted a substitute amendment to the Specification with the present Amendment to comply with the Office's request. See Decision on Renewed Petition of March 9, 2010, at page 2.

Oath/Declaration

The Office asserts that the Declaration of November 20, 2006, is without effect, for the reason that a priority claim under 37 C.F.R. § 1.55 to an identified foreign application has not been made. Final Office Action, at pages 3-4. As set forth, *supra*, the concurrently-submitted petition will render this objection moot.

35 U.S.C. § 112, first paragraph

Claims 1 and 6-11 stand rejected under 35 U.S.C. § 112, first paragraph, for assertedly failing to comply with the written description requirement. Final Office Action, at page 4. Specifically, the Office asserts that, while there is support in the Specification for "various, specified times," there is "no support in the specification for a predetermined amount of time." Id. Claim 9 has been canceled, rendering the rejection of this claim moot. Without agreeing that the Specification does not provide ample description of selection for stable transfectants by growth in selective media for predetermined times, the applicants have amended independent claims 1 (from which claims 6 and 7 depend) and 8 (from which claims 10 and 11 depend) to

remove recitation of “for a predetermined amount of time.” For at least this reason, the applicants respectfully request the rejection of claims 1, 6-8, 10, and 11 under 35 U.S.C. § 112, first paragraph, be withdrawn.

35 U.S.C. § 112, second paragraph

Claims 1 and 6-11 stand rejected under 35 U.S.C. § 112, second paragraph, for assertedly being indefinite. Final Office Action, at page 4. Specifically, the Office asserts that the term, “predetermined amount of time,” is vague. *Id.* Applicants do not agree that “predetermined amount of time” renders claims 1 and 6-11 indefinite; for example, one of ordinary skill in the art would know what is meant by selecting transfectants with a selectable marker by growth in selective media for a predetermined amount of time. Applicants have canceled claim 9, render the rejection of this claim moot. And, the applicants have amended the claims, as set forth, *supra*, to remove recitation of “for a predetermined amount of time.” For at least this reason, the applicants respectfully request the rejection of claims 1, 6-8, 10, and 11 under 35 U.S.C. § 112, second paragraph, be withdrawn.

35 U.S.C. § 103

Claims 1, 6, and 7 stand rejected under 35 U.S.C. § 103(a) as assertedly being unpatentable over U.S. Patent 6,821,512 to Gao *et al.* (hereinafter “the ‘512 Patent”) in view of International PCT Publication WO 00/63403 by Hateboer *et al.* (hereinafter “the ‘403 publication”). Final Office Action, at pages 5-7. Applicants respectfully traverse the rejection.

Applicants note that claim 9 was not subject to the rejection under 35 U.S.C. § 103(a). Without agreeing that any of claims 1, 6, and 7 are obvious in view of the cited references, the applicants have amended independent claim 1 (from which claims 6 and 7 depend) to incorporate the subject matter of claim 9. For at least this reason, the applicants respectfully request the rejection of claims 1, 6, and 7 under 35 U.S.C. § 103(a) be withdrawn.

Nonstatutory double patenting rejection

Claims 1, 6, and 7 stand rejected on the grounds of nonstatutory obviousness-type double

patenting as being assertedly unpatentable over claims 1, 3, 6-7, and 9 of U.S. Patent No. 7,429,486 ('486 Patent). Further, claims 1, 6, and 7 stand rejected on the grounds of nonstatutory obviousness-type double patenting as being assertedly unpatentable over claims 1, 2, and 5-7 of U.S. Patent No. 7,262,028 ('028 Patent).

Applicants note that claim 9 was not subject to a nonstatutory obviousness-type double patenting rejection over either the '486 Patent or the '028 Patent. Without agreeing that any of claims 1, 6, and 7 are not patentably distinct from the claims of either patent, the applicants have amended claim 1 (from which claims 6 and 7 depend) to incorporate the subject matter of claim 9. For at least this reason, the applicants respectfully request the nonstatutory obviousness-type double patenting rejections of claims 1, 6, and 7 be withdrawn.

Claims 1, 6, 7, 22, and 23 stand provisionally rejected on the ground of non-statutory obviousness-type double patenting as being assertedly unpatentable over the claims of co-pending application 12/291,881 (hereinafter "the '881 application") in view of Gao *et al.* Pursuant to MPEP § 804(I)(B)(1), the applicants respectfully submit this provisional rejection should be withdrawn, in view of the fact that the present application has an earlier filing date than the '881 application. The '881 application has a filing date of November 14, 2008. The present application has a filing date of August 20, 2003.

As provided for in the MPEP § 804(I)(B)(1),

If a "provisional" nonstatutory obviousness-type double patenting (ODP) rejection is the only rejection remaining in the earlier filed of the two pending applications, while the later-filed application is rejectable on other grounds, the examiner should withdraw that rejection and permit the earlier-filed application to issue as a patent without a terminal disclaimer. If the ODP rejection is the only rejection remaining in the later-filed application, while the earlier-filed application is rejectable on other grounds, a terminal disclaimer must be required in the later-filed application before the rejection can be withdrawn.

If "provisional" ODP rejections in two applications are the only rejections remaining in those applications, the examiner should withdraw the ODP rejection in the earlier filed application thereby permitting that application to issue without need of a terminal disclaimer. A terminal disclaimer must be required in the later-filed application before the ODP rejection can be withdrawn and the application permitted to issue. If both applications are filed on the same day, the examiner should determine which application claims the base invention and which application claims the improvement (added limitations). The ODP rejection in the base

application can be withdrawn without a terminal disclaimer, while the ODP rejection in the improvement application cannot be withdrawn without a terminal disclaimer.

Where there are three applications containing claims that conflict such that an ODP rejection is made in each application based upon the other two, it is not sufficient to file a terminal disclaimer in only one of the applications addressing the other two applications. Rather, an appropriate terminal disclaimer must be filed in at least two of the applications to link all three together. This is because a terminal disclaimer filed to obviate a double patenting rejection is effective only with respect to the application in which the terminal disclaimer is filed; it is not effective to link the other two applications to each other.

Id. (Emphasis added).

Accordingly, applicants respectfully request that the Office withdraw the provisional obviousness-type double patenting rejection based upon the '881 application.

Rejoinder


Applicants respectfully request rejoinder of claims 12 and 14-20. If an applicant elects claims directed to a product, and a product claim is subsequently found allowable, withdrawn process claims which depend from, or otherwise include all elements of the allowable product claim, will be rejoined. MPEP § 821.04. Applicants respectfully submit that claims directed to a product (*e.g.*, claim 1) were previously elected by the applicants. Applicants currently believe the product claims to be in condition for allowance in view of the present amendments. As such, applicants respectfully request rejoinder of process claims 12 and 14-20, which include all elements of an allowable product claim.

COPY

Serial No. 10/644,256

In view of the foregoing amendments and remarks, the application is believed to be in condition for allowance. If questions remain after consideration of the foregoing, the Office is kindly requested to contact the applicants' attorney at the address or telephone number given herein.

Respectfully submitted,



Alexander T. Stein, Ph.D.

Registration No. 66,296

Attorney for Applicants

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: May 17, 2010

ATS/ats

Enclosures: Petition for Acceptance of Unintentionally Delayed Priority Claims

PATENT COOPERATION TREATY

From the RECEIVING OFFICE

PCT

To: Klein, Bart CRUCELL HOLLAND B.V. Postbus 2048 Archimedesweg 4 2301 CA Leiden PAYS-BAS	Ref. No. <i>Gongwo Ro Pct</i> <div style="border: 1px solid black; padding: 5px; text-align: center;"> RECEIVED 24 SEP 2003 </div> Due date <i>—</i> Attorney <i>RUE</i>	Client <i>Stabus</i> NOTIFICATION THAT INTERNATIONAL APPLICATION CONSIDERED TO BE WITHDRAWN (PCT Article 14(1) or (3) and Rule 29.1 or 92.4(g)(i)) <div style="text-align: right; font-weight: bold;">23 SEP 2003</div> Date of mailing <i>23 SEP 2003</i> Action <i>Withdrawal</i>
Applicant's or agent's file reference 0079WOP00PRI		IMPORTANT NOTIFICATION
International application No. PCT/EP 03/ 50201		International filing date (day/month/year) 27/05/2003
Applicant CRUCELL HOLLAND B.V.		

The applicant is hereby notified that the international application is declared by this receiving Office to be considered withdrawn for the reason indicated below:

1. ☐ **Failure to correct certain defects:** An invitation (Form PCT/RO/106) to correct defects in the international application was mailed by this receiving Office on _____
 However: ☐ no corrections, in response to that invitation, have been received within the prescribed time limit.
☐ applicant's corrections as submitted do not properly correct the defects noted in that invitation.
2. ☒ **Failure to pay prescribed fees:** An invitation (Form PCT/RO/133) to pay the prescribed fees was mailed by this receiving Office on 04. 08. 03
 However, within the time limit referred to in that invitation :
☒ no fees have been paid.
☐ the following fees have not been paid or the amounts paid are not sufficient to cover:

☐ the transmittal fee

☐ the search fee

☐ the late payment fee

☐ the basic fee

☐ at least one designation fee
3. ☐ **Failure to furnish the original of the international application:** An invitation (Form PCT/RO/141) to furnish the original of the international application (transmitted earlier by facsimile machine) was mailed by this receiving Office on _____
 However, the original was not furnished within the time limit fixed in that invitation.
4. A copy of this notification has been sent to the International Bureau ☒ and to the International Searching Authority.

Name and mailing address of the Receiving Office European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040 Fax: (+31-70) 340-3016	Authorized officer <div style="text-align: right;"> C.A.J.A. PASCRE </div>
---	--

PATENT COOPERATION TREATY

From the RECEIVING OFFICE

PCT

To:

Klein, Bart
CRUCELL HOLLAND B.V.
Postbus 2048
Archimedesweg 4
2301 CA Leiden
PAYS-BAS

**INVITATION TO PAY PRESCRIBED FEES
TOGETHER WITH LATE PAYMENT FEE**

(PCT Rule 16bis)

<p>Date of mailing (day/month/year) 0 4 AUG 2003</p>	
<p>Applicant's or agent's file reference 0079WOP00PRI</p>	<p>PAYMENT DUE within ONE MONTH from the above date of mailing</p>
<p>International application No. PCT/EP 03/ 50201</p>	<p>International filing date/ Date of receipt (day/month/year) 27/05/2003</p>
<p>Applicant CRUCELL HOLLAND B.V.</p>	

1. This receiving Office has found that the prescribed fees (i.e., transmittal fee, search fee, basic fee and/or designation fee) have not been paid (in full), within the time limits prescribed under Rules 14, 15 and 16. See below for details of the calculation.
2. The applicant is hereby invited, within the time limit indicated above, to pay the following total amount (see the Annex for details):

EUR <u>2722</u>	+	EUR <u>444</u>	=	EUR <u>3166</u>
Total unpaid fees		Late payment fee		Total amount due

3. Failure to pay the total amount within the time limit indicated above may result in the international application or designation(s) being considered withdrawn by this Receiving Office.

The applicant's attention is drawn to Rules 16bis.1(c) and 29.

4. Additional observations (if any):

☐ Other observations :

<p>0079WOP00PRI</p> <p>RECEIVED</p> <p>05 AUG 2003</p>	
Due date	CPI
Attorney EVE	Action no

5. A copy of this Invitation is being sent to the International Bureau.

<p>Name and mailing address of the Receiving Office</p> <p> European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040 Fax: (+31-70) 340-3016</p>	<p>Authorized officer</p> <p style="text-align: center;"> C.A.J.A. PASCHE</p>
--	--

ANNEX TO FORM PCT/RO/133
CALCULATION OF THE PRESCRIBED FEES

International application No.

PCT/EP 03/ 50201

☒ **T** Transmittal Fee

Prescribed amount : EUR 100 ☒ T

Amount paid : - EUR - ☐ correct amount

Balance : = EUR 100 ☐ overpayment

☒ unpaid fees

☒ **S** Search Fee

Prescribed amount : EUR 945 ☒ S

Amount paid : - EUR - ☐ correct amount

Balance : = EUR 945 ☐ overpayment

☒ unpaid fees

☒ **I** International Fee

☒ **B** Basic Fee

Fixed amount for first 30 sheets : EUR 444 ☒ b1

137 x EUR 10 = EUR 1370 ☒ b2

Number of sheets in excess of 30 Fee per sheet

Additional component 400 x EUR = EUR - ☒ b3

Fee per sheet

Prescribed amount (b1 + b2 + b3): = EUR 1814 ☒ B

☒ **D** Designation Fee

Amount of designation fee : EUR ☒ d1

Number of designation fees payable (maximum 5): x ☒ d2

Prescribed amount (d1 x d2): = EUR ☒ D

☒ **R** Reduction where PCT-EASY software is used
(See the PCT Applicant's Guide, Volume I, General Part, for details on the availability of this reduction):

- EUR 137 ☒ R

Prescribed total amount (B + D - R): = EUR 1677 ☒ I

Amount paid : - EUR - ☐ correct amount

Balance : = EUR 1677 ☐ overpayment

☒ unpaid fees

Late Payment Fee

The amount of the late payment fee corresponds to ☐ 50% of total unpaid fees.

☐ the transmittal fee (minimum amount of the late payment fee).

☒ the basic fee (maximum amount of the late payment fee).

Additional observations, (if necessary) :

- ☐ The designation fee has been calculated on the basis of the amount applicable on the last day of the one year period from the priority date (see Rules 15.4(b)(i) and 16bis.1(b)).
- ☐ The amount paid for the designation fee covers the following designations : _____
- ☐ Other (specify) : _____



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets



Receipt of Electronic Submission

It is hereby acknowledged that a PCT patent application has been received via the Secure Electronic Submission Software of the EPO. Upon receipt, an application number and a date of receipt (Administrative Instructions Part 7) were automatically assigned.

Submission Number:	261	
Application Number:	PCT/EP03/50201	
Date of Receipt:	27 May 2003	
Receiving Office:	European Patent Office, The Hague	
Your Reference:	0079WOP00PRI	
Applicant:	CRUCCELL HOLLAND B.V.	
Number of Applicants:	5	
Title:	RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES	
Documents Submitted:	Pct101.PDF text,0079wop00pri.zip Fees.PDF application-body.xml pct101.GML request.xml	package-data.xml text,0079wop00pri.pdf figs,0079wop00pri.pdf indication-bio-deposit.xml fee-sheet.xml
Submitted by:	CN=M. Custers-Van Spronsen, O=Crucell Holland B.V, C=NL	
Timestamp of Receipt:	27 May 2003 17:34:38	
Official Digest of Submission:	D7:DD:A7:2B:DB:A8:42:13:49:8D:00:29:C1:76:11:02:3A :7C:14:39	

/The Hague, Receiving Section/

PCT REQUEST

0079WOP00PRI

Draft (NOT for submission) - printed on Tuesday, 27 May, 2003 05:47:32 PM

0	For receiving Office use only	
0-1	International Application No.	
0-2	International Filing Date	
0-3	Name of receiving Office and "PCT International Application"	
0-4	Form - PCT/RO/101 PCT Request	
0-4-1	Prepared using	epoline® online filing PCT plug-in (updated 01.07.2002)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	European Patent Office (EPO) (RO/EP)
0-7	Applicant's or agent's file reference	0079WOP00PRI
I	Title of invention	RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
II	Applicant	
II-1	This person is:	applicant only
II-2	Applicant for	all designated States except US
II-4	Name	CRUCCELL HOLLAND B.V.
II-5	Address:	Archimedesweg 4 NL-2333 CN Leiden Netherlands
II-6	State of nationality	NL
II-7	State of residence	NL
II-8	Telephone No.	+31 (0) 71 5248701
II-9	Facsimile No.	+31 (0) 71 5248702
II-10	e-mail	b.klein@crucell.com
III-1	Applicant and/or inventor	
III-1-1	This person is:	applicant and inventor
III-1-2	Applicant for	US only
III-1-4	Name (LAST, First)	VAN BERKEL, Patrick, Hendrikus, Cornelis
III-1-5	Address:	Rodenrijseweg 315 NL-2651 BS Berkel en Rodenrijs Netherlands
III-1-6	State of nationality	NL
III-1-7	State of residence	NL

PCT REQUEST

0079WOP00PRI

Draft (NOT for submission) - printed on Tuesday, 27 May, 2003 05:47:32 PM

III-2	Applicant and/or inventor	
III-2-1	This person is:	applicant and inventor
III-2-2	Applicant for	US only
III-2-4	Name (LAST, First)	BRUS, Ronald, Hendrik, Peter
III-2-5	Address:	Leidseweg 193 NL-2253 AD Voorschoten Netherlands
III-2-6	State of nationality	NL
III-2-7	State of residence	NL
III-3	Applicant and/or inventor	
III-3-1	This person is:	applicant and inventor
III-3-2	Applicant for	US only
III-3-4	Name (LAST, First)	BOUT, Abraham
III-3-5	Address:	Van Swaanswijckstraat 38 NL-2751 XL Moerkapelle Netherlands
III-3-6	State of nationality	NL
III-3-7	State of residence	NL
III-4	Applicant and/or inventor	
III-4-1	This person is:	applicant and inventor
III-4-2	Applicant for	US only
III-4-4	Name (LAST, First)	LOGTENBERG, Ton
III-4-5	Address:	Jachtrustlaan 1 NL-3985 MK Werkhoven Netherlands
III-4-6	State of nationality	NL
III-4-7	State of residence	NL
V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT EP: AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT

PCT REQUEST

0079WOP00PRI

Draft (NOT for submission) - printed on Tuesday, 27 May, 2003 05:47:32 PM

V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH&LI CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
V-5	Precautionary Designation Statement In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
V-6	Exclusion(s) from precautionary designations	NONE
VI	Priority claim	NONE
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)
VIII	Declarations	Number of declarations
VIII-1	Declaration as to the identity of the inventor	-
VIII-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-
VIII-3	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	-
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	-
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-

PCT REQUEST

0079WOP00PRI

Draft (NOT for submission) - printed on Tuesday, 27 May, 2003 05:47:32 PM

IX	Check list	number of sheets	electronic file(s) attached
IX-1	Request (including declaration sheets)	4	-
IX-2a	Specification	132	text,0079wop00pri.p df
IX-2b	Pre-conversion archive	-	text,0079wop00pri.z ip
IX-5	Drawings	31	figs,0079wop00pri.p df
IX-7	TOTAL	167	
	Accompanying items	paper document(s) attached	electronic file(s) attached
IX-8	Fee calculation sheet	-	-
IX-17	PCT-EASY diskette	-	-
IX-19	Figure of the drawings which should accompany the abstract		
IX-20	Language of filing of the international application	English	

Europäisches
Patentamt

European Patent
Office

Office européen
des brevets



Bescheinigung

Die angehefteten Unterlagen
stimmen mit der ursprünglich
eingereichten Fassung der auf
dem nächsten Blatt bezeichneten
internationalen Patentanmeldung
überein.

Certificate

The attached documents
are exact copies of
the international patent
application described on the
following page, as originally
filed

Attestation

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de la
demande de brevet internationale
spécifiée à la page suivante.

Den Haag, den
The Hague,
La Haye, le

07-04-2010

Der Präsident des Europäischen Patentamts, i.A.
For the President of the European Patent Office
Le Président de l'Office européen des brevets, p.o.

JOSEPH Viviane



Patentanmeldung Nr.
Patent application no.
Demande de brevet n°

PCT/EP 2003/50201



Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldenummer :
Application no. : PCT/EP 2003/50201
Demande n° :

Anmelder : 1. CRUCELL HOLLAND B.V. - Leiden, The Netherlands
Applicant(s) : 2. VAN BERKEL, Patrick, Hendrikus, Cornelis - Berkel en Rodenrijs,
Demandeur(s) : The Netherlands (US only)
: 3. BRUS, Ronald, Hendrik, Peter - Voorschoten, The Netherlands (US only)
: 4. BOUT, Abraham - Moerkapelle, The Netherlands (US only)
: 5. LOGTENBERG, Ton - Werkhoven, The Netherlands (US only)

Bezeichnung der Erfindung :
Title of the invention : Recombinant production of mixtures of antibodies
Titre d'invention :

Anmeldetag :
Date of filing : 27 May 2003 (27.05.2003)
Date de dépôt :

In Anspruch genommene Priorität(en) :
Priority(ies) claimed :
Priorité(s) revendiquée(s) :

Staat	:	Tag	:	Aktenzeichen	:
State	:	Date	:	File no.	:
Pays	:	Date	:	Numéro de dépôt	:

Benennung von Vertragsstaaten : Siehe Formblatt PCT/RO/101 (beigefügt)
Designation of contracting states : See Form PCT/RO/101 (enclosed)
Désignation d'états contractants : Voir Formulaire PCT/RO/101 (ci-joint)

2/4

PCT REQUEST

0079WOP00PRI

Draft (NOT for submission) - printed on Tuesday, 27 May, 2003 05:30:44 PM

V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p>AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT</p> <p>EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT</p> <p>EP: AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT</p> <p>OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT</p>

3/4

PCT REQUEST

0079WOP00PRI

Draft (NOT for submission) - printed on Tuesday, 27 May, 2003 05:30:44 PM

V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p>AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH&LI CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW</p>
V-5	Precautionary Designation Statement In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
V-6	Exclusion(s) from precautionary designations	NONE
VI	Priority claim	NONE
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)
VIII	Declarations	Number of declarations
VIII-1	Declaration as to the identity of the	

Ro/EP

-1-

Title: Recombinant production of mixtures of antibodies

Field of the invention

The present invention relates to the field of medicine,
5 more in particular to the field of production of
antibodies, more in particular to the production of
mixtures of antibodies.

Background of the invention

10 The essential function of the immune system is the
defence against infection. The humoral immune system
combats molecules recognized as non-self, such as
pathogens, using immunoglobulines. These
immunoglobulines, also called antibodies, are raised
15 specifically against the infectious agent, which acts as
an antigen, upon first contact (Roitt, Essential
Immunology, Blackwell Scientific Publications, fifth
edition, 1984; all references cited herein are
incorporated in their entirety by reference). Antibodies
20 are multivalent molecules comprising heavy (H) chains and
light (L) chains joined with interchain disulfide bonds.
Several isotypes of antibodies are known, including IgG1,
IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM. An IgG contains
two heavy and two light chains. Each chain contains
25 constant (C) and variable (V) regions, which can be
broken down into domains designated C_{H1} , C_{H2} , C_{H3} , V_H , and
 C_L , V_L (Fig. 1). Antibody binds to antigen via the
variable region domains contained in the Fab portion, and
after binding can interact with molecules and cells of
30 the immune system through the constant domains, mostly
through the Fc portion.

B-lymphocytes can produce antibodies in response to exposure to biological substances like bacteria, viruses and their toxic products. Antibodies are generally epitope specific and bind strongly to substances carrying these epitopes. The hybridoma technique (Kohler and Milstein 1975) makes use of the ability of B-cells to produce monoclonal antibodies to specific antigens and to subsequently produce these monoclonal antibodies by fusing B-cells from mice exposed to the antigen of interest to immortalized murine plasma cells. This technology resulted in the realization that monoclonal antibodies produced by hybridoma's could be used in research, diagnostics and therapies to treat different kinds of diseases like cancer and auto-immune related disorders.

Because antibodies that are produced in mouse hybridoma's induce strong immune responses in humans, it has been appreciated in the art that antibodies required for successful treatment of humans needed to be less or preferably non-immunogenic. For this, murine antibodies were first engineered by replacing the murine constant regions with human constant regions (referred to as chimeric antibodies). Subsequently, domains between the complementarity determining regions (CDRs) in the variable domains, the so-called framework regions, were replaced by their human counterparts (referred to as humanized antibodies). The final stage in this humanization process has been the production of fully human antibodies.

In the art, also bispecific antibodies, which have binding specificities for two different antigens, have been described. These are generally used to target a

therapeutic or diagnostic moiety, e.g. T-cell, a cytotoxic trigger molecule or a chelator that binds a radionuclide, that is recognized by one variable region of the antibody to a cell that is recognized by the other variable region of the antibody, e.g. a tumor cell (see for bispecific antibodies Segal et al, 2001).

One very useful method known in the art to obtain fully human monoclonal antibodies with desirable binding properties employs phage display libraries. This is an *in vitro*, recombinant DNA-based, approach that mimics key features of the humoral immune response (see for phage display methods e.g. CF Barbas III et al, Phage Display. A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001). For the construction of phage display libraries, collections of human monoclonal antibody heavy and light chain variable region genes are expressed on the surface of bacteriophage particles, usually in single chain Fv (scFv) or in Fab format. Large libraries of antibody fragment-expressing phages typically contain more than 10^9 antibody specificities and may be assembled from the immunoglobulin V regions expressed in the B lymphocytes of immunized- or non-immunized individuals. Alternatively, phage display libraries may be constructed from immunoglobulin variable regions that have been partially assembled or rearranged *in vitro* to introduce additional antibody diversity in the library (semi-synthetic libraries) (De Kruif et al, 1995b). For example, *in vitro* assembled variable regions contain stretches of synthetically produced, randomized or partially randomized DNA in those regions of the molecules that are important for antibody specificity.

The genetic information encoding the antibodies identified by phage display, can be used for cloning the antibodies in a desired format, e.g. IgG, IgA or IgM, to produce the antibody with recombinant DNA methods (Boel
5 et al, 2000).

An alternative method to provide fully human antibodies uses transgenic mice that comprise genetic material encoding a human immunoglobulin repertoire (Fishwild et al, 1996; Mendez et al, 1997). Such mice can be immunized
10 with a target antigen, and the resulting immune response will produce fully human antibodies. The sequences of these antibodies can be used in recombinant production methods.

Production of monoclonal antibodies routinely is
15 performed by use of recombinant expression of the nucleic acid sequences encoding the H and L chains of antibodies in host cells (see e.g. EP0120694; EP0314161; EP0481790; US patent 4,816,567; WO 00/63403).

To date, many different diseases are being treated
20 with either humanized or fully human monoclonal antibodies. Products based on monoclonal antibodies that are currently approved for use in humans include HerceptinTM (anti-Her2/Neu), ReoproTM (anti-Glycoprotein IIB/IIIA receptor), MylotargTM (anti-CD33), RituxanTM
25 (Rituximab, anti-CD20), SimulectTM (anti-CD25), RemicadeTM (anti-TNF), SynagisTM (anti-RSV), ZenapaxTM (IL2-receptor), CAMPATHTM (anti-CD52). Despite these successes, there is still room for new antibody products and for considerable improvement of existing antibody products. The use of
30 monoclonal antibodies in cancer treatment has shown that so-called "antigen-loss tumor variants" can arise, making the treatment with the monoclonal antibody less

effective. Treatment with the very successful monoclonal antibody Rituximab (anti-CD20) has for instance shown that antigen-loss escape variants can occur, leading to relapse of the lymphoma (Massengale et al, 2002). In the art, the potency of monoclonal antibodies has been increased by fusing them to toxic compounds, such as radionuclides, toxins, cytokines, and the like. Each of these approaches however has its limitations, including technological and production problems and/or high toxicity.

Furthermore, it appears that the gain in specificity of monoclonal antibodies compared to traditional undefined polyclonal antibodies, goes at the cost of loss of efficacy. In vivo, antibody responses are polyclonal in nature, i.e. a mixture of antibodies is produced because various B-cells respond to the antigen, resulting in various specificities being present in the polyclonal antibody mixture. Polyclonal antibodies can also be used for therapeutic applications, e.g. for passive vaccination or for active immunotherapy, and currently are usually derived from pooled serum from immunized animals or from humans who recovered from the disease. The pooled serum is purified into the proteinaceous or gamma globulin fraction, so named because it contains predominantly IgG molecules. Polyclonal antibodies that are currently used for treatment include anti-rhesus polyclonal antibodies, gamma-globulin for passive immunization, anti-snake venom polyclonal (CroFab), ThymoglobulinTM for allograft rejection, anti-digoxin to neutralize the heart drug digoxin, and anti-rabies polyclonal. In currently marketed therapeutic antibodies, an example of the higher efficacy of polyclonal

antibodies compared to monoclonal antibodies can be found in the treatment of acute transplant rejection with anti-T-cell antibodies. The monoclonal antibodies on the market (anti-CD25 basiliximab) are less efficacious than
5 a rabbit polyclonal antibody against thymocytes (Thymoglobulin™) (press releases dated March 12, April 29, and August 26, 2002, on www.sangstat.com). The use of pooled human sera however potentially bears the risk of infections with viruses such as HIV or hepatitis, with
10 toxins such as lipopolysaccharide, with proteinaceous infectious agents such as prions, and with unknown infectious agents. Furthermore, the supply that is available is limited, and insufficient for widespread human treatments. Problems associated with the current
15 application of polyclonal antibodies derived from animal sera in the clinic include a strong immune response of the human immune system against such foreign antibodies. Therefore such polyclonals are not suitable for repeated treatment, or for treatment of individuals that were
20 injected previously with other serum preparations from the same animal species.

The art describes the idea of the generation of animals with a human immunoglobulin repertoire, which can subsequently be used for immunization with an antigen to
25 obtain polyclonal antibodies against this antigen from the transgenic animals (WO 01/19394). However, much technological hurdles still will have to be overcome before such a system is a practical reality in larger animals than mice, and it will take years of development
30 before such systems can provide the polyclonal antibodies in a safe and consistent manner in sufficient quantities. Moreover, antibodies produced from pooled sera, whether

production rates of the antibodies should remain stable for all the individual clones of the non-clonal population in order to keep the ratio of antibodies in the polyclonal antibody mixture more or less constant.

5 Thus, while the need for mixtures of antibodies may have been recognized in the art, no acceptable solutions exist to make mixtures of antibodies economically in a pharmaceutically acceptable way. It is the object of the present invention to provide novel means for producing a
10 mixture of antibodies in recombinant hosts.

being from human or animal origin, will always comprise a high amount of unrelated and undesired specificities, as only a small percentage of the antibodies present in a given serum will be directed against the antigen used for immunization. It is for instance known that in normal, i.e. non-transgenic, animals about 1-10% of the circulating immunoglobulin fraction is directed against the antigen used for hyper-immunization, hence the vast majority of circulating immunoglobulins is not specific.

One approach towards expression of polyclonal antibody libraries has been described (WO 95/20401; US patents 5,789,208 and 6,335,163). A polyclonal library of Fab antibody fragments is expressed using a phage display vector, and selected for reactivity towards an antigen. The selected heavy and light chain variable region gene combinations are transferred in mass, as linked pairs, to a eukaryotic expression vector that provides constant region genes, to obtain a sublibrary of intact polyclonal antibodies. Upon transfection of this sublibrary into myeloma cells, stable clones produce monoclonal antibodies that can be mixed to obtain a polyclonal antibody mixture. While in theory it would be possible to obtain polyclonal antibodies directly from a single recombinant production process using this method by culturing a mixed population of transfected cells, potential problems would occur concerning the stability of the mixed cell population, and hence the consistency of the produced polyclonal antibody mixture. The control of a whole population of different cells in a pharmaceutically acceptable large (i.e. industrial) scale process, is a daunting task. It would seem, that characteristics such as growth rates of the cells and

Brief description of the figures

Fig. 1 Schematic representation of an antibody. The heavy and light chains are paired via interchain disulfide bonds (dotted lines). The heavy chain can be either of the α , γ , μ , δ or ϵ isotype. The light chain is either κ or λ . An antibody of IgG1 isotype is shown.

Fig. 2 Schematic representation of a bi-specific monoclonal antibody. A bi-specific antibody contains two different functional F(Ab) domains, indicated by the different patterns of the V_H - V_L regions.

Fig. 3 Sequence alignment of V_L and V_H of K53, UBS-54 and 02-237.

Fig. 4 Overview of plasmids pUBS3000Neo and pCD46_3000 (Neo).

Fig. 5 A. IEF of transiently expressed pUBS3000Neo, pCD46_3000(Neo) and a combination of both. B. The upper part shows a schematic representation of the expected molecules when a single light chain and a single heavy chain are expressed in a cell, leading to monoclonal antibodies UBS-54 or K53. The lower part under the arrow shows a schematic representation of the combinations produced when both heavy chains and the common light chain are co-expressed in a host cell, with theoretical amounts when both heavy chains are expressed at equal levels and pair to each other with equal efficiency. The common light chain is indicated with the vertically striped bars.

Fig. 6. Schematic representation of a possible embodiment of the method according to the invention (see e.g. Examples 9). (1) Introduction of nucleic acid sequences encoding one light chain and three different heavy chains capable of pairing to the common light chain to give functional antibodies into host cells; (2) selection of stable clones; (3) clones can be screened for e.g. expression levels, binding; (4) expand clones; (5) production of functional mixtures of antibodies. Some or all of steps 2-5 could be performed simultaneously or in different order.

Fig. 7. Sequence of V_H and V_L of phages directed against CD22, CD72 and HLA-DR.

15

Fig. 8. Map of pUBS54-IgA (pCRU-L01 encoding human IgA1 against EPCAM).

Fig. 9. Dimeric bi-specific IgA with a single light chain (indicated by horizontally striped bar). The method of the invention will produce a mixture of forms wherein different heavy chains can be paired, and only the most simple form is depicted in this schematic representation. A J-chain is shown to join the two monomers.

25

Fig. 10. Pentameric multispecific IgM with a single light chain (indicated by horizontally striped bars). The method of the invention will produce a mixture of many different forms wherein different heavy chains can be paired, and only the most simple form when 5 different heavy chains are expressed with a single light chain, and all 5 different heavy chains are incorporated in the pentamer and paired to the same heavy chain, is depicted

30

in this schematic representation. Pentamers with less specificities can also be formed by incorporation of less than 5 different heavy chains. Especially when the J-chain is not expressed, hexamers can also be obtained.

5

Fig. 11. Expression of a mixture of human IgG isotypes consisting of a common light chain, but with different binding specificities in a single cell to avoid the formation of bispecific antibodies. The different binding specificities are indicated by the different colours of the VH sequences. The common light chain is indicated with the vertically striped bars. The IgG1 isotype is indicated with the grey Fc, the IgG3 isotype is indicated with the black Fc part.

15

Fig. 12. DNA and protein sequences of variable domains heavy and light chains of K53, UBS54 and 02-237 IgG.

20 Fig. 13 Alignment of the variable sequences of the heavy chains of K53, 02-237 and UBS54. CDR1, CDR2 and CDR3 regions are indicated in bold.

Fig. 14 BIACORE analysis of K53 and 02-237. Affinity purified human CD46 from LS174T cells was coupled (640 RU) to CM5 chips (BIACORE BR-1000-14). Binding of 1000 (A), 500 (B), 250 (C), 125 (D), 63 (E), 31 (F), 16 (G), 8 (H) or 0 (I) nM 02-237 or k53 purified from stable PER.C6TM derived cell lines to the CD46 was monitored using a BIACORE 3000 system at 37°C. Using this experimental set-up, a Kd of 9.1×10^{-7} and 2.2×10^{-8} was found for K53 and 02-237, respectively.

30

Fig. 15 Binding of K53 and 02-237 to LS174T cells. Serial dilutions of purified 02-237 (■), K53 (*) and the negative control GBSIII (◇) conjugated to biotin were incubated with LS147T cells preincubated with normal
5 human serum to block Fcγ receptor interaction. Binding (MFI, ordinate) was determined by FACS after incubation with streptavidin conjugated-phycoerythrin.

Fig. 16. SDS-PAGE analysis of purified IgG fractions.
10 Three µg purified IgG was analysed on a non-reduced (A) and reduced (B) 4-20% Nupage gel (Novex) according to recommendations of the manufacturer. Proteins were visualized by staining with colloidal blue (Novex cat. No LC6025) according to recommendations of the manufacturer.
15 Clone identity is indicated on top of the SDS-PAGE. Each gel contains a control, which is either purified 02-237 or K53. NR, Non-reduced; R, reduced.

Fig. 17. IEF analysis of purified IgG fractions. Ten µg
20 purified IgG was analysed on an Isogel 3-10 gel (BMA) according to recommendations of the manufacturer. Proteins were visualized by staining with colloidal blue (Novex, cat. No LC6025) according to recommendations of the manufacturer. Clone identity is indicated on top of
25 the IEF. Each gel contains a control, consisting of a 1:1:1 mixture of 02-237, K53 and UBS54.

Fig. 18. IEF analysis of polyclonal mixtures 241, 280, 282, 361 and 402 in comparison to single K53, 02-237 and
30 UBS54. Ten µg purified IgG was analysed on an Isogel 3-10 gel (BMA) according to recommendations of the manufacturer. Proteins were visualized by staining with

colloidal blue (Novex, cat. No LC6025) according to recommendations of the manufacturer. IgG identity is indicated on top of the IEF.

5 Fig. 19. Mass chromatograms of CDR3 peptides of K53, 02-
237, UBS54 and the two unique light chain peptides L1-
K53/UBS54 and L1-237 in IgG fraction Poly1-280. On the
right-hand side of each mass chromatogram, the isotopic
10 pattern of the peptide is shown. The doubly charged ion
at m/z 1058.98 (Mw 2115.96 Da) results from peptide H11-
K53. The doubly charged ion at m/z 1029.96 (Mw 2057.92
Da) results from peptide H11-02-237. The triply charged
ion at m/z 770.03 (Mw 2307.09 Da) results from peptide
15 H9-UBS54. The doubly charged ion at m/z 1291.08 (Mw
2580.16 Da) results from peptide L1-K53/UBS54. The doubly
charged ion at m/z 1278.11 (Mw 2554.22 Da) results from
peptide L1-02-237.

Purified IgG was dissolved in a 0.1% RapiGestTM (Waters)
in 50 mM NH_4HCO_3 . The disulfides were reduced using 1 M
20 DTT (1,4-dithio-DL-threitol), followed by incubation at
65°C for 30 minutes. Then, for alkylation of all
sulfhydryl groups, 1 M iodoacetamide was added, followed
by incubation at room temperature for 45 minutes in dark.
Alkylation was stopped by addition of 1 M DTT. The buffer
25 was exchanged to 25 mM NH_4HCO_3 , pH 7.5. Finally, the
antibodies were digested overnight at 37 °C by addition
of a freshly prepared trypsin solution in 25 mM NH_4HCO_3 .
The peptide mixture was analysed by LC-MS. The LC-system
consisted of a Vydac reversed-phase C18 column, that was
30 eluted by applying a gradient of solvent A (5/95/1
acetonitrile, water, glacial acetic acid v/v/v) and
solvent B (90/10/1 acetonitrile, water, glacial acetic

acid v/v/v). The LC was on-line coupled to a Q-TOF2 mass spectrometer (Micromass), equipped with an electrospray source operated at 3 kV. Mass spectra were recorded in positive ion mode from m/z 50 to 1500 at a cone voltage of 35 V. The instrumental resolution of >10,000 enabled unambiguous determination of the charge, and therefore the mass of most ions up to at least +7. In this way, all peptides were identified according to their molecular weight. The amino acid sequence of the peptide was confirmed by MS/MS-experiments. MS/MS spectra were recorded in positive ion mode from m/z 50-2000 with collision energy between 20 and 35 eVolts.

Fig. 20. BIACORE analysis of polyclonal 280. Affinity purified human CD46 from LS174T cells was coupled (640 RU) to CM5 chips (BIACORE BR-1000-14). Binding of 1000 (A), 500 (B), 250 (C), 125 (D), 63 (E), 31 (F), 16 (G), 8 (H) or 0 (I) nM Poly1-280 to CD46 was monitored using a BIACORE 3000 system at 37°C.

20

Fig. 21. IEF analysis of sub-clones from clones poly 1-241, poly 1-280 and poly 1-402 producing a mixture of antibodies.

A. Clones poly 1-241 and poly 1-280. Lane 1 contains a pI marker (Amersham, Cat. No. 17-0471-01). Lane 2 contains isolated IgG from the parent clone poly 1-241 (as in Fig. 18). Lanes 3, 4 and 5 respectively contain isolated IgG from 3 independent sub-clones derived from poly 1-241 by limiting dilution. Lane 6 contains isolated IgG from the parent clone poly 1-280 (as in Fig. 18). Lanes 7, 8 and 9 respectively contain isolated IgG from three independent sub-clones derived from poly 1-280 by limiting dilution.

30

B. Clone poly 1-402. Lanes 1 and 7 contain a pI marker. Lane 2 contains isolated IgG from the parent clone poly 1-402 (as in Fig. 18). Lanes 3, 4 and 5 respectively contain isolated IgG from 3 independent sub-clones
5 derived from poly 1-402 by limiting dilution. Lane 6 contains a control (a 1:1:1 mixture of 02-237, K53 and UBS54).

Summary of the invention

In one aspect the present invention provides for a method of producing a mixture of antibodies in a recombinant host, the method comprising the step of:

- 5 expressing in a recombinant host cell a nucleic acid sequence or nucleic acid sequences encoding at least one light chain and at least three different heavy chains that are capable of pairing with said at least one light chain. A further aspect of the invention is the
- 10 elimination of the production of potentially non-functional light-heavy chain pairing by using pre-selected combinations of heavy and light chains. It has been recognized that phage display libraries built from a single light chain and many different heavy chains can
- 15 encode antibody fragments with very distinct binding properties. This feature can be used to find different antibodies having the same light chain but different heavy chains, against the same target or different targets, wherein a target can be a whole antigen or an
- 20 epitope thereof. Such different targets may for instance be on the same surface (e.g. cell or tissue). Such antibody fragments obtained by phage display can be cloned into vectors for the desired format, e.g. IgG, IgA or IgM, and the nucleic acid sequences encoding these
- 25 formats can be used to transfect host cells. In one approach, H and L chains can be encoded by different constructs that, upon transfection into a cell wherein they are expressed, give rise to intact Ig molecules. When different H chain constructs are transfected into a
- 30 cell with a single L chain construct, H- and L-chains will be assembled to form all possible combinations. However, in contrast to approaches where different light

chains are expressed such as for the production of bispecific antibodies, this method will result only in functional binding regions. It would be particularly useful when the host, e.g. a single cell line, is capable of expressing acceptable levels of recombinant antibodies, without the necessity to first amplify in said cell the nucleic acid sequences encoding the antibodies. The advantage is that cell lines with only a limited copy number of said nucleic acids are expected to be genetically more stable, because there will be less recombination between the sequences encoding the heavy chains, than in cell lines where a multitude of these copies is present. A cell line suitable for use in the methods according to the invention is the human cell line PER.C6TM. Using this method a mixture of antibodies with defined specificities can be produced from a single cell clone in a safe, controlled, and consistent manner.

The invention provides a method for production of a mixture of antibodies in a recombinant host, the method comprising the step of: expressing a nucleic acid sequence or nucleic acid sequences encoding at least one light chain and at least three different heavy chains that are capable of pairing with said at least one light chain in a recombinant host cell. In a preferred aspect, the recombinant host cell comprises a nucleic acid sequence encoding a common light chain that is capable of pairing with said at least three different heavy chains, such that the produced antibodies comprise a common light chain. Obviously, those of skill in the art will recognize that "common" also refers to functional equivalents of the light chain of which the amino acid sequence is not identical. Many variants of said light

chain exist wherein mutations (deletions, substitutions, additions) are present that do not materially influence the formation of functional binding regions.

5 The invention further provides a composition comprising a mixture of recombinantly produced antibodies, wherein at least three different heavy chain sequences are represented in said mixture. In one embodiment, the light chains of such mixtures have a common sequence. The mixture of antibodies can be
10 produced by the method according to the invention. Preferably, the mixture of antibodies is more efficacious than the individual antibodies it comprises, more preferably, the mixture acts synergistically in a functional assay.

15 The invention further provides a recombinant host cell for producing mixtures of antibodies, and methods for making such host cells.

Independent clones obtained from the transfection of nucleic acid sequences encoding a light chain and more
20 than one heavy chain may express the different antibodies in the mixture at different levels. It is another aspect of the invention to select a clone using a functional assay, for the most potent mixture of antibodies. The invention therefore further provides a method for
25 identifying at least one host cell clone that produces a mixture of antibodies, wherein said mixture of antibodies has a desired effect according to a functional assay, the method comprising the steps of: (i) providing a host cell with nucleic acid sequence encoding at least one light
30 chain and nucleic acid sequences encoding at least two different heavy chains, wherein said heavy and light chains are capable of pairing with each other; (ii)

culturing at least one clone of said host cell under conditions conducive to expression of said nucleic acid sequences; (iii) screening said at least one clone of the host cell for production of a mixture of antibodies
5 having the desired effect by a functional assay; and (iv) identifying at least one clone that produces a mixture of antibodies having the desired effect. This method according to the invention can be performed using high-throughput procedures, if desired. The clones identified
10 by the method can be used to produce antibody mixtures according to the invention.

The invention further provides transgenic non-human animals and transgenic plants or transgenic plant cells capable of expressing mixtures of antibodies, and
15 mixtures of antibodies produced by these.

The invention further provides pharmaceutical compositions comprising a mixture of recombinantly produced antibodies and a suitable carrier.

The invention further provides mixtures of
20 antibodies for use in the treatment or diagnosis and for the preparation of a medicament for use in the treatment or diagnosis of a disease or disorder in a human or animal subject.

The invention further provides a method for
25 producing a mixture of antibodies comprising different isotypes from a single host cell clone.

The invention further provides a method for identifying a mixture of antibodies having a desired effect in a functional assay.

30 The invention further provides a method for producing a mixture of antibodies that are capable of binding to a target, the method comprising the steps of:

i) bringing a phage library comprising antibodies into
contact with material comprising a target, ii) at least
one step of selecting phages binding to said target, iii)
identifying at least two phages that comprise antibodies
5 binding to said target, wherein said at least two
antibodies comprise a common light chain, iv) introducing
a nucleic acid sequence encoding the light chain and a
nucleic acid sequence or sequences encoding the heavy
chains of said at least two antibodies into a host cell,
10 v) culturing a clone of said host cell under conditions
conducive to expression of said nucleic acid sequences.

Detailed description of the invention

It is an object of the present invention to provide a method for producing a mixture of antibodies in a recombinant host, the method comprising the step of:
5 expressing in a recombinant host cell a nucleic acid sequence or nucleic acid sequences encoding at least one light chain and at least three different heavy chains that are capable of pairing with said at least one light chain. According to the invention, the light and heavy
10 chains when paired form functional antigen binding domains. A functional antigen binding domain is capable of specifically binding to an antigen.

In one aspect according to the invention, the method for producing a mixture of antibodies according to the
15 invention further comprises the step of recovering the antibodies from the cell or the host cell culture to obtain a mixture of antibodies suitable for further use. In one embodiment of the invention, a method is provided for production of a mixture of antibodies, the method
20 comprising the step of: expressing in a recombinant host cell a nucleic acid sequence encoding a common light chain and nucleic acid sequence or sequences encoding at least three different heavy chains that are capable of pairing with said common light chain, such that the
25 antibodies that are produced comprise common light chains. In one aspect the common light chain is identical in each light chain/heavy chain pair.

The term "antibody" as used herein means a polypeptide containing one or more domains that bind an
30 epitope on an antigen, where such domains are derived from or have sequence identity with the variable region of an antibody. The structure of an antibody is

schematically represented in Fig.1. Examples of antibodies according to the invention include full length antibodies, antibody fragments, bispecific antibodies, immunoconjugates, and the like. An antibody according to the invention may be isotype IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, IgM, and the like, or a derivative of these. Antibody fragments include Fv, Fab, Fab', F(ab')₂ fragments, and the like. Antibodies according to the invention can be of any origin, including murine, of more than one origin, i.e. chimeric, humanized, or fully human antibodies. Immunoconjugates comprise antigen binding domains and a non-antibody part such as a toxin, a radiolabel, an enzyme, and the like. An "antigen binding domain" preferably comprises variable regions of a heavy and a light chain, and is responsible for specific binding to an antigen of interest. Recombinant antibodies are prepared by expressing both a heavy and a light chain in a host cell. Similarly, by expressing two chains with their respective light chains (or a common light chain), wherein each heavy chain/light chain has its own specificity, so-called "bispecific" antibodies can be prepared. "Bispecific antibodies" comprise two non-identical heavy-light chain combinations (Fig. 2), and both antigen binding regions of a bispecific antibody may recognize different antigens or different epitopes on an antigen.

A "common light chain" according to the invention refers to light chains which may be identical or have amino acid sequence differences. Said light chains may comprise mutations which do not alter the specificity of the antibody when combined with the same heavy chain, without departing from the scope of the present

invention. It is for instance possible within the scope of the definition of common light chains as used herein, to prepare or find light chains that are not identical but still functionally equivalent, e.g. by introducing
5 and testing conservative amino acid changes, changes of amino acids in regions that do not or only partly contribute to binding specificity when paired with the heavy chain, and the like. It is an aspect of the present invention to use as common light chain one identical
10 light chain to combine with different heavy chains to form antibodies with functional antigen binding domains. The use of one common light chain avoids the formation of heterodimers in which pairing of light and heavy chains results in antigen binding domains that are not
15 functional, in other words which are not capable of binding to the target antigen or antigens. The use of a common light chain and two heavy chains has been proposed by (Merchant et al, 1998; WO 98/50431) for a different purpose, viz. to increase the formation of functional
20 bispecific antibodies at the expense of antibody mixture complexity. These publications teach a method for preferentially producing one defined and desired bispecific antibody, thereby *minimizing* the complexity of the produced mixture. Hence, Merchant specifically
25 teaches to prevent the production of monospecific antibodies, because these are undesired byproducts in the process for bispecific antibody production described in those publications. Clearly, there is no teaching in the prior art to prepare a complex mixture of antibodies from
30 a recombinant host cell avoiding the formation of non-functional binding domains or the benefits thereof, let alone how. In the method according to the present

invention, at least three different heavy chains that are capable of pairing with the common light chain are expressed. In other embodiments, the host cell according to the invention is provided with nucleic acid sequences
5 encoding for 4, 5, 6, 7, 8, 9, 10, or more heavy chains capable of pairing with the common light chain, to increase the complexity of the produced mixture of antibodies.

"Different heavy chains" according to the invention
10 may differ in the variable region and have the same constant region. In other embodiments, where it is clear from the context, they may have the same variable region and differ in the constant region, e.g. be of a different isotype. The use of a mixture of antibodies having
15 different constant regions, such as the Fc-portion, may be advantageous if different arms of the immune system are to be mobilized in the treatment of the human or animal body. In yet other embodiments, also to be clear from the context, both the variable and the constant
20 regions may differ.

A "mixture of antibodies" according to the invention comprises at least two non-identical antibodies, but may comprise 3, 4, 5, 6, 7, 8, 9, 10, or more different antibodies, and may resemble a polyclonal or at least an
25 oligoclonal antibody mixture with regard to complexity and number of functional antigen binding molecules. The mixtures produced according to the present invention usually will comprise bispecific antibodies. If desired, formation of monospecific antibodies in the mixture can
30 be favoured over the formation of bispecific antibodies. When n heavy chains and one common light chain are expressed according to the invention in a host cell at

equal levels, the theoretical percentage of bispecific antibodies produced by the method according to the invention is $(1-1/n)*100\%$. The total number of different antibodies in the mixture produced by the method

5 according to the invention is theoretically $n + \{(n^2-n)/2\}$, of which $(n^2-n/2)$ are bispecific antibodies. Distortion of the ratio of expression levels of the different heavy chains may lead to values deviating from the theoretical values. The amount of bispecific antibodies can also be

10 decreased, compared to these theoretical values, if not all heavy chains pair with equal efficiency. It is for instance possible to engineer the heavy chains, e.g. by introducing specific and complementary interaction surfaces between selected heavy chains, to promote

15 homodimer pairing over heterodimer pairing, contrary to what has been proposed by Merchant, *supra*. Heavy chains may also be selected so as to minimize heterodimer formation in the mixture. A special form of this embodiment involves heavy chains of two or more different

20 isotypes (e.g. IgG1, IgG3, IgA). When heavy chains of different isotype are expressed in the same host cell in accordance with the present invention and one light chain that can pair to these heavy chains, the amount of bispecific antibodies will be reduced, possibly to very

25 low or even to undetectable levels. Thus, when bispecific antibodies are less desirable, it is possible to produce a mixture of antibodies according to the invention, wherein a nucleic acid sequence encoding a common light chain and nucleic acid sequences encoding at least two

30 different heavy chains with a different variable region capable of pairing to said common light chain are expressed in a recombinant host, and wherein said heavy

chains further differ in their constant regions sufficiently to reduce or prevent pairing between the different heavy chains. The mixtures of antibodies according to the invention may be produced from a clone
5 that was derived from a single host cell, i.e. from a population of cells containing the same recombinant nucleic acid sequences.

It will be understood that the different heavy chains according to the invention can be encoded on
10 separate nucleic acid molecules, but may also be present on one nucleic acid molecule comprising different regions encoding said at least three heavy chains. The nucleic acid molecules usually encode precursors of the light and/or heavy chains, which when expressed are secreted
15 from the host cells, thereby becoming processed to yield the mature form. These and other aspects of expressing antibodies in a host cell are well known to those having ordinary skill in the art.

A "recombinant host cell" as used herein is a cell
20 comprising one or more so-called transgenes, i.e. recombinant nucleic acid sequences not naturally present in said cell. These transgenes are expressed in said host cell to produce recombinant antibodies encoded by these nucleic acid sequences, when these cells are cultured
25 under conditions conducive to expression of said nucleic acid sequences. The host cell according to the invention can be present in the form of a culture from a clone that is derived from a single host cell wherein the transgenes have been introduced. To obtain expression of nucleic
30 acid sequences encoding antibodies, it is well known to those skilled in the art that sequences capable of driving such expression can be functionally linked to the

nucleic acid sequences encoding the antibodies.
Functionally linked is meant to describe that the nucleic acid sequences encoding the antibody fragments or precursors thereof is linked to the sequences capable of driving expression such that these sequences can drive expression of the antibodies or precursors thereof.
Useful expression vectors are available in the art, e.g. the pcDNA vector series of Invitrogen. Where the sequence encoding the polypeptide of interest is properly inserted with reference to sequences governing the transcription and translation of the encoded polypeptide, the resulting expression cassette is useful to produce the polypeptide of interest, referred to as expression. Sequences driving expression may include promoters, enhancers and the like, and combinations thereof. These should be capable of functioning in the host cell, thereby driving expression of the nucleic acid sequences that are functionally linked to them. Promoters can be constitutive or regulated, and can be obtained from various sources, including viruses, prokaryotic, or eukaryotic sources, or artificially designed. Expression of nucleic acids of interest may be from the natural promoter or derivative thereof or from an entirely heterologous promoter. Some well-known and much used promoters for expression in eukaryotic cells comprise promoters derived from viruses, such as adenovirus, e.g. the E1A promoter, promoters derived from cytomegalovirus (CMV), such as the CMV immediate early (IE) promoter, promoters derived from Simian Virus 40 (SV40), and the like. Suitable promoters can also be derived from eukaryotic cells, such as methallothionein (MT) promoters, elongation factor 1 α (EF-1 α) promoter, actin promoter, an immunoglobulin

promoter, heat shock promoters, and the like. Any promoter or enhancer/promoter capable of driving expression of the sequence of interest in the host cell is suitable in the invention. In one embodiment the
5 sequence capable of driving expression comprises a region from a CMV promoter, preferably the region comprising nucleotides -735 to +95 of the CMV immediate early gene enhancer/promoter.

Protein production in recombinant host cells has been
10 extensively described, e.g. in Current Protocols in Protein Science, 1995, Coligan JE, Dunn BM, Ploegh HL, Speicher DW, Wingfield PT, ISBN 0-471-11184-8; Bendig, 1988. Culturing a cell is done to enable it to metabolize, and/or grow and/or divide and/or produce
15 recombinant proteins of interest. This can be accomplished by methods well known to persons skilled in the art, and includes but is not limited to providing nutrients for the cell. The methods comprise growth adhering to surfaces, growth in suspension, or
20 combinations thereof. Several culturing conditions can be optimized by methods well known in the art to optimize protein production yields. Culturing can be done for instance in dishes, roller bottles or in bioreactors, using batch, fed-batch, continuous systems, hollow fiber, and the like. In order to achieve large scale
25 (continuous) production of recombinant proteins through cell culture it is preferred in the art to have cells capable of growing in suspension, and it is preferred to have cells capable of being cultured in the absence of
30 animal- or human-derived serum or animal- or human-derived serum components. Thus purification is easier and safety is enhanced due to the absence of additional

animal or human proteins derived from the culture medium, while the system is also very reliable as synthetic media are the best in reproducibility.

"Host cells" according to the invention may be any host
5 cell capable of expressing recombinant DNA molecules, including bacteria such as Eschericia (e.g. E.coli), Enterobacter, Salmonella, Bacillus, Pseudomonas, Streptomyces, yeasts such as S.cerevisiae, K.lactis, P.pastoris, Candida, or yarrowia, filamentous fungi such
10 as Neurospora, Aspergillus oryzae, Aspergillus nidulans and Aspergillus niger, insect cells such as Spodoptera frugiperda SF-9 or SF-21 cells, mammalian cells such as Chinese hamster ovary (CHO) cells, BHK cells, mouse cells including SP2/0 cells and NS-0 myeloma cells, primate
15 cells such as COS and Vero cells, MDCK cells, BRL 3A cells, hybridomas, tumor-cells, immortalized primary cells, human cells such as W138, HepG2, HeLa, HEK293, HT1080 or embryonic retina cells such as PER.C6TM, and the like. Often, the expression system of choice will involve
20 a mammalian cell expression vector and host so that the antibodies are appropriately glycosylated. A human cell line, preferably PER.C6TM, can advantageously be used to obtain antibodies with a completely human glycosylation pattern. The conditions for growing or multiplying cells
25 (see e.g. Tissue Culture, Academic Press, Kruse and Paterson, editors (1973)) and the conditions for expression of the recombinant product may differ somewhat, and optimization of the process is usually performed to increase the product yields and/or growth of
30 the cells with respect to each other, according to methods generally known to the person skilled in the art. In general, principles, protocols, and practical

techniques for maximizing the productivity of mammalian cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach (M. Butler, ed., IRL Press, 1991). Expression of antibodies in recombinant
5 host cells has been extensively described in the art (see e.g. EP0120694; EP0314161; EP0481790; EP0523949; US patent 4816567; WO 00/63403). The nucleic acid molecules encoding the light and heavy chains may be present as extrachromosomal copies and/or stably integrated into the
10 chromosome of the host cell. With regard to stability of production, the latter is preferred.

The antibodies are expressed in the cells according to the invention, and may be recovered from the cells or preferably from the cell culture medium, by methods.
15 generally known to persons skilled in the art. Such methods may include precipitation, centrifugation, filtration, size-exclusion chromatography, affinity chromatography, cation- and/or anion-exchange chromatography, hydrophobic interaction chromatography,
20 and the like. For a mixture of antibodies comprising IgG molecules, protein A or protein G affinity chromatography can be suitably used (see e.g. US patents 4,801,687 and 5,151,504).

In one embodiment, at least two antibodies from the
25 mixture produced according to the invention comprise a heavy-light chain dimer having different specificities and/or affinities. The specificity determines which antigen or epitope thereof is bound by the antibody. The affinity is a measure for the strength of binding to a
30 particular antigen or epitope. Specific binding is defined as binding with an affinity (K_a) of at least 5×10^4 liter/mole, more preferably 5×10^5 , more

preferably more than 5×10^6 , still more preferably 5×10^7 , or more. Typically, monoclonal antibodies may have affinities which go up to 10^{10} liter per mole, or even higher. The mixture of antibodies produced according to the present invention may contain at least two antibodies that bind to different epitopes on the same antigen molecule and/or may contain at least two antibodies that bind to different antigen molecules present in one antigen comprising mixture. Such an antigen comprising mixture may be a mixture of partially or wholly purified antigens such as toxins, membrane components and proteins, viral envelope proteins, or it may be a healthy cell, a diseased cell, a mixture of cells, a tissue or mixture of tissues, a tumor, an organ, a complete human or animal subject, a fungus or yeast, a bacteria or bacterial culture, a virus or virus stock, combinations of these, and the like. Unlike monoclonal antibodies that are able to bind to a single antigen or epitope only, the mixture of antibodies according to the present invention may therefore have many of the advantages of a polyclonal or oligoclonal antibody mixture.

In a preferred embodiment, the host cell according to the method of the invention is capable of high-level expression of human immunoglobulin, i.e. at least 1 pg/cell/day, preferably at least 10 pg/cell/day and even more preferably at least 20 pg/cell/day or more without the need for amplification of the nucleic acid molecules encoding the heavy and light chains in said host cell. Preferably, host cells according to the invention contain in their genome between 1 and 10 copies of each recombinant nucleic acid to be expressed. In the art, amplification of the copy number of the nucleic acid

sequences encoding a protein of interest in e.g. CHO cells can be used to increase expression levels of the recombinant protein by the cells (see e.g. Bendig, 1988; Cockett et al, 1990; US patent 4,399,216). This is
5 currently a widely used method. However, a significant time-consuming effort is required before a clone with a desired high copy number and high expression levels has been established, and moreover clones harbouring very high copy numbers (up to hundreds) of the expression
10 cassette often are unstable (e.g. Kim et al., 1998). It is therefore a preferred embodiment of the present invention to use host cells that do not require such amplification strategies for high-level expression of the antibodies of interest. This allows fast generation of
15 stable clones of host cells that express the mixture of antibodies according to the invention in a consistent manner. We provide evidence that host cells according to the invention can be obtained, subcloned and further propagated for at least around 30 cell divisions
20 (population doublings) while expressing the mixture of antibodies according to the invention in a stable manner, in the absence of selection pressure. Therefore, in certain aspects the methods of the invention include culturing the cells for at least 20, preferably 25, more preferably 30 population doublings, and in other aspects
25 the host cells according to the invention have undergone at least 20, preferably 25, more preferably 30 population doublings and are still capable of expressing a mixture of antibodies according to the invention. The invention
30 also provides a culture of cells producing a mixture of immunoglobulins from a single cell, said mixture comprising at least three different heavy chains. The

invention also provides a culture of cells producing at least three different monospecific immunoglobulins from a single cell. In certain preferred aspects, said culture produces said mixture or said at least three different
5 monospecific immunoglobulins in a single cell for more than 20, preferably more than 25, more preferably more than 30 population doublings.

Preferably host cells according to the method of the invention are derived from human retina cells that have
10 been immortalized or transformed with adenoviral E1 sequences. A particularly preferred host cell according to methods of the present invention is PER.C6TM as deposited under ECACC no. 96022940, or a derivative thereof. PER.C6-derived clones can be generated fast,
15 usually contain a limited number of copies (about 1-10) of the transgene, and are capable of high-level expression of recombinant antibodies (Jones et al, 2003). Therefore, such clones are expected to maintain a stable copy number over many generations, which is an advantage
20 in the production of biopharmaceuticals. PER.C6TM cells have been extensively characterized and documented, demonstrating good process of scaling up, suspension growth and growth factor independence. Furthermore, PER.C6TM can be incorporated into a suspension in a highly
25 reproducible manner, making it particularly suitable for large-scale production. In this regard, the PER.C6TM cell line has been characterized for bioreactor growth, where it can grow to very high densities. The use of PER.C6TM for recombinant production of antibodies has been
30 described in detail in publication WO 00/63403 and in (Jones et al., 2003).

It is another aspect of the present invention to provide a mixture of antibodies that is obtainable by a method according to the invention. Such mixtures of antibodies are expected to be more effective than the
5 sole components it comprises, in analogy to polyclonal antibodies usually being more effective than monoclonal antibodies to the same target. Such mixtures can be prepared against a variety of target antigens or epitopes.

10

It is another aspect of the present invention to provide a recombinant host cell comprising a nucleic acid sequence encoding a light chain and a nucleic acid sequence or nucleic acid sequences encoding at least
15 three different heavy chains of an antibody, wherein said light chain and heavy chains are capable of pairing, preferably to form a functional binding domain. The paired heavy and light chain form functional antigen binding regions against the target antigen or target
20 antigens. The host cells according to the invention are useful in the method according to the invention. They can be used to produce mixtures of antibodies according to the invention.

25

It is another aspect of the present invention to provide a composition comprising a mixture of recombinantly produced antibodies, wherein at least three different heavy chain sequences are represented in the mixture of recombinant antibodies. Monoclonal antibodies
30 are routinely produced by recombinant methods. The present invention discloses mixtures of antibodies useful for diagnosis or treatment in various fields. The

compositions according to the invention comprise mixtures of at least three different heavy chains paired to light chains in the form of antibodies. Preferably, the light chains of the antibodies in said mixtures have a common
5 light chain. The mixtures may comprise bispecific antibodies. The mixtures may be produced from a clone that was derived from a single host cell, i.e. from a population of cells containing the same recombinant nucleic acid sequences. The mixtures can be obtained by
10 methods according to the invention, or be produced by host cells according to the invention. In other embodiments, the number of heavy chains represented in said mixture is 4, 5, 6, 7, 8, 9, 10, or more. The optimal mixture for a certain purpose may be determined
15 empirically by methods known to the person skilled in the art, or by methods provided by the present invention. Such compositions according to the invention may have several of the advantages of a polyclonal antibody mixture, without the disadvantages usually inherently
20 associated with polyclonal antibody mixtures, because of the manner in which they are produced. It is furthermore expected that the mixture of antibodies is more efficacious than separate monoclonal antibodies. Therefore the dosage, and hence the production capacity
25 required, may be less for the mixtures of antibodies according to the invention than for monoclonal antibodies.

It has for instance been described that although no single monoclonal antibody to botulinum neurotoxin
30 (BoNT/A) significantly neutralized toxin, a combination of three such monoclonal antibodies (oligoclonal antibody) neutralized 450,000 50% lethal doses of BoNT/A,

a potency 90 times greater than human hyperimmune globulin (Nowakowski et al, 2002). This result demonstrates that oligoclonal mixtures of antibodies comprising only 2 to 3 different specificities may have
5 very high potency.

Furthermore, the chances of a mixture of the invention losing its activity due to target or epitope loss is reduced, when compared to a single monoclonal antibody. In particular embodiments, 2, 3, 4, 5, 6, 7, 8,
10 9, 10, or more of the antibodies present in the mixture according to the invention have different specificities. Said different specificities may be directed to different epitopes on the same antigen and/or may be directed to different antigens present in one antigen comprising
15 mixture. A composition according to the invention further may also comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, or more antibodies having different affinities for the same epitope. Antibodies with differing affinities for the same epitope may for instance be generated by methods of
20 affinity maturation, known to the person skilled in the art.

In a particularly preferred embodiment, the composition according to the invention has an effect that is greater than the effect of each individual monospecific antibody
25 present in said composition. Said effect can be measured in a functional assay. A "functional assay" according to the present invention is an assay that can be used to determine one or more desired parameters of the antibody or the mixture of antibodies subject to the assay
30 conditions. Suitable functional assays may be binding assays, apoptosis assays, antibody dependent cellular cytotoxicity (ADCC) assays, complement dependent

cytotoxicity (CDC) assays, inhibition of cell growth or proliferation (cytostatic effect) assays, cell killing (cytotoxic effect) assays, cell signaling assays, assays for measuring inhibition of binding of pathogen to target
5 cell, assays to measure the secretion of vascular endothelial growth factor (VEGF) or other secreted molecules, assays for bacteriostasis, bactericidal activity, neutralization of viruses, assays to measure the attraction of components of the immune system to the
10 site where antibodies are bound, including in situ hybridization methods, labeling methods, and the like. Clearly, also in vivo assays such as animal models, including mouse tumor models, models of autoimmune disease, virus-infected or bacteria-infected rodent or
15 primate models, and the like, can be used for this purpose. The efficacy of a mixture of antibodies according to the invention can be compared to individual antibodies in such models by methods generally known to the person skilled in the art.

20

It is another aspect of the present invention to provide a method for identifying at least one host cell clone that produces a mixture of antibodies, wherein said mixture of antibodies has a desired effect according to a
25 functional assay, the method comprising the steps of: (i) providing a host cell comprising a nucleic acid sequence encoding at least one light chain and nucleic acid sequence or sequences encoding at least two different heavy chains, wherein said heavy and light chains are
30 capable of pairing with each other; (ii) culturing at least one clone of said host cell under conditions conducive to expression of said nucleic acid sequences;

(iii) screening said at least one clone of the host cell for production of a mixture of antibodies having the desired effect by a functional assay; and (iv) identifying at least one clone that produces a mixture of antibodies having the desired effect. Preferably, said host cell comprises a nucleic acid sequence encoding a common light chain that is capable of pairing with said at least two different heavy chains, such that produced antibodies comprise common light chains, as described above. In specific embodiments said culturing in step (ii) and said screening in step (iii) of the method is performed with at least two clones. The method may optionally include an assay for measuring the expression levels of the antibodies that are produced, which assay may be during or after step (ii) according to the method, or later in the procedure. Such assays are well known to the person skilled in the art, and include protein concentration assays, immunoglobulin specific assays such as ELISA, RIA, DELFIA, and the like. In particular embodiments of said method according to the invention, the host cell comprises nucleic acid sequence or sequences encoding at least 3, 4, 5, 6, 7, 8, 9, 10, or more heavy chains capable of pairing with said at least one light chain. Functional assays useful for the method according to the invention may be assays for apoptosis, ADCC, CDC, cell killing, inhibition of proliferation, virus neutralization, bacterial opsonization, receptor-mediated signaling, cell signaling, bactericidal activity, and the like. Useful screening assays for anti-cancer antibodies have for instance been described in US patent 6,180,357. Such assays may also be used to identify a clone according to the method of the present

invention. It is for instance possible to use enzyme linked immunosorbent assays (ELISAs) for the testing of antibody binding to their target. Using such assays, it is possible to screen for antibody mixtures that most
5 avidly bind the target antigen (or mixture of target antigens against which the mixture of antibodies is to be tested). Another possibility that can be explored is to directly screen for cytotoxicity or cytostatic effects. It is possible that upon such a different screen, other
10 or the same clones producing mixtures of antibodies will be chosen than with the ELISA mentioned above. The screening for cell killing or cessation of growth of cancerous cells may be suitably used according to the invention. Cell death can be measured by various
15 endpoints, including the absence of metabolism or the denaturation of enzymes. In one possible embodiment of the present invention, the assay is conducted by focusing on cytotoxic activity toward cancerous cells as an endpoint. For this assay, a live/dead assay kit, for
20 example the LIVE/DEAD[®] Viability/Cytotoxicity Assay Kit (L-3224) by Molecular Probes, can suitably be used. Other methods of assessing cell viability, such as trypan blue exclusion, ⁵¹Cr release, Calcein-AM, Alamar Blue[™], LDH activity, and similar methods can also be used. The
25 assays may also include screening of the mixture of antibodies for specificity to the desired antigen comprising tissue. The antibodies according to the invention may have a limited tissue distribution. It is possible to include testing the mixtures of antibodies
30 against a variety of cells, cell types, or tissues, to screen for mixtures of antibodies that preferably bind to cells, cell types or tissues of interest.

Irrespective of a functional assay as described above, the present invention also teaches ways to determine the identity of the antibodies expressed by a clone, using methods such as iso-electric focusing (IEF), mass-
5 spectrometry (MS), and the like. It is therefore an aspect of the invention to provide use of MS and/or IEF in selecting a clone that expresses a mixture of antibodies according to the invention.

When monoclonal antibodies are produced by recombinant
10 host cells, a screening step is usually performed to assess expression levels of the individual clones that were generated. The addition of more heavy chains to produce mixtures adds a level of complexity to the production of antibodies. When host cells are transfected
15 with nucleic acid molecules encoding the light and heavy chains that will form the mixture of antibodies desired, independent clones may arise containing the same genetic information, but nevertheless differing in expression levels, thereby producing different ratios of the encoded
20 antibodies, giving rise to different mixtures of antibodies from the same genetic repertoire. The method according to the invention is useful for identifying a clone that produces an optimal mixture for a certain purpose.

25 The culturing and/or screening according to steps (ii) and (iii) respectively, may be suitably performed using high-throughput procedures, optionally in an automated fashion. Clones can e.g. be cultured in 96-well or other multi-well plates, e.g. in arrayed format, and
30 screened for production of a desired mixture. Robotics may be suitably employed for this purpose. Methods to implement high-throughput culturing and assays are

generally available and known to the person skilled in the art. It will be clear that also for this method according to the invention, it is beneficial to use host cells capable of high level expression of proteins,
5 without the need for amplification of the nucleic acid encoding said proteins in said cell. In one embodiment, said host cell is derived from a human embryonic retinoblast cell, that has been immortalized or transformed by adenoviral E1 sequences. In a preferred
10 embodiment, said cell is derived from PER.C6™. This cell line has already been shown to be amenable to high-throughput manipulations, including culturing (WO 99/64582).

In specific embodiments of the present invention,
15 said mixture of antibodies according to the method of identifying at least one host cell according to the invention, comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or more antibodies having different specificities and/or affinities.

20 A potential advantage of the method will be that it will allow exploring many possible combinations simultaneously, the combinations inherently including the presence of bispecific antibodies in the produced mixture. Therefore more combinations can be tested than
25 by just mixing purified known monoclonal antibodies, both in number of combinations and in ratios of presence of different antibodies in these combinations.

The clone that has been identified by the method according to the invention, can be used for producing a
30 desired mixture of antibodies. It is therefore another aspect of the present invention to provide a method of producing a mixture of antibodies, the method comprising

the step of: culturing a host cell clone identified by the method of identifying at least one host cell clone that produces a mixture of antibodies according to the invention, said culturing being under conditions

5 conducive to expression of the nucleic acid molecules encoding the at least one light chain and the at least two different heavy chains. The produced antibodies may be recovered from the host cells and/or from the host cell culture, e.g. from the culture medium. The mixture

10 of antibodies can be recovered according to a variety of techniques known to the person skilled in the art. It is yet another aspect of the present invention to provide a mixture of antibodies that is obtainable by the method according to the invention, described above. Said

15 mixtures can be used for a variety of purposes, such as in treatment or diagnosis of disease, and may replace, or be used in addition to, monoclonal or polyclonal antibodies.

20 The methods according to the present invention may suitably use nucleic acid molecules for encoding the antibodies, which nucleic acid molecules have been obtained by any suitable method, including in vivo, e.g. immunization, methods or in vitro, e.g. antibody display

25 methods (A. Plückthun et al, In vitro selection and evolution of proteins. In: Adv. Prot. Chem., F.M. Richards et al, Eds, Academic Press, San Diego, 2001, vol 55: 367-403), such as phage display, ribosome display or mRNA display (C. Schaffitzel et al., In vitro selection

30 and evolution of protein-ligand interactions by ribosome display. In: Protein-Protein Interactions. A Molecular Cloning Manual, E. Golemis, Ed., Cold Spring Harbor

Laboratory Press, New York, 2001, pp 535-567), and yeast display (e.g. WO 99/36569). Methods of identifying antibodies to a certain target, which target may be a known antigen or an unknown antigen present in an antigenic mixture, by phage display are known to the person skilled in the art. In general, a library of phages that express an antigen binding domain or derivative thereof on their surface, said antigen binding domain encoded by genetic material present in said phages, is incubated with the antigen or antigen mixture of interest, after which binding of a subpopulation of the phages that display antigen binding sites binding to the desired antigen is obtained whereas the non-binding phages are discarded. Such selection steps may be repeated one, two, or more times to obtain a population of phages that are more or less specific for the antigen of interest. Phage display methods to obtain antibodies, parts or derivatives thereof have been extensively described in e.g. (CF Barbas III et al, Phage Display. A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001). The library used for such screening may be generated by using the genetic information of one or more light chains, combined with genetic information encoding a plurality of heavy chains. The library described by De Kruif et al. (1995b) comprises 7 light chains. Therefore, in a panel of phages binding to a target, which can e.g. be obtained by methods described in De Kruif et al (supra); US patent 6,265,150; not more than 7 different light chains will be represented, and if the panel is large enough, several phages with the same light chain coupled to unrelated heavy chains may be found. Such phages can be used to

obtain the nucleic acid molecules useful in the methods according to the present invention.

It is another aspect of the present invention to provide a method for producing a mixture of antibodies to a target, the method comprising the steps of: i) bringing an antibody display library comprising antibodies or antibody fragments into contact with material comprising a target, ii) at least one step of selecting antibodies or antibody fragments binding to said target, iii) identifying at least two antibodies or antibody fragments binding to said target, wherein said at least two antibodies or antibody fragments comprise a common light chain, iv) introducing a nucleic acid sequence encoding the light chain and a nucleic acid sequence or nucleic acid sequences encoding the heavy chains of said at least two antibodies into a host cell, v) culturing a clone of said host cell under conditions conducive to expression of said nucleic acid sequences. The antibody display library may be a phage display library, a ribosome display library, an mRNA display library, or a yeast display library. Step i) and ii) may optionally be repeated one or more times.

The nucleic acid sequences encoding the antibodies obtained by the phage display, ribosome display or yeast display method may be converted to encode any desired antibody format such as IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgD, IgE, before introducing them into a host cell, using standard molecular cloning methods and means known to the person skilled in the art (e.g. described in Boel et al, 2000).

It will be clear to the skilled person that libraries in which only one light chain is represented are especially

light chain but different specificities (see e.g. example 1: antibodies binding to EpCAM and to CD46, described in WO 01/48485 and WO 02/18948, respectively). Besides screening a phage library against a target, it will be
5 also possible to start with an antibody that has already proven its merits, and use the light chain of this antibody in the preparation of a library of heavy chains combined with this particular light chain only, according to methods known to the person skilled in the art, such
10 as phage display. Using this strategy, a monoclonal antibody can be used to obtain a mixture of antibodies according to the invention, functionally resembling a polyclonal or oligoclonal antibody to the same target. Alternatively, a method reminiscent of the method
15 described by Jespers et al (1994) to obtain a human antibody based on a functional rodent antibody can be used. The heavy chain of a known antibody of non-human origin is first cloned and paired as a template chain with a repertoire of human light chains for use in phage
20 display, after which the phages are selected for binding to the antigen or mixture of antigens. The selected light chain is in turn paired with a repertoire of human heavy chains displayed on a phage, and the phages are selected again to find several heavy chains that when paired with
25 the light chain are able to bind to the antigen or mixture of antigens of interest. This enables creating a mixture of human antibodies against a target for which thus far only a non-human monoclonal antibody is described. It is possible that a mixture according to the
30 present invention already has beneficial functional effects when the individual antibodies do not have high affinities for the target, whereas high affinities are

useful in light of the present invention, since all antibodies that can be obtained from such a library, will have a common light chain that is functional in binding target antigen with each of the heavy chains. In other words, in accordance with the methods of the invention the formation of non-functional light chain-heavy chain dimers is avoided. Phage antibody display libraries having extensive H chain repertoires and unique or very few L chain sequences have been disclosed in the art (Nissim et al, 1994; Vaughan et al, 1996). In general, the specificity of an antibody appears to be determined to a large extent by its heavy chain, which is supported by the following observations. In the process of receptor editing, a mechanism of B-cells to monitor if their immunoglobulin receptor encodes a potentially harmful autoantibody, B-cells expressing an autoantibody replace the expressed heavy chain with another heavy chain while retaining the the expressed light chain. Thus, a new antibody specificity is generated that does not encode an autoantibody. This shows that a single light chain can successfully dimerize with multiple heavy chains to form different antibody specificities (Nemazee, 2000; Casellas et al, 2001). Series of transfected cell lines using a single heavy chain gene with different light chain genes have been reported, the antibodies produced to a large extent maintaining their specificity, regardless of the light chain (Radic et al, 1991). Different antibodies have been obtained from a library that has been constructed using a single light chain (Nissim et al, 1994). We have obtained several antibodies from the library described by De Kruif et al (1995), which was constructed using 7 light chains, that have the same

often required for monoclonal antibodies to be effective. This would have the advantage that affinity maturation may be required in less instances for methods and mixtures according to the present invention than when an
5 approach with monoclonal antibodies is envisaged.

The heavy and light chain coding sequences can be introduced simultaneously or consecutively into the host cell. It is also an aspect of the invention to prepare a
10 host cell comprising a recombinant nucleic acid encoding a light chain of an antibody. Such a cell can for instance be obtained by transfection of said nucleic acid, and optionally a clone can be identified that has a high expression of the light chain. An established clone
15 may then be used to add genetic information encoding 2, 3, 4, 5, 6, 7, 8, 9, 10, or more heavy chains of the invention by introducing the nucleic acid molecules encoding these into cells of the clone that already contains the light chain. The nucleic acid molecules
20 encoding the heavy chains may be introduced into said host cell concomitantly. It is of course also possible to introduce them consecutively, e.g. by using different selection markers, which can be advantageous if not all heavy chains can be introduced simultaneously because the
25 cells do not take up enough copies of recombinant nucleic acid molecules. Methods to introduce recombinant nucleic acid molecules into host cells are well known to the person skilled in the art, and include transfection, electroporation, calcium phosphate precipitation, virus
30 infection, and the like. The skilled person has several possibilities to introduce more vectors with nucleic acid sequences of interest into the same host cell, see e.g.

Sambrook, Fritsch and Maniatis, Molecular Cloning: A Laboratory Manual, 2nd edition, 1989; Current Protocols in Molecular Biology, Ausubel FM, et al, eds, 1987; the series Methods in Enzymology (Academic Press, Inc.).

5 Suitable dominant selection markers for introducing nucleic acids into eukaryotic host cells according to the invention may be G418 or neomycin (geneticin), hygromycin or mycophenolic acid, puromycin, and the like, for which genes encoding resistance are available on expression

10 vectors. Further possibilities include for instance the use of vectors containing DHFR genes or glutamate synthetase to select in the presence of methotrexate in a DHFR⁻ cell or the absence of glutamine in a glutamine auxotroph, respectively. The use of expression vectors

15 with different selection markers enables subsequent transfections with heavy chain sequences of interest into the host cell, which already stably contains other heavy chains introduced previously by use of other selection markers. It is also possible to use selection markers

20 that can be used more than once, e.g. when containing mutations, introns, or weakened promoters that render them concentration dependent (e.g. EP0724639; WO01/32901; US patent 5,733,779). Alternatively, a selection marker may be re-used by deleting it from the host cell after

25 use, e.g. by site-specific recombination. A selectable marker located between sequences recognized by a site-specific recombinase, e.g. lox-sites or FRT-sites, is used for the generation of the first stable transfectant (see for Cre-lox site-specific recombination Wilson and

30 Kola, 2001). Subsequently, the selectable marker is excised from the host cell DNA by the matching site-specific recombinase, e.g. Cre or Flp. A subsequent

transfection can suitably use the same selection marker. Different host cell clones each comprising the genetic information encoding a different light chain may be prepared. If the antibodies are identified by an antibody display method, it is thus possible to prepare several host cells, each comprising one light chain present in the antibody display library. After identifying antibodies that bind to a target using antibody display, the nucleic acid molecules encoding the heavy chains can be introduced into the host cell containing the common light chain that is capable of pairing to the heavy chains. It is therefore an aspect of the present invention to provide a method for making a host cell for production of a mixture of antibodies, the method comprising the steps of: introducing into said host cell a nucleic acid sequence encoding a light chain and nucleic acid sequence or sequences encoding 3, 4, 5, 6, 7, 8, 9, 10, or more different heavy chains that are capable of pairing with said light chain, wherein said nucleic acid molecules are introduced consecutively or simultaneously. It is of course also possible to introduce at least two of said nucleic acid molecules simultaneously, and introduce at least one other of said nucleic acid molecules consecutively. In yet another aspect according to the invention, a method is provided for making a recombinant host cell for production of a mixture of antibodies, the method comprising the step of: introducing a nucleic acid sequence or nucleic acid sequences encoding 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different heavy chains into a recombinant host cell comprising a nucleic acid sequence encoding a light chain

capable of pairing with at least two of said heavy chains.

In case it would appear that a recombinant host cell according to the invention does not express sufficient
5 light chain to dimerize with all of the expressed at least two heavy chains, extra copies of the nucleic acid molecules encoding the light chain may be transfected into the cell.

Besides random integration after transfection,
10 methods to integrate the transgenes in predetermined positions of the genome resulting in favorable expression levels, can also be used according to the invention. Such methods may for instance employ site-specific integration by homologous recombination (see e.g. WO 98/41645), or
15 make use of site-specific recombinases (Gorman and Bullock, 2000).

It is yet another aspect of the present invention to provide a transgenic non-human mammal or a transgenic
20 plant comprising a nucleic acid sequence encoding a light chain and a nucleic acid sequence or nucleic acid sequences encoding at least two different heavy chains that are capable of pairing with said light chain, wherein said nucleic acid sequences encoding said light
25 and heavy chains are under the control of a tissue-specific promoter. Promoters in plants may also be non-tissue specific, and general gene expression elements, such as the CaMV 35S promoter and nopaline synthase polyA addition site can also be used. Said light chain is a
30 common light chain according to the invention. In specific embodiments, the transgenic animal or plant according to the invention comprises 3, 4, 5, 6, 7, 8, 9,

10, or more heavy chain sequences. Besides cell culture as a production system for recombinant proteins, the art also discloses the use of transgenic animals, transgenic plants, and for instance transgenic chickens to produce
5 proteins in the eggs, and the like to produce recombinant proteins of interest (Pollock et al, 1999; Larrick and Thomas, 2001; WO 91/08216). These usually comprise the recombinant gene or genes encoding one or more proteins of interest in operable association with a tissue-
10 specific promoter. It has for instance been shown that recombinant antibodies can be produced at high levels in the milk of transgenic animals, that contain the nucleic acids encoding a heavy and a light chain behind a mammary gland specific promoter (e.g. Pollock et al, 1999; WO
15 95/17085). Particularly useful in this respect are cows, sheep, goats, pigs, rabbits, mice, and the like, which can be milked to obtain antibodies. Useful promoters are the casein promoters, such as the β -casein promoter, the α S1-casein promoter, the whey acidic protein (WAP)
20 promoter, the β -lactoglobulin promoter, the α -lactalbumin promoter, and the like. Production of biopharmaceutical proteins in the milk of transgenic mammals has been extensively described (e.g. Pollock et al, 1999). Besides mammary gland specific promoters, also other tissue-
25 specific promoters may be used, directing the expression to the blood, urine, saliva, and the like. The generation of transgenic animals comprising recombinant nucleic acid molecules has been extensively documented, and may include micro-injection of oocytes (see e.g. Wilmut and
30 Clark, 1991), nuclear transfer after transfection (e.g. Schnieke et al, 1997), infection by recombinant viruses (e.g. US patent 6291740), and the like. Nuclear transfer

and cloning methods for mammalian cells are known to the person skilled in the art, and are e.g. described in (Campbell et al, 1996; Wilmut et al, 1997; Dinnyes et al, 2002; WO 95/17500; WO 98/39416). It is nowadays possible
5 to clone most of these animals, to generate lines of animals that are genetically identical, which renders it possible for a person skilled in the art to create such a line once an individual animal producing the desired mixture of antibodies has been identified. Alternatively,
10 classical breeding methods can be used to generate transgenic offspring. Strategies for the generation of transgenic animals for production of recombinant proteins in milk are described in Brink et al, 2000.

Transgenic plants or plant cells producing
15 antibodies have also been described (Hiatt et al, 1989; Peeters et al, 2001), and useful plants for this purpose include corn, maize, tobacco, soybean, alfalfa, rice, and the like. Constitutive promoters that can for instance be used in plant cells are the CaMV 35S and 19S promoters,
20 Agrobacterium promoters *nos* and *ocs*. Other useful promoters are light inducible promoters such as *rbcS*. Tissue-specific promoters can for instance be seed-specific, such as promoters from zein, napin, beta-phaseolin, ubiquitin, or tuber-specific, leaf-specific
25 (e.g. useful in tobacco), root-specific, and the like. It is also possible to transform the plastid organelle by homologous recombination, to express proteins in plants. Methods and means for expression of proteins in recombinant plants or parts thereof, or recombinant plant
30 cell culture, are known to the person skilled in the art and have been for instance been described in (Giddings et al, 2000; WO 01/64929; WO 97/42313; US patents 5888789,

6080560; See for practical guidelines: Methods In
Molecular Biology vol. 49 "Plant Gene Transfer And
Expression Protocols", Jones H, 1995). Other transgenic
systems for producing recombinant proteins have also been
5 described, including the use of transgenic birds to
produce recombinant proteins in eggs (e.g WO 97/47739),
and the use of transgenic fish (e.g. WO 98/15627), and
can be used in combination with the teachings of the
present invention to obtain mixtures of antibodies. It is
10 also possible to use an in vitro transcription/translation
or in vitro translation system for the expression of
mixtures of antibodies according to the present
invention. It will be clear to the skilled person that
the teachings of the current invention will allow
15 producing mixtures of antibodies in systems where
recombinant nucleic acid encoding the light chain and
heavy chains can be introduced and expressed. Preferably
such systems are able to produce antibodies encoded by
said nucleic acid sequences, without the use of
20 amplification of said nucleic acid sequences in said
systems. In another aspect of the invention, a cell from
a transgenic non-human animal or a transgenic plant
according to the invention is provided. Such cells can be
used to generate the animals or plants according to the
25 invention, using techniques known to the person skilled
in the art, such as nuclear transfer or other known
methods of cloning whole organisms from single cells. The
cells according to the invention may also be obtained by
introducing the light and at least two heavy chain
30 sequences into isolated cells of non-human animals or
plants, which cells are capable of becoming part of a
transgenic animal or plant. Particularly useful for such

purposes are embryonic stem cells. These can contribute to the germ line, and therefore the genetic information introduced into such cells can be passed to future generations. In addition, plant cell cultures of cotton, corn, tomato, soybean, potato, petunia, and tobacco can be utilized as hosts, when transformed with the nucleic acid molecules encoding the light chain and the heavy chains, e.g. by use of the plant transforming bacterium *Agrobacterium tumefaciens* or by particle bombardment, or by infecting with recombinant plant viruses.

It is another aspect of the present invention to provide a pharmaceutical composition comprising a mixture of recombinantly produced antibodies and a suitable carrier, wherein at least two different heavy chains are represented in said mixture of recombinantly produced antibodies. Pharmaceutically acceptable carriers as used herein are exemplified, but not limited to, adjuvants, solid carriers, water, buffers, or other carriers used in the art to hold therapeutic components, or combinations thereof. In particular embodiments, 3, 4, 5, 6, 7, 8, 9, 10, or more different heavy chains are represented in said mixture. Said mixture can be obtained by mixing recombinantly produced monoclonal antibodies, but may also be obtained by methods according to the present invention. Said mixture may therefore comprise a common light chain for said antibodies. Said mixture may comprise bispecific antibodies. Said mixture may be produced from a clone that was derived from a single host cell, i.e. from a population of cells containing the same recombinant nucleic acid molecules. The term "recombinantly produced" as used herein refers to

production by host cells that produce antibodies encoded by recombinant nucleic acids introduced in such host cells or ancestors thereof. It does therefore not include the classical method of producing polyclonal antibodies, whereby a subject is immunized with an antigen or antigen comprising mixture, after which the antibodies produced by this subject are recovered from the subject, e.g. from the blood.

10 It is another aspect of the present invention to provide a mixture of antibodies wherein at least two heavy chains are represented, for use in the treatment or diagnosis of a human or animal subject. In another aspect, the invention provides the use of a mixture of
15 antibodies wherein at least two different heavy chains are represented, for the preparation of a medicament for use in the treatment or diagnosis of a disease or disorder in a human or animal subject. In particular embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more heavy
20 chains are represented in said mixture. Said mixtures of antibodies may be mixtures of antibodies according to the invention, or obtained by methods according to the invention. Antibodies present in said mixture may preferably comprise a common light chain. The mixtures
25 may comprise bispecific antibodies, and may be recombinantly produced from a clone that was derived from a single host cell, i.e. from a population of cells containing the same recombinant nucleic acid molecules. The targets may be used to screen an antibody display
30 library, as described supra, to obtain 2, 3, 4, 5, 6, 7, 8, 9, 10, or more antibodies comprising a common light chain that bind to the target, and produce a mixture of

these according to the teachings of the present invention. Virtually any area of medicine where monoclonal antibodies can be used is amenable for the use of the mixtures according to the invention. This can e.g.

5 include treatment of auto-immune diseases and cancer, including solid tumors of the brain, head- and neck, breast, prostate, colon, lung, and the like, as well as hematologic tumors such as B-cell tumors. Neoplastic disorders which can be treated with the mixtures

10 according to the present invention include leukemias, lymphomas, sarcomas, carcinomas, neural cell tumors, squamous cell carcinomas, germ cell tumors, metastases, undifferentiated tumors, seminomas, melanomas, myelomas, neuroblastomas, mixed cell tumors, neoplasias caused by

15 infectious agents, and other malignancies. Targets for the antibody mixtures may include, but are not limited to, the HER-2/Neu receptor, other growth factor receptors such as VEGFR1 and VEGFR2 receptor, B-cell markers such as CD19, CD20, CD22, CD37, CD72, etc, T-cell markers such

20 as CD3, CD25, etc, other leukocyte cell surface markers such as CD33 or HLA-DR, etc, cytokines such as TNF, interleukins, receptors for these cytokines such as members of the TNF receptor family, and the like. It is anticipated that the use of such mixtures of antibodies

25 in the treatment of cancerous tissues or other complex multi-antigen comprising cells such as microorganisms or viruses will give rise to less occurrence of epitope-loss escape variants than the use of single monoclonal antibodies. Several treatments nowadays use polyclonal

30 mixtures of antibodies, which are derived from immunized humans or animals. These treatments may be replaced by use of the mixtures according to the present invention.

Use of these mixtures can also include use in graft-versus-host rejections, known in the art of transplantation, e.g. by use of anti-thymocyte antibodies. It is anticipated that the mixtures of
5 antibodies are superior to monoclonal antibodies in the treatment of complex antigens or antigen comprising mixtures such as bacteria or viruses. Therefore, use according to the invention can also include use against strains of bacteria and fungi, e.g. in the treatment of
10 infectious diseases due to pathogenic bacteria such as multidrug resistant *S.aureus* and the like, fungi such as *Candida albicans* and *Aspergillus* species, yeast and the like. The mixtures according to the invention may also be used for post exposure profylaxis against viruses, such
15 as members of the genus *Lyssavirus* e.g. rabies virus, or for therapeutic or prophylactic use against viruses such as *Varicella-Zoster Virus*, *Adenoviruses*, *Respiratory Syncytium Virus*, *Human Immunodeficiency Virus*, *Human Metapneumovirus*, *Influenzavirus*, *West Nile Virus*, the
20 virus causing *Severe Acute Respiratory Syndrome (SARS)*, and the like. Mixtures according to the inventions can also be used to protect against agents, both bacteria and viruses, and against toxic substances that are potential threats of biological warfare. Therefore, use according
25 to the invention can also include use against strains of bacteria such as *Bacillus anthracis*, *Clostridium botulinum* toxin, *Clostridium perfringens* epsilon toxin *Yersinia Pestis*, *Francisella tulariensis*, *Coxiella burnetii*, *Brucella* species, *Staphylococcus enterotoxin B*,
30 or against viruses such as *Variola major*, alphaviruses causing meningoencephalitis syndromes (EEEV, VEEV, and WEEV), viruses known to cause hemorrhagic fevers such as

Ebola, Marburg and Junin virus or against viruses such as Nipah virus, Hantaviruses, Tickborne encephalitis virus and Yellow fever virus or against toxins e.g. Ricin toxin from *Ricinus communis* and the like. Use of the mixtures according to the invention can also include use against unicellular or multicellular parasites. Recombinant mixtures of antibodies according to the invention may become a safe alternative to polyclonal antibodies obtained from pools of human sera for passive immunization, or from sera of hyper-immunized animals. The mixtures may be more efficacious than recombinant monoclonal antibodies in various therapeutic applications, including cancer, allergy, viral diseases, chronic inflammation, and the like.

It has been described that homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells (Ghetie et al, 1997). Possibly, when antibodies against receptors or other surface antigens on target cells, such as tumor cells or infectious microorganisms, are produced according to the present invention, the bispecific antibodies present in mixtures according to the invention may also crosslink different receptors or other antigens on the surface of target cells, and therefore such mixtures may be very suitable for killing such cells. Alternatively, when bispecific antibodies are less desirable, the present invention also provides methods to recombinantly produce mixtures of antibodies comprising mainly monospecific antibodies. It has been described that the efficacy of treatment with RituximabTM (anti-CD20 monoclonal antibody) was increased when anti-CD59 antibodies were added (Herjunpaa et al, 2000).

Therefore, it is expected that inclusion of antibodies against CD59 in a mixture according to the invention comprising anti-tumor antibodies in the form of B-cell receptor recognizing antibodies increases the sensitivity of tumor cells to complement attack. It has also been shown that a triple combination cocktail of anti-CD19, anti-CD22, and anti-CD38-saporin immunotoxins is much more effective than the individual components in the treatment of human B-cell lymphoma in an immunodeficient mouse model (Flavell et al, 1997). Many other combinations may also be feasible and can be designed by the person skilled in the art. In general, the use of antibody mixtures that are capable of recognizing multiple B-cell epitopes will likely decrease the occurrence of escape variants.

Another possible target is a transmembrane tyrosine kinase receptor, encoded by the Her-2/Neu (ErbB2) proto-oncogene (see e.g. US patents 5,772,997 and 5,783,186 for anti-Her2 antibodies). Her-2 is overexpressed on 30% of highly malignant breast cancers, and successful antibodies against this target, marketed under the name HerceptinTM (Trastuzumab), have been developed. It has been shown that targeting multiple Her-2 epitopes with a mixture of monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo (Spiridon et al, 2002). Her-2 may therefore be a good target for antibody mixtures according to the present invention. Antibodies useful for this purpose can be obtained by methods described in the present invention, including antibody display methods.

Human antibodies are capable of eliciting effector

function via binding to immunoglobulin receptors on immune effector cells. Human IgG, and in particular IgG₁ and IgG₃, fix complement to induce CDC and interact with Fc γ receptors to induce antibody dependent cell mediated cytotoxicity (ADCC), phagocytosis, endocytosis, induction of respiratory burst and release of inflammatory mediators and cytokines. Human IgA interacts with Fc α R, also to result in efficient activation of ADCC and phagocytosis of target cells. Hence, due to the differential distribution of Fc γ R and Fc α R on peripheral blood cells (Huls et al., 1999), using a mixture of antibodies directed against the target and consisting of both IgG and IgA would potentially maximize the recruitment and activation of different immune effector cells. Such a mixture of both IgG and IgA could be obtained by producing the IgG and IgA monoclonal antibody in a separate production process using two distinct production cell lines, but could also be obtained from a single cell line producing both the IgG and the IgA monoclonal antibody. This would have the advantage that only a single production process has to be developed. Thus when different heavy chains are mentioned, also heavy chains differing in their constant regions are encompassed in the invention. The principle of using a common light chain can also be used for the production of a mixture of isotypes from a host cell. It is therefore yet another aspect of the present invention to provide a method for producing a mixture of antibodies comprising different isotypes from a host cell, the method comprising the step of: culturing a host cell comprising a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding at least two heavy chains

of different isotype that are capable of pairing with said light chain, under conditions conducive to expression of said nucleic acid sequences. According to this aspect of the invention, different heavy chains may have identical variable regions, and only differ in their constant regions (i.e. be of different isotype and have the same specificity). In a particular embodiment, said isotypes comprise at least an IgG and an IgA and/or IgM, preferably IgG1 or IgG3 and IgA. Other combinations of IgG1, IgG2, IgG3 and IgG4 can also be used. In these embodiments, bispecific antibodies will not be produced because the variable regions are the same.

In other embodiments according to this aspect of the invention, not only the constant regions of the heavy chains may differ, but also the variable regions, thereby giving rise to different specificities, paired with the same light chain. When bispecific antibodies are not desired for a given purpose, e.g. because the mixtures of antibodies are less efficacious because of the presence of the bispecific antibodies, it is possible to use at least two heavy chains combined with the common light chain according to the invention wherein said heavy chains differ sufficient in their constant regions to reduce or prevent pairing between the different heavy chains, e.g. by using heavy chains of different isotypes, e.g. an IgG1 and an IgG3 (see Fig. 11 for a schematic representation). It is anticipated that the heavy chains of different isotype will pair much less efficient, if at all, compared to the same heavy chains. Alternatively, it is also possible to engineer the different heavy chains in their constant region such that homodimerization is favored over heterodimerization, e.g. by introducing

self-complementary interactions (see e.g. WO 98/50431 for possibilities, such as "protuberance-into-cavity" strategies (see WO 96/27011)). It is therefore another aspect of the present invention to provide a method for
5 producing a mixture of antibodies in a recombinant host, the method including the step of: expressing in a recombinant host cell a nucleic acid sequence encoding a common light chain and nucleic acid sequences encoding at least two different heavy chains that differ in the
10 variable region and that are capable of pairing with said common light chain, and wherein said heavy chains further differ in their constant regions sufficiently to reduce or prevent pairing between the different heavy chains. In one embodiment, said heavy chains are of different
15 isotype. In specific embodiments, 3, 4, 5, 6, 7, 8, 9, 10, or more different heavy chains are expressed. Mixtures of antibodies obtainable by this method are also embodied in the present invention. Such mixtures will comprise mainly monospecific antibodies.

20 The teachings of the present invention can also be used to obtain novel multispecific antibodies or mixtures thereof. Therefore, in another aspect, the invention provides a method for producing a mixture of antibodies comprising dimeric IgA isotype $\{(IgA)_2\}$ antibodies in a
25 recombinant host, wherein at least part of said dimeric IgA antibodies have different binding regions in each of the IgA subunits, the method comprising the step of: expressing in a recombinant host cell a nucleic acid sequence encoding a common light chain and nucleic acid
30 sequences encoding at least two different heavy chains of IgA isotype capable of pairing to said common light chain, wherein said different heavy chains differ in

their variable region. Dimerization of the IgA molecules can be enhanced by co-expressing J-chain (Yoo et al, 1999). Said dimeric IgA antibodies have two specificities (see Fig. 9 for a schematic representation of one possible form produced and present in the mixture). In yet another aspect the invention provides a method for producing a mixture of antibodies comprising an IgM antibody having at least two different specificities, the method comprising the step of expressing in a recombinant host cell a nucleic acid sequence encoding a common light chain and nucleic acid sequences encoding at least two different heavy chains of IgM isotype, wherein said heavy chains are capable of pairing to said common light chain and form functional antigen binding regions. Up to five specificities can be comprised in an IgM pentamer in the presence of J-chain, and up to six in an IgM hexamer in the absence of J-chain (Yoo et al, 1999). Therefore, in specific embodiments, 3, 4, 5, or 6 IgM heavy chains are co-expressed with the common light chain according to this aspect of the invention. See Fig. 10 for a schematic representation of one of the possible forms that can be produced and present in the mixture according to this aspect of the invention, when five different heavy chains are expressed with a common light chain. The invention also provides for IgA dimers, IgM pentamers or hexamers having at least two different specificities. These molecules can be produced from a clone of a single host cell according to the invention. Such molecules, harbouring antigen binding regions with different specificities, can bind different epitopes on the same antigen, different antigens on one cell, or different antigens on different cells, thereby crosslinking the

antigens or cells.

It is yet another aspect of the present invention to provide a method for identifying a mixture of antibodies having a desired effect in a functional assay, the method comprising the steps of i) adding a mixture of antibodies in a functional assay, and ii) determining the effect of said mixture in said assay, wherein said mixture of antibodies comprises antibodies having a common light chain. In a preferred embodiment said mixture is comprised in a composition according to the present invention.

15 **Examples**

The following examples are provided to illustrate the invention, and are not to be construed in any way to limit the scope of the invention. The practice of this invention will employ, unless otherwise indicated, conventional techniques of immunology, molecular biology, microbiology, cell biology, and recombinant DNA, which are within the skill of the art. See e.g. Sambrook, Fritsch and Maniatis, Molecular Cloning: A Laboratory Manual, 2nd edition, 1989; Current Protocols in Molecular Biology, Ausubel FM, et al, eds, 1987; the series Methods in Enzymology (Academic Press, Inc.); PCR2: A Practical Approach, MacPherson MJ, Hams BD, Taylor GR, eds, 1995; Antibodies: A Laboratory Manual, Harlow and Lane, eds, 1988.

30

Example 1 Production of a mixture of monoclonal

antibodies with a common light chain and two different heavy chain variable regions in a single cell

Clone UBS-54 and Clone K53 were previously isolated by selections on the colorectal cell line SW40 (Huls et al., 1999) and on a heterogeneous mixture of mononuclear cells of a patient with multiple myeloma (WO 02/18948), respectively, with a semi-synthetic library (de Kruif et al., 1995b). Further studies revealed that clone UBS-54 and K53 bound to the EP-CAM homotypic adhesion molecule (Huls et al., 1999) and the membrane cofactor protein CD46 (WO 02/18948), respectively. DNA sequencing of the clones revealed that they were unique in the Heavy chain CDRs, but that they contained an identical light chain sequence (Fig. 3). The V_H and V_L of clones UBS-54 and K53 were inserted into an expression vector containing the HAVT20 leader sequence and all the coding sequences for the constant domains of a human IgG1 with a Kappa light chain by a method essentially as described (Boel et al., 2000), which resulted in plasmids pUBS3000Neo and pCD46_3000(Neo) (Fig. 4). These plasmids were transiently expressed either alone or in combination in PER.C6TM cells. In brief, each 80 cm² flask was transfected by incubation for 4 hours with 140 μ l lipofectamine + 10 μ g DNA (either pUBS3000Neo, pCD46_3000(Neo) or 10 μ g of both) in serum-free DMEM medium at 37°C. After 4 hours, this was replaced with DMEM + 10% FBS, and the cells were grown overnight at 37°C. Cells were then washed with PBS and the medium was replaced with Excell 525 medium (JRH Bioscience). The cells were allowed to grow at 37°C for 6 days, after which the cell culture supernatant was harvested. Human IgG specific ELISA analysis (described in WO 00/63403) indicated that IgG was present at

approximately 10 µg/ml for all flasks containing expression plasmids. No IgG1 was present in a control flask which was not transfected with expression plasmid. Human IgG from each supernatant was subsequently purified using Protein A affinity chromatography (Hightrap Protein A HP, cat.no. 1-040203) according to standard procedures, following recommendations of the manufacturer (Amersham Biosciences). After elution, samples were concentrated in a Microcon YM30 concentrator (Amicon) and buffer exchanged to 10 mM sodium phosphate, pH 6.7. Twelve µg of purified IgG was subsequently analyzed on Isoelectric focusing gels (Serva Pre-cast IEF gels, pH range 3-10, cat.no. 42866). The samples were loaded on the low pH side and after focussing stained with colloidal blue (Fig. 5). Lane 1 shows transiently expressed K53, Lane 2 shows transiently expressed UBS-54 and Lane 3 shows the IgG sample of the cells in which both antibodies were co-transfected. Clearly, K53 and UBS-54 each have a unique pI profile and the sample from the cotransfection showed other unique isoforms, with the major isoform having a pI in between those of K53 and UBS-54. This is also anticipated on the basis of the theoretic pI when calculated with the ProtParam tool provided on the Expasy homepage (<http://www.expasy.ch>; Appel et al., 1994). K53 and UBS-54 have a theoretic pI of 8.24 and 7.65, respectively, whereas an isoform representing a heterodimer of one UBS-54 heavy chain and one K53 heavy chain has a theoretical pI of 8.01. Assembly of such a heterodimer can only occur when a single cell translates both the heavy chain of K53 and the heavy chain of UBS-54 and assembles these into a full length IgG molecule together with the common light chain.

Therefore, this experiment shows that it is possible to express two unique human IgG molecules in a single cell and that a heterodimer consisting of these two unique binding specificities is also efficiently formed.

5

**Example 2 Production of a mixture of antibodies
against human B-cell markers in a PER.C6TM cell line
derived clone.**

10 A method for producing a mixture of antibodies according
to the invention, using expression in a recombinant host
cell of a single light chain and three different heavy
chains capable of pairing to the single light chain to
form functional antibodies, is exemplified herein and is
15 schematically shown in Fig. 6. Phages encoding antibodies
capable of binding proteins present on human B-cells,
i.e. CD22, CD72 and Major Histocompatibility Complex
(MHC) class II (further referred to as HLA-DR) were
previously isolated from a semi-synthetic phage library
20 (de Kruif et al., 1995; van der Vuurst de Vries &
Logtenberg, 1999). DNA sequencing of the V_H and V_L
sequences of the phages clone B28 (anti-CD22), clone I-2
(anti-HLA-DR) and clone II-2 (anti-CD72) revealed that
they all contain a unique V_H sequence, but a common light
25 chain sequence (V λ 3) with an identical CDR region (Fig.
7).

The V_H and V_L sequences of clones B28, I-1 and II-2 are
cloned behind the HAVT20 leader sequences of an
expression plasmid comprising a heavy chain. An example
30 of such a plasmid is pCRU-K01 (contains kappa heavy chain
sequences, that can easily be interchanged for lambda
heavy chain sequences if desired, by a person skilled in

the art), as deposited at the ECACC under number 03041601. The cloning gives rise to plasmids encoding a full length human IgG₁ with binding specificities for CD22, CD72 and HLA-DR. These plasmids will further be referred to as pCRU-CD22, pCRU-CD72 and pCRU-HLA-DR, respectively.

Stable PER.C6TM derived cell lines are generated, according to methods known to the person skilled in the art (see e.g. WO 00/63403), the cell lines expressing antibodies encoded by genetic information on either pCRU-CD22, pCRU-CD72 or pCRU-HLA-DR and a cell line expressing antibodies encoded by all three plasmids. Therefore, PER.C6TM cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture conditions (10% CO₂ concentration and 37°C). The next day, transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 µg pCRU-CD22, 1-2 µg pCRU-CD72, 1-2 µg pCRU-HLA-DR or 1 µg of a mixture of pCRU-CD22, pCRU-CD72 and pCRU-HLA-DR. As a control for transfection efficiency, a few dishes are transfected with a LacZ control vector, while a few dishes will be not transfected and serve as negative controls.

After 4 to 5 hours, cells are washed twice with DMEM and refed with fresh medium without selection. The next day, medium are replaced with fresh medium containing 500 µg/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22 days after seeding, a large number of colonies are

visible and from each transfection at least 300 are
picked and grown via 96-well and/or 24-well via 6-well
plates to T25 flasks. At this stage, cells are frozen (at
least 1, but usually 4 vials per sub-cultured colony) and
5 production levels of recombinant human IgG antibody are
determined in the supernatant using an ELISA specific for
human IgG₁ (described in WO 00/63403). Also, at this stage
G418 is removed from the culture medium and never re-
applied again. For a representative number of colonies
10 larger volumes will be cultured to purify the recombinant
human IgG₁ fraction from the conditioned supernatant using
Protein A affinity chromatography according to standard
procedures. Purified human IgG₁ from the various clones is
analyzed on SDS-PAGE, Iso-electric focusing (IEF) and
15 binding to the targets CD22, CD72 and HLA-DR using cell
transfectants expressing these human antigens on their
cell surface (transfectants expressing CD72 and HLA-DR
have been described by van der Vuurst-de Vries and
Logtenberg, 1999; a CD22 transfectant has been prepared
20 according to similar standard procedures in PER.C6TM).
Colonies obtained from the co-transfection with pCRU-
CD22, pCRU-CD72 and pCRU-HLA-DR are screened by PCR on
genomic DNA for the presence or absence of each of the
three constructs. The identity of the PCR products is
25 further confirmed by DNA sequencing.
Next, it is demonstrated that a clonal cell line accounts
for the production of each of the three binding
specificities, i.e. proving that a single cell is able to
produce a mixture of more than two functional human
30 IgG's. Therefore, a limited number of colonies, which
screened positive for the production of each of the three
binding specificities (both by PCR at the DNA level as

well as in the specified binding assays against CD22, CD72 and HLA-DR), are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton & Dickinson FACS VANTAGE SE). Alternatively, colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth. Clonal cell populations, hereafter designated as sub-clones, are refreshed once a week with fresh medium. Sub-clones are grown and transferred from 96-wells via 24- and 6-wells plates to T25 flasks. At this stage, sub-clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgG₁ antibody are determined in the supernatant using a human IgG₁ specific ELISA. For a representative number of sub-clones, larger volumes are cultured to purify the recombinant human IgG₁ fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures.

Purified human IgG₁ from the various sub-clones is subsequently analyzed as described above for human IgG₁ obtained from the parental clones, i.e. by SDS-PAGE, Isoelectric focusing (IEF) and binding to the targets CD22, CD72 and HLA-DR. Sub-clones will also be screened by PCR on genomic DNA for the presence or absence of each of the three constructs pCRU-CD22, pCRU-CD72 and pCRU-HLA-DR.

The identity of the PCR products is further confirmed by DNA sequencing.

Other methods such as Southern blot and/or FISH can also be used to determine whether each of the three constructs are present in the clonal cell line.

Sub-clones that are proven to be transgenic for each of the three constructs are brought into culture for an extensive period to determine whether the presence of the

transgenes is stable and whether expression of the antibody mixture remains the same, not only in terms of expression levels, but also for the ratio between the various antibody isoforms that are secreted from the cell. Therefore, the sub-clone culture is maintained for at least 25 population doubling times either as an adherent culture or as a suspension culture. At every 4-6 population doublings, a specific production test is performed using the human IgG specific ELISA and larger volumes are cultured to obtain the cell pellet and the supernatant. The cell pellet is used to assess the presence of the three constructs in the genomic DNA, either via PCR, Southern blot and/or FISH. The supernatant is used to purify the recombinant human IgG₁ fraction as described supra. Purified human IgG₁ obtained at the various population doublings is analyzed as described, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to the targets CD22, CD72 and HLA-DR using cell transfectants expressing these antigens.

20

Example 3 Screening of clones expressing multiple human IgGs for the most potent mixture of functional human IgGs

Functionality of the antibody mixture is analyzed in cell-based assays to determine whether the human IgG₁ mixture inhibits proliferation and/or induces apoptosis of B-cell lines, such as for example Ramos. Other cell lines can also be used. In addition the antibody mixtures are analyzed for their potential to induce antibody dependent cellular toxicity and complement dependent cytotoxicity of for example Ramos cells.

30

In each of the following experiments the functionality of the antibody mixture recognizing the targets CD22, CD72 and HLA-DR is analyzed and can be compared to each of the individual IgG1 antibodies and to an equimolar
5 combination of the three individual IgG1 specificities.

To assess the ability of the antibody mixtures to inhibit the proliferation of Ramos cells, these cells are incubated in 96-well plates ($0.1 - 1.0 \times 10^5/\text{ml}$) with
10 several concentrations ($5 - 20 \mu\text{g}/\text{ml}$) of the antibody mixtures against CD22, CD72 and HLA-DR for 24 hours. The proliferation of the cells is measured by ^3H -thymidine incorporation during another 16 hours of culture. Inhibition of growth is determined by plotting the
15 percentage of ^3H -thymidine incorporation compared to untreated cells (taken as 100% reference value).

To analyze apoptosis induction of Ramos cells, these cells are stimulated in 48-well plates ($0.2 - 1.0 \times 10^6/\text{ml}$) with several concentrations ($5 - 20 \mu\text{g}/\text{ml}$) of the
20 antibody mixtures against the targets CD22, CD72 and HLA-DR for 24 or 48 hours. After the incubation period the phosphatidyl serine exposure on apoptotic cells is analyzed (Koopman G et al, 1994). Therefore, the cells
25 are harvested, washed twice with PBS and are incubated at RT for 10 min with 100 μl FITC-labelled annexin V (Caltag) diluted 1:25 in annexin V binding buffer (Caltag). Prior to the analysis of the samples by flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA)
30 propidium iodide (PI) (Sigma) is added to a final concentration of $5 \mu\text{g}/\text{ml}$ to distinguish necrotic cells (annexin V-/PI+) from apoptotic cells (annexin V+/PI-,

early apoptotic cells; annexin V+/PI+, late apoptotic cells).

In an alternative assay, apoptosis is induced by crosslinking the antibody mixtures against CD22, CD72 and
5 HLA-DR on the cell surface of Ramos cells with 25 µg/ml of F(ab)2 of goat-anti-human (Fc-specific) polyclonal antibodies (Jackson Immunoresearch Laboratories, West Grove, PA) during the incubation period.

In another alternative assay, apoptosis is induced by
10 incubating the Ramos cells with several concentrations (5 - 20 µg/ml) of the antibody mixtures against CD22, CD72 and HLA-DR while co-incubating them with the chemosensitizing agents doxorubicin (Calbiochem) or dexamethasone (UMCU, Utrecht, the Netherlands).

15 Antibody Dependent Cellular Cytotoxicity of the antibody mixtures is analyzed using peripheral blood mononuclear cells as effector cells in a standard ⁵¹Cr release assay (Huls et al, 1999). To this purpose, 1-3 x 10⁶ Ramos cells
20 are labelled with 100 µCi (Amersham, Buckinghamshire, UK) for 1 hour at 37°C. After three washes with medium, the Ramos target cells are plated in U bottom 96 well plates at 5 x 10³ cells/well. Peripheral blood mononuclear cells that are obtained from healthy donors by Ficoll-Hypaque
25 density gradients are then added to each well at effector:target ratios ranging from 80:1 to 10:1 in triplicate. The cells are incubated at 37°C in the presence of various concentrations of the antibody mixtures (5 - 20 µg/ml) in a final volume of 200 µl.
30 After 4 hours of incubation part of the supernatant is harvested and ⁵¹Cr release is measured. The percentage of specific lysis is calculated using the following formula:

% specific lysis = ([experimental cpm - spontaneous cpm]/[maximal cpm - spontaneous cpm] x 100%). Maximal ⁵¹Cr release is determined by adding triton X-100 to a final concentration of 1% to the target cells and spontaneous
5 release is determined after incubation of the target cells with medium alone.

Complement dependent cytotoxicity is determined in a similar assay. Instead of the effector cells, now 50 µl human serum is added to the target cells. Subsequently,
10 the assay is performed in the same manner. Alternatively, ADCC and CDC of the antibody mixtures is determined using a Europium release assay (Patel and Boyd, 1995) or using an LDH release assay (Shields et al, 2001).

15

**Example 4 Use of phage display to isolate multiple phages with an identical V_L sequence against a predefined target (Her-2), and production in a recombinant host cell
20 of a mixture of antibodies capable of binding this target.**

Phages displaying scFv fragments capable of binding multiple epitopes present on the same protein, for example the epidermal growth factor receptor Her-2, can
25 be isolated from a semi-synthetic phage library (de Kruif et al., 1995a,b). It is possible to identify several of such phages and select the ones comprising the same light chain sequence, for further use according to the invention. The semi-synthetic library is formed by mixing
30 7 sub-libraries that each contain a different light chain (de Kruif et al, 1995a,b). It is therefore particularly practical to use such a sub-library, containing only one

light chain and many heavy chains, for screening so that multiple antibodies with an identical V_L sequence are obtained, and further used for expressing the antibody mixtures according to the invention.

5 For the selection of phages against Her-2 several fusion proteins are generated comprising different parts of the extracellular domain of Her-2 that are fused to the CH2 and CH3 domains of human IgG1. For this purpose a pCDNA3.1zeo expression vector (InVitrogen) has been
10 constructed that contains in its multiple cloning region an XhoI restriction site in the hinge region in frame prior to the CH2 and CH3 domains of human IgG1. Using a Her-2 cDNA clone as a template PCR fragments is generated using standard molecular biology techniques known to a
15 person skilled in the art. These fragments consist of a unique 5' restriction site, a start codon followed by a eukaryotic leader sequence that is linked in frame to either the total extracellular (EC) domain of Her-2 or to a part of the EC domain of Her-2 that is followed in
20 frame by an XhoI restriction site. These PCR fragments are subsequently cloned in frame with the CH2-CH3 IgG1 region into the pCDNA3.1zeo expression vector. In addition to the fusion protein containing the total EC domain of Her-2, several smaller fusion proteins are
25 generated containing non-overlapping fragments of the Her-2 EC domain. These constructs encoding the Her-2-Ig fusionproteins are used for transient transfection of 293T cells using the lipofectamine reagent (Gibco). Five days after transfection the supernatants of the 293T
30 cells are harvested and Her-2-Ig fusion proteins are purified using protein A affinity chromatography according to standard procedures.

Her-2-Ig fusion proteins containing non-overlapping fragments of the Her-2 EC domain are coated for 2 hours at 37° onto the surface of Maxisorp™ plastic tubes (Nunc) at a saturating concentration (0.5 - 5 µg/ml). The tubes
5 are blocked for 1 h in 2% fat free milk powder dissolved in PBS (MPBS). Simultaneously, 500 µl (approximately 10¹³ cfu) of a semi-synthetic phage display library (a sub-library according to the terminology used above) in which only one Vkappa1 light chain is represented prepared as
10 described by De Kruif et al (1995a,b) and references therein, is added to two volumes of 4% MPBS. In addition, human serum is added to a final concentration of 15% and blocking is allowed to proceed for 30-60 min. The Her-2-Ig-coated tubes are emptied and the blocked phage library
15 is added. The tube is sealed and rotated slowly for 1 h, followed by 2 h of incubation without rotation. The tubes are emptied and washed 10 times in PBS containing 0.1% Tween-20, followed by washing 5 times in PBS. 1 ml glycine-HCL, 0.05 M, pH 2.2 is added, and the tube is
20 rotated slowly for 10 min. The eluted phages are added to 500 µl 1M Tris-HCl pH 7.4. To this mixture, 3.5 ml of exponentially growing XL-1 blue bacterial culture is added. The tubes are incubated for 30 min at 37°C without shaking. Subsequently, the bacteria are plated on 2TY
25 agar plates containing ampicillin, tetracycline and glucose. After overnight incubation of the plates at 37°C, the colonies are scraped from the plates and used to prepare an enriched phage library, essentially as described by De Kruif et al. (1995a). Briefly, scraped
30 bacteria are used to inoculate 2TY medium containing ampicillin, tetracycline and glucose and are grown at 37°C to an OD_{600nm} of ~0.3. Helper phages are added and

allowed to infect the bacteria after which the medium is changed to 2TY containing ampicillin, tetracycline and kanamycin. Incubation is continued overnight at 30°C. The next day, the bacteria are removed from the 2TY medium by
5 centrifugation after which the phages are precipitated using polyethylene glycol 6000/NaCl. Finally, the phages are dissolved in a small volume of PBS-1% BSA, filter-sterilized and used for a next round of selection. The selection/re-infection procedure is performed twice.
10 After the second round of selection, individual *E.coli* colonies are used to prepare monoclonal phage antibodies. Essentially, individual colonies are grown to log-phase and infected with helper phages after which phage antibody production is allowed to proceed overnight.
15 Phage antibody containing supernatants are tested in ELISA for binding activity to Her-2-total EC-Ig coated 96 wells plates.

Selected phage antibodies that are obtained in the screen
20 described above, are validated by ELISA for specificity. For this purpose, Her-2-Ig fusion proteins containing non-overlapping fragments of the Her-2 EC domain are coated to Maxisorp ELISA plates. After coating, the plates are blocked in 2% MPBS. The selected phage
25 antibodies are incubated in an equal volume of 4% MPBS. The plates are emptied, washed once in PBS, after which the blocked phages are added. Incubation is allowed to proceed for 1 h, the plates are washed in PBS 0.1% Tween-20 and bound phages are detected using an anti-M13
30 antibody conjugated to peroxidase. The procedure is performed simultaneously using a control phage antibody

directed against thyroglobulin (De Kruif et al. 1995a,b), which serves as a negative control.

In another assay the selected phage antibodies are analyzed for their ability to bind BT474 human breast
5 cancer cells that express Her-2. For flow cytometry analysis, phage antibodies are first blocked in an equal volume of 4% MPBS for 15 min at 4°C prior to the staining of the BT474 cells. The binding of the phage antibodies to the cells is visualized using a biotinylated anti-M13
10 antibody (Santa Cruz Biotechnology) followed by streptavidin-phycoerythrin (Caltag).

Alternatively, phage antibodies recognizing multiple epitopes on Her-2 are selected using a method based upon
15 competition of phage binding to Her-2 with binding of the well characterized murine anti-Her-2 antibodies HER50, HER66 and HER70 (Spiridon et al, 2002). To this purpose 2×10^6 BT474 cells are incubated at 4°C with approximately 10^{13} cfu (0.5 ml) of a semi-synthetic phage
20 display library in which only one Vkappa1 light chain is represented prepared as described supra and blocked with 2 volumes of medium containing 10% of FBS. The mixture is slowly rotated at 4°C for 2 hours in a sealed tube. Subsequently, non-bound phages are removed by two washes
25 with 50 ml of cold medium containing 10% FBS. Hereafter, phages recognizing multiple epitopes on Her-2 are eluted by resuspending the BT474 cells in 1 ml of cold medium containing saturating concentrations (5-20 µg/ml) of the HER50, HER66 and HER70 murine anti-Her-2 antibodies. The
30 cells are left on ice for 10 min, spun down and the supernatant containing the anti-Her-2 phage antibodies is used to reinfect XL1-Blue cells as described supra.

From the panel of Her-2-specific phage antibodies generated by de screens described above, three phage antibodies are selected that are recognizing three
5 different non-overlapping epitopes on the Her-2 protein. The V_H sequences and the unique Vkappa1 light chain sequence of these clones, provisionally designated VK1HER2-1, VK1HER2-2 and VK1HER2-3, are cloned behind the
HAVT20 leader sequences of expression plasmid pCRU-K01
10 (ECACC deposit 03041601), or a similar expression plasmid, to obtain plasmids encoding a full length human IgG₁-kappa with binding specificities for Her-2. These plasmids are provisionally designated as pCRU-VK1HER2-1, pCRU-VK1HER2-2 and pCRU-VK1HER2-3, respectively.
15 Stable PER.C6TM derived cell lines are generated, according to methods known to the person skilled in the art, the cell lines expressing antibodies encoded by genetic information on either pCRU-VK1HER2-1, pCRU-VK1HER2-2 or pCRU-VK1HER2-3 and a cell line expressing
20 antibodies encoded by all three plasmids. Therefore, PER.C6TM cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture conditions (10% CO₂
25 concentration and 37°C). The next day, transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 µg pCRU-VK1HER2-1, 1-2 µg pCRU-VK1HER2-2, 1-2 µg pCRU-VK1HER2-3 or 1 µg of a mixture of pCRU-VK1HER2-1, pCRU-VK1HER2-2 and pCRU-VK1HER2-3. As a control for
30 transfection efficiency, a few dishes are transfected

with a LacZ control vector, while a few dishes are not transfected and serve as negative controls.

After 5 hours cells are washed twice with DMEM and refed with fresh medium without selection. The next day, medium
5 is replaced with fresh medium containing 500 µg/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22 days after seeding, a large number of colonies are visible and from each transfection at least 300 are
10 picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks. At this stage, cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG antibody are determined in the supernatant using an ELISA specific for
15 human IgG₁. Also, at this stage G418 is removed from the culture medium and never re-applied again. For a representative number of colonies larger volumes are cultured to purify the recombinant human IgG₁ fraction from the conditioned supernatant using Protein A affinity
20 chromatography according to standard procedures. Purified human IgG₁ from the various clones is analyzed on SDS-PAGE, Iso-electric focusing (IEF), assayed binding to Her-2-Ig fusion proteins by ELISA, and analyzed for binding to Her-2 on the surface of BT474 cells by flow
25 cytometry.

Clones obtained from the co-transfection of pCRU-VK1HER2-1, pCRU-VK1HER2-2 and pCRU-VK1HER2-3 are screened by PCR on genomic DNA for the presence or absence of each of the three constructs. The identity of the PCR products is
30 further confirmed by DNA sequencing.

Next, it is demonstrated that a clonal cell line accounts for the production of each of the three binding

specificities. Therefore, a limited number of colonies, which screened positive for the production of each of the three binding specificities (both by PCR at the DNA level as well as in the specified binding assays against Her-2), are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton & Dickinson FACS VANTAGE SE). Alternatively, colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth. Clonal cell populations, hereafter designated as sub-clones, are refreshed once a week with fresh medium. Sub-clones are grown and transferred from 96-wells via 24- and 6-wells plates to T25 flasks. At this stage, sub-clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgG₁ antibody are determined in the supernatant using a human IgG₁ specific ELISA. For a representative number of sub-clones, larger volumes are cultured to purify the recombinant human IgG₁ fraction from the conditioned supernatant using Protein A affinity chromatography according to standard procedures.

Purified human IgG₁ from the various sub-clones is subsequently analyzed as described above for human IgG₁ obtained from the parental clones, i.e. by SDS-PAGE, Isoelectric focusing (IEF) and binding to Her-2. Sub-clones will also be screened by PCR on genomic DNA for the presence or absence of each of the three constructs pCRU-VK1HER2-1, pCRU-VK1HER2-2 and pCRU-VK1HER2-3. The identity of the PCR products is further confirmed by DNA sequencing.

Other methods such as Southern blot and/or FISH can also be used to determine whether each of the three constructs are present in the clonal cell line.

Sub-clones that are proven to be transgenic for each of the three constructs are brought into culture for an extensive period to determine whether the presence of the transgenes is stable and whether expression of the antibody mixture remains the same, not only in terms of expression levels, but also for the ratio between the various antibodies that are secreted from the cell. Therefore, the sub-clone culture is maintained for at least 25 population doubling times either as an adherent culture or as a suspension culture. At every 4-6 population doublings, a specific production test is performed using the human IgG specific ELISA and larger volumes are cultured to obtain the cell pellet and the supernatant. The cell pellet is used to assess the presence of the three constructs in the genomic DNA, either via PCR, Southern blot and/or FISH. The supernatant is used to purify the recombinant human IgG₁ fraction as described supra. Purified human IgG₁ obtained at the various population doublings is analyzed as described, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to Her-2 by ELISA and by flow cytometry using BT474 cells.

Functionality of the antibody mixture of anti-Her-2 antibodies is analyzed in cell-based assays to determine whether the human IgG₁ mixture inhibits proliferation and/or induces apoptosis of BT474 cells. In addition the antibody mixtures are analyzed for their potential to induce antibody dependent cellular toxicity and complement dependent cytotoxicity of BT474 cells.

In each of the experiments described below the functionality of the antibody mixture recognizing Her-2 can be analyzed and compared to each of the individual IgG1 antibodies and to an equimolar combination of the three individual monospecific IgG1 molecules.

To assess the ability of the antibody mixtures to inhibit the proliferation of BT474 cells, these cells are allowed to adhere overnight in 96-well plates (1.5×10^5 /well) and are subsequently incubated with several concentrations (5 - 20 $\mu\text{g/ml}$) of the antibody mixtures against Her-2 for 72 hours. The proliferation of the cells is measured by ^3H -thymidine incorporation during the last 6 hours of culture. Inhibition of growth is determined by plotting the percentage of ^3H -thymidine incorporation compared with untreated cells (taken as 100% reference value).

To analyze apoptosis induction of BT474 cells, these cells are allowed to adhere overnight in 48-well plates (2.5×10^5 /well in 1ml) and are subsequently incubated with several concentrations (5 - 20 $\mu\text{g/ml}$) of the antibody mixtures against Her-2 for 4 hours. Hereafter the cells are harvested by trypsinization, are washed twice with PBS and are incubated at RT for 10 min with 100 μl FITC-labelled annexin V (Caltag) diluted 1:25 in annexin V binding buffer (Caltag). Prior to the analysis of the samples by flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA) propidium iodide (PI) (Sigma) is added to a final concentration of 5 $\mu\text{g/ml}$ to distinguish necrotic cells (annexin V^-/PI^+) from apoptotic cells (annexin V^+/PI^- , early apoptotic cells; annexin V^+/PI^+ , late apoptotic cells).

Antibody Dependent Cellular Cytotoxicity of the antibody mixtures is analyzed using peripheral blood mononuclear cells as effector cells and BT474 cells as target cells in a standard ^{51}Cr release assay as described supra (Huls et al, 1999). Complement dependent cytotoxicity is determined in a similar assay. Instead of the effector cells, now 50 μl human serum is added to the target cells. Subsequently, the assay is performed as described supra.

Alternatively, ADCC and CDC of the antibody mixtures is determined using a Europium release assay (Patel and Boyd, 1995) or using an LDH release assay (Shields et al, 2001).

The functionality of the antibody mixtures against Her-2 is also tested using in vivo animal models, such as for instance described in Spiridon et al, 2002.

20

Example 5

Expression of different functional human IgGs in the milk of transgenic animals

The V_H and V_H sequences of phages against proteins present on human B-cells, i.e. CD22 (clone B28), CD72 (clone II-2) and HLA-DR (clone I-2) (Fig. 7) are cloned into expression plasmid pBC1 (as provided in the pBC1 Mouse Milk Expression System, Invitrogen Life Technologies) to obtain mammary-gland and lactation-specific expression of these human IgG molecules in transgenic animals, according to the manufacturers instructions. These mammary-gland specific expression vectors, encoding the

antibody sequences for anti-CD22, anti-CD72 and anti-HLA-DR are introduced into the murine germline according to the manufacturers instructions. Obtained pups are screened for the presence of each of the three constructs by PCR on DNA isolated from the tail. Pups, either male or female, confirmed for being transgenic for each of the three antibodies, are weaned and matured. Female transgenic mice are fertilized at the age of 6-8 weeks and milk samples are obtained at several time points after gestation. Male transgenic mice are mated with non-transgenic females and female transgenic offspring (as determined with PCR as described above) is mated and milked as described above for the female transgenic founders. Whenever needed, female or male transgenic founders are mated for another generation to be able to obtain sufficient amounts of transgenic milk for each founder line. Transgenic milk is analyzed for the presence of human IgG with a human IgG specific ELISA, which does not cross-react with mouse IgG or other mouse milk components. Human IgG is purified from transgenic mouse milk using Protein A affinity chromatography according to standard procedures. Purified human IgG is analyzed on SDS-PAGE, Isoelectric focusing and binding on the targets CD22, CD72 and HLA-DR. Functionality of the antibody mixture is analyzed as described supra.

Example 6 Production of an IgA/IgG mixture against a predefined target in a PER.C6™ derived clone.

The V_H - V_L sequences of the phage UBS-54 directed against the homotypic adhesion molecule EP-CAM (Huls et al., 1999) was not only cloned into a vector encoding the

constant domains of a human IgG1 with Kappa light chain (expression vector pUBS3000Neo), but also into an expression vector encoding the constant domains of a human IgA1 with Kappa light chain (expression vector pUBS54-IgA, Fig. 8). Hence, antibodies derived from pUBS3000Neo and pUBS54-IgA do bind to the same epitope on EPCAM. The only differences antibodies derived from pUBS3000Neo and pUBS54-IgA are in the sequences encoding the constant domains of the heavy chain, resulting in either an IgG₁ or IgA₁ isotype. The Kappa light chain sequences of these two vectors are identical. Stable PER.C6TM derived cell lines expressing antibodies encoded by genetic information on pUBS3000Neo and pUBS54-IgA are generated by procedures well known to persons skilled in the art. Therefore, PER.C6TM cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture conditions (10% CO₂ concentration and 37°C). The next day, transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 µg pUBS3000Neo and pUBS54-IgA. As a control for transfection efficiency, a few dishes are transfected with a LacZ control vector, while a few dishes are not transfected and serve as negative controls. After 4-5 hours, cells are washed twice with DMEM and refed with fresh medium without selection. The next day, medium is replaced with fresh medium containing 500 µg/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22

days after seeding, a large number of colonies is visible and from each transfection at least 300 are picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks. At this stage, cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG and human IgA antibody are determined in the supernatant using an ELISA specific for human IgG1 as well as an ELISA specific for human IgA. Also, at this stage G418 is removed from the culture medium and never re-applied again. For a representative number of colonies larger volumes are cultured to purify the recombinant human IgG₁ and human IgA fraction from the conditioned supernatant using for instance (a combination of) Protein L or LA affinity chromatography, cation exchange chromatography, hydrophobic interaction chromatography and gel filtration. Purified human immunoglobulins from the various clones are analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the target EPCAM using cell lines having a high expression of this molecule. The clones will also be screened by PCR on genomic DNA for the presence or absence of pUBS3000Neo and pUBS54-IgA. The identity of the PCR products is further confirmed by DNA sequencing.

A limited number of clones, which are screened positive for the production of both EPCAM IgG₁ and EPCAM IgA, are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton Dickinson FACS VANTAGE SE). Alternatively, colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth. Clonal cell populations, hereafter designated as sub-clones, are refreshed once a week with fresh medium. Sub-clones are grown and transferred from 96-wells via 24- and 6-wells

plates to T25 flasks. At this stage, sub-clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgG₁ and IgA antibody are determined in the supernatant using a human IgG₁ specific ELISA and a human IgA specific ELISA. For a representative number of sub-clones, larger volumes are cultured to purify the recombinant human IgG₁ and human IgA₁ fraction from the conditioned supernatant using for instance (a combination of) Protein L or LA affinity chromatography, cation exchange chromatography, hydrophobic interaction chromatography and gel filtration. Purified human immunoglobulins from the various clones are analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the target EPCAM using cell lines having a high expression of this molecule. Sub-clones will also be screened by PCR on genomic DNA for the presence or absence of pUBS3000Neo and pUBS54-IgA. The identity of the PCR products is further confirmed by DNA sequencing. Other methods such as Southern blot and/or FISH may also be used to determine whether both constructs are present in the clonal cell line.

Example 7 Production of a human IgG₁/IgG₃ mixture against multiple targets in a clonal PER.C6™ cell line
Phage clone UBS-54 and Clone K53 (Fig. 3) were obtained as described in Example 1. The V_H and V_L of clone UBS-54 was inserted into an expression vector containing the HAVT20 leader sequence and all the coding sequences for the constant domains of a human IgG₁ with a Kappa light chain by a method essentially as described (Boel et al,

2000). The resulting plasmid was designated as pUBS3000Neo (Fig. 4). It will be clear that expression vectors containing heavy chain constant domains of any desired isotype can be constructed by routine methods of molecular biology, using the sequences of these regions that are all available in the art. The V_H and V_L sequences of Phage clone K53 are cloned into an expression vector containing the HAVT20 leader sequence and all the coding sequences for the constant domains of a heavy chain of a human IgG₃ with a Kappa light chain by a method essentially as described (Boel et al, 2000). This expression vector is designated as pK53IgG3. These plasmids are transiently expressed either alone or in combination in PER.C6TM cells. In brief, each 80 cm² flask is transfected by incubation for 4 hours with 140 µl lipofectamine + 10 µg DNA (either pUBS3000Neo, pK53IgG3 or 10 µg of both) in serum-free DMEM medium at 37°C. After 4 hours, this is replaced with DMEM + 10% FBS, and the cells are grown overnight at 37°C. Cells are then washed with PBS and the medium is replaced with Excell 525 medium (JRH Bioscience). The cells are allowed to grow at 37°C for 6 days, after which the cell culture supernatant is harvested. Human IgG specific ELISA analysis, i.e. measuring all IgG sub-types, is done to determine the IgG concentration in transfected and non-transfected PER.C6TM cells. Human IgG from each supernatant is subsequently purified using Protein A affinity chromatography (Hightrap Protein A HP, cat.no. 1-040203) according to standard procedures, following recommendations of the manufacturer (Amersham Biosciences). After elution, samples are concentrated in a Microcon YM30 concentrator (Amicon) and buffer

exchanged to 10 mM sodium phosphate, pH 6.7. Samples are analysed for binding to the targets EPCAM and CD46 using cell lines having a high expression of these molecules such as LS174T cells. Twelve µg of purified IgG, either
5 transiently expressed UBS-54 IgG1, K53 IgG3 or IgG from the cells in which both antibodies were co-transfected, is subsequently analyzed on Isoelectric focusing gels (Serva Pre-cast IEF gels, pH range 3-10, cat.no. 42866). Samples are loaded on the low pH side and after focussing
10 stained with colloidal blue. The pI values of the major isoforms for each sample are determined to illustrate whether there has been expression of UBS-54 IgG1, K53 IgG3 or bispecific heterodimers, depending on how the cells were transfected. The identification of
15 heterodimers would indicate that single cells have translated both the IgG3 heavy chain of K53 and the IgG1 heavy chain of UBS-54 and assembled these into a full length IgG molecule together with the common light chain. The absence of bispecific heterodimers indicates that it
20 is possible to translate both the IgG3 heavy chain of K53 and the IgG1 heavy chain of UBS-54 in single cells, but that these do not assemble into a full length IgG molecule together with the common light chain, i.e. there is preferential binding of IgG1 and IgG3 heavy chains.
25 This could however also be explained by the lack of co-expression of UBS-54 IgG₁ and K53 IgG₃. Therefore, stable clonal cell lines expressing both pUBS3000Neo and pK53IgG3 are generated by procedures as such well known to persons skilled in the art. PER.C6TM cells are seeded
30 in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture

conditions (10% CO₂ concentration and 37°C). The next day, transfections are performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 µg pUBS3000Neo, pK53IgG3 or both. As a control for transfection efficiency, a few dishes are transfected with a LacZ control vector, while a few dishes will be not transfected and serve as negative controls.

After 4-5 hours, cells are washed twice with DMEM and refed with fresh medium without selection. The next day, medium is replaced with fresh medium containing 500 µg/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22 days after seeding, a large number of colonies is visible and from each transfection at least 300 are picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks. At this stage, cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG antibody are determined in the supernatant using an ELISA specific for all subtypes of human IgG. Also, at this stage G418 is removed from the culture medium and never re-applied again. For a representative number of colonies larger volumes are cultured to purify the recombinant human IgG from the conditioned supernatant using Protein A affinity chromatography (Hightrap Protein A HP, cat.no. 1-040203) according to standard procedures, following recommendations of the manufacturer (Amersham Biosciences). Purified human immunoglobulins from the various clones are analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the targets EPCAM and CD46

using cell lines having a high expression of these molecules such as LS174T cells. The clones are also screened by PCR on genomic DNA for the presence or absence of pUBS3000Neo and pK53IgG3. The identity of the PCR products is further confirmed by DNA sequencing. A limited number of clones, which are screened positive for the production of both EPCAM IgG1 and K53 IgG3, are subjected to single cell sorting using a fluorescence activated cell sorter (FACS) (Becton Dickinson FACS VANTAGE SE). Alternatively, colonies are seeded at 0.3 cells/well to guarantee clonal outgrowth. Clonal cell populations, hereafter designated as sub-clones, are refreshed once a week with fresh medium. Sub-clones are grown and transferred from 96-wells via 24- and 6-wells plates to T25 flasks. At this stage, sub-clones are frozen (at least 1, but usually 4 vials per sub-clone) and production levels of recombinant human IgG antibody are determined in the supernatant using a human IgG specific ELISA. For a representative number of sub-clones, larger volumes are cultured to purify the recombinant human IgG fraction from the conditioned supernatant using Protein A affinity chromatography (Hightrap Protein A HP, cat.no. 1-040203) according to standard procedures, following recommendations of the manufacturer (Amersham Biosciences). Purified human immunoglobulins from the various clones are analyzed on SDS-PAGE, Iso-electric focusing (IEF) and binding to the targets EPCAM and CD46 using cell lines having a high expression of this molecules, such as for instance LS174T cells, or transfectants expressing these molecules. Sub-clones are also screened by PCR on genomic DNA for the presence or absence of pUBS3000Neo and pK53IgG3. The

identity of the PCR products is further confirmed by DNA sequencing.

Other methods such as Southern blot and/or FISH may also be used to determine whether both constructs are present
5 in the clonal cell line.

Once the clonal sub-clones are available and confirmed positive for the expression of both UBS-54 IgG1 and K53 IgG3, the presence of functional K53 and UBS-54 shows that it is possible to generate a mixture of functional
10 IgG's with different isotypes with the common light chain in a single cell. Analysis of the expression of bispecific antibodies binding both EpCAM and CD46 will reveal to what extent the different heavy chains having a different subtype will pair, which will influence the
15 amount of bispecific antibodies produced. It is expected that no or very low levels of bispecific antibodies will be found in this case.

20 **Example 8. Selection of phage carrying single chain Fv fragments specifically recognizing rabies virus glyco protein (RVGP) using RVGP-Ig fusion protein, and expression of mixtures of antibodies against the rabies virus.**

25 This example describes the production of mixtures of antibodies against the rabies virus, as another potential target. As an antigen, the Rabies Virus Glycoprotein (RVGP) is chosen, but other rabies antigens may be chosen or included as well for this purpose. Several monoclonal
30 antibodies recognizing RVGP have already been described in the art, and polyclonal antibodies have been recognized to be useful in treatment of rabies infections

as well (e.g. EP0402029; EP0445625).

Antibody fragments are selected using antibody phage display libraries and MAbstractTM technology, essentially as described in US patent 6,265,150 and in WO 98/15833.

5 All procedures are performed at room temperature unless stated otherwise. The sequence of RVGP is available to the person skilled in the art, for cloning purposes (e.g. Yelverton et al, 1983). An RVGP-Ig fusion protein consisting of whole RVGP fused genetically to the CH2 and
10 CH3 domains of human IgG1 is produced using vector pcDNA3.1 Zeo-CH2-CH3 expressed in PER.C6TM and coated for 2 hours at 37° onto the surface of MaxisorpTM plastic tubes (Nunc) at a concentration of 1.25 µg/ml. The tubes are blocked for 1 h in 2% fat free milk powder dissolved
15 in PBS (MPBS). Simultaneously, 500 µl (approximately 10¹³ cfu) of a phage display library expressing single chain Fv fragments (scFv's) essentially prepared as described by De Kruif et al (1995a,b) and references therein, is added to two volumes of 4% MPBS. In this experiment,
20 selections are performed using fractions of the original library constructed using only one single variable light chain gene species (e.g. a 'VK1'-library). In addition, human serum is added to a final concentration of 15% and blocking is allowed to proceed for 30-60 min. The RVGP-Ig-coated tubes are emptied and the blocked phage library
25 is added. The tube is sealed and rotated slowly for 1 h, followed by 2 h of incubation without rotation. The tubes are emptied and washed 10 times in PBS containing 0.1% Tween-20, followed by washing 5 times in PBS. 1 ml
30 glycine-HCL, 0.05 M, pH 2.2 is added, and the tube is rotated slowly for 10 min. The eluted phages are added to 500 µl 1M Tris-HCl pH 7.4. To this mixture, 3.5 ml of

exponentially growing XL-1 blue bacterial culture is added. The tubes are incubated for 30 min at 37°C without shaking. Then, the bacteria are plated on 2TY agar plates containing ampicillin, tetracycline and glucose. After
5 overnight incubation of the plates at 37°C, the colonies are scraped from the plates and used to prepare an enriched phage library, essentially as described by De Kruif et al. (1995a,b). Briefly, scraped bacteria are used to inoculate 2TY medium containing ampicillin,
10 tetracycline and glucose and grown at a temperature of 37°C to an OD_{600nm} of ~0.3. Helper phages are added and allowed to infect the bacteria after which the medium is changed to 2TY containing ampicillin, tetracycline and kanamycin. Incubation is continued overnight at 30°C. The
15 next day, the bacteria are removed from the 2TY medium by centrifugation after which the phages are precipitated using polyethylene glycol 6000/NaCl. Finally, the phages are dissolved in a small volume of PBS-1% BSA, filter-sterilized and used for a next round of selection. The
20 selection/re-infection procedure is performed twice. After the second round of selection, individual *E.coli* colonies are used to prepare monoclonal phage antibodies. Essentially, individual colonies are grown to log-phase and infected with helper phages after which phage
25 antibody production is allowed to proceed overnight. Phage antibody containing supernatants are tested in ELISA for binding activity to human RVGP-Ig coated 96 wells plates.

30 Selected phage antibodies that are obtained in the screen described above, are validated in ELISA for specificity. For this purpose, human RVGP-Ig is coated to

Maxisorp ELISA plates. After coating, the plates are blocked in 2% MPBS. The selected phage antibodies are incubated in an equal volume of 4% MPBS. The plates are emptied, washed once in PBS, after which the blocked
5 phages are added. Incubation is allowed to proceed for 1 h, the plates are washed in PBS 0.1% Tween-20 and bound phages are detected using an anti-M13 antibody conjugated to peroxidase. As a control, the procedure is performed simultaneously using a control phage antibody directed
10 against thyroglobulin (De Kruif et al. 1995a,b), which serves as a negative control.

The phage antibodies that bind to human RVGP-Ig are subsequently tested for binding to human serum IgG to exclude the possibility that they recognized the Fc part
15 of the fusion protein.

In another assay the phage antibodies are analyzed for their ability to bind PER.C6TM cells that express RVGP. To this purpose PER.C6TM cells are transfected with a plasmid carrying a cDNA sequence encoding RVGP or with
20 the empty vector and stable transfectants are selected using standard techniques known to a person skilled in the art (e.g. Coligan, J.E. et al. (2001) Current protocols in protein science, volume I. John Wiley & Sons, Inc. New York). For flow cytometry analysis, phage
25 antibodies are first blocked in an equal volume of 4% MPBS for 15 min at 4°C prior to the staining of the RVGP- and control transfected PER.C6TM cells. The blocked phages are added to a mixture of unlabelled control transfected PER.C6TM cells and RGVP transfected PER.C6TM cells that
30 have been labelled green using a lipophylic dye (PKH67, Sigma). The binding of the phage antibodies to the cells is visualized using a biotinylated anti-M13 antibody

(Santa Cruz Biotechnology) followed by streptavidin-phycoerythrin (Caltag). Anti RVGP scFv selectively stains the PER.C6TM RVGP transfectant while they do not bind the control transfectant.

5 An alternative way of screening for phages carrying single chain Fv fragments specifically recognizing human RVGP, is by use of RVGP-transfected PER.C6TM cells. PER.C6TM cells expressing membrane bound RVGP are produced as described supra. Phage selection experiments are
10 performed as described supra, using these cells as target. A fraction of the phage library comprised of scFv-phage particles using only one single scFv species (500 μ l, approximately 10^{13} cfu) is blocked with 2 ml RPMI/10%FCS/1%NHS for 15' at RT. Untransfected PER.C6TM
15 cells ($\sim 10 \times 10^6$ cells) are added to the PER.C6-RVGP cells ($\sim 1.0 \times 10^6$ cells). This mixture is added to the blocked light chain restricted phage-library and incubated for 2,5 hr while slowly rotating at 4°C. Subsequently, the cells are washed twice and were resuspended in 500 μ l
20 RPMI/10%FCS and incubated with a murine anti-RVGP antibody (Becton Dickinson) followed by a phycoerythrin (PE)-conjugated anti-mouse-IgG antibody (Caltag) for 15' on ice. The cells are washed once and transferred to a 4 ml tube. Cell sorting is performed on a FACSvantage
25 fluorescence-activated cell sorter (Becton Dickinson) and RVGP (PE positive) cells are sorted. The sorted cells are spun down, the supernatant is saved and the bound phages are eluted from the cells by resuspending the cells in 500 μ l 50mM Glycin pH2.2 followed by incubation for 5 min.
30 at room temperature. The mixture is neutralized with 250 μ l 1M Tris-HCl pH 7.4 and added to the rescued supernatant. Collectively these phages are used to

prepare an enriched phage library as described above. The selection/re-infection procedure is performed twice. After the second round of selection, monoclonal phage antibodies are prepared and tested for binding to RVGP-PER.C6TM cells and untransfected PER.C6TM cells as described supra. Phages that are positive on RVGP-transfected cells are subsequently tested for binding to the RVGP-IgG fusion protein in ELISA as described supra.

10 The selected scFv fragments are cloned in a human IgG1 format, according to methods known in the art (e.g. Boel et al, 2000). To this purpose, the VL fragment shared by the selected scFv is PCR amplified using oligo's that add appropriate restriction sites. A similar
15 procedure is used for the VH genes. Thus modified genes are cloned in expression pCRU-K01 (ECACC deposit 03041601), which results in expression vectors encoding a complete huIgG1 heavy chain and a complete human light chain gene having the same specificity as the original
20 phage clone. By this method, three different heavy chains are cloned into separate expression vectors, while only one of the vectors needs to comprise the common light chain sequence. These expression vectors are provisionally designated pCRU-RVGP-1, pCU-RVGP-2, and
25 pCRU-RVGP-3. Alternatively, these three vectors may lack DNA encoding the VL region, which can then be encoded in a fourth, separate expression vector not encoding a heavy chain. It is also possible to have VL sequences present in all three or two of the three vectors comprising the
30 different V_H sequences.
Stable PER.C6TM derived cell lines are generated, according to methods known to the person skilled in the

art (see e.g. WO 00/63403), the cell lines expressing antibodies encoded by genetic information on either pCRU-RVGP-1, pCRU-RVGP-2 or pCRU-RVGP-3 and a cell line expressing antibodies encoded by all three plasmids.

5 Therefore, PER.C6TM cells are seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) or T80 flasks with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture conditions (10% CO₂ concentration and 37°C). The next day, transfections are
10 performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with either 1-2 µg pCRU-RVGP-1, 1-2 µg pCRU-RVGP-2, 1-2 µg pCRU-RVGP-3 or 1 µg of a mixture of pCRU-RVGP-1, pCRU-RVGP-2 and pCRU-
15 RVGP-3. As a control for transfection efficiency, a few dishes are transfected with a LacZ control vector, while a few dishes will not be transfected and serve as negative controls.

After 4 to 5 hours, cells are washed twice with DMEM and
20 refed with fresh medium without selection. The next day, medium are replaced with fresh medium containing 500 µg/ml G418. Cells are refreshed every 2 or 3 days with medium containing the same concentrations of G418. About 20-22 days after seeding, a large number of colonies are
25 visible and from each transfection at least 300 are picked and grown via 96-well and/or 24-well via 6-well plates to T25 flasks. At this stage, cells are frozen (at least 1, but usually 4 vials per sub-cultured colony) and production levels of recombinant human IgG antibody are
30 determined in the supernatant using an ELISA specific for human IgG₁ (described in WO 00/63403). Also, at this stage G418 is removed from the culture medium and never re-

applied again. For a representative number of colonies
larger volumes will be cultured to purify the recombinant
human IgG₁ fraction from the conditioned supernatant using
Protein A affinity chromatography according to standard
5 procedures. Purified human IgG₁ from the various clones is
analyzed on SDS-PAGE, Iso-electric focusing (IEF) and
binding to the target RVGP using an RVGP PER.C6-
transfectant described above.

Colonies obtained from the co-transfection with pCRU-
10 RVGP-1, pCRU-RVGP-2 and pCRU-RVGP-3 are screened by PCR
on genomic DNA for the presence or absence of each of the
three constructs. The identity of the PCR products is
further confirmed by DNA sequencing.

A limited number of colonies, which screened positive for
15 the production of each of the three binding specificities
(both by PCR at the DNA level as well as in the specified
binding assays against RVGP), are subjected to single
cell sorting using a fluorescence activated cell sorter
(FACS) (Becton & Dickinson FACS VANTAGE SE).

20 Alternatively, colonies are seeded at 0.3 cells/well to
guarantee clonal outgrowth. Clonal cell populations,
hereafter designated as sub-clones, are refreshed once a
week with fresh medium. Sub-clones are grown and
transferred from 96-wells via 24- and 6-wells plates to
25 T25 flasks. At this stage, sub-clones are frozen (at
least 1, but usually 4 vials per sub-clone) and
production levels of recombinant human IgG₁ antibody are
determined in the supernatant using a human IgG₁ specific
ELISA. For a representative number of sub-clones, larger
30 volumes are cultured to purify the recombinant human IgG₁
fraction from the conditioned supernatant using Protein A
affinity chromatography according to standard procedures..

Purified human IgG₁ from the various sub-clones is subsequently analyzed as described above for human IgG₁ obtained from the parental clones, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to the target RVGP.

5 Sub-clones are also screened by PCR on genomic DNA for the presence or absence of each of the three constructs pCRU-RVGP-1, pCRU-RVGP-2 and pCRU-RVGP-3. The identity of the PCR products is further confirmed by DNA sequencing. Other methods such as Southern blot and/or FISH can also
10 be used to determine whether each of the three constructs are present in the clonal cell line.

Sub-clones that are proven to be transgenic for each of the three constructs are brought into culture for an extensive period to determine whether the presence of the
15 transgenes is stable and whether expression of the antibody mixture remains the same, not only in terms of expression levels, but also for the ratio between the various antibody isoforms that are secreted from the cell. Therefore, the sub-clone culture is maintained for
20 at least 25 population doubling times either as an adherent culture or as a suspension culture. At every 4-6 population doublings, a specific production test is performed using the human IgG specific ELISA and larger volumes are cultured to obtain the cell pellet and the
25 supernatant. The cell pellet is used to assess the presence of the three constructs in the genomic DNA, either via PCR, Southern blot and/or FISH. The supernatant is used to purify the recombinant human IgG₁ fraction as described supra. Purified human IgG₁ obtained
30 at the various population doublings is analyzed as described, i.e. by SDS-PAGE, Iso-electric focusing (IEF) and binding to the target RVGP.

The efficacy of the antibody mixtures against rabies is tested in in vitro cell culture assays where the decrease in spread of rabies virus is measured, as well as in in vivo animal models infected by rabies. Such models are known to the person skilled in the art, and are e.g. described in EP0402029.

Example 9. Production of a mixture of antibodies with a common light chain and three different heavy chain variable regions in a single cell.

A method for producing a mixture of antibodies according to the invention, using expression in a recombinant host cell of a single light chain and three different heavy chains capable of pairing to the single light chain to form functional antibodies, is exemplified herein and is schematically shown in Fig. 6.

Human IgG's UBS54 and K53 against the EP-CAM homotypic adhesion molecule (Huls et al., 1999) and the membrane cofactor protein CD46 (WO 02/18948), respectively, are described in Example 1. Another clone that was identified to bind to cofactor protein CD46 was clone 02-237 (sequence of VH provided in Fig. 12). DNA sequencing of this clone revealed that it contained the same light chain as UBS54 and K53, but a unique heavy chain variable sequence (see alignment in Fig. 3). As a result, the CDR3 of the heavy chain of 02-237 differs at 4 positions from that of K53 (see alignment in Fig. 13). The heavy and light chain variable sequences of phage 02-237 were cloned into the expression plasmid pCRU-K01, (pCRU-K01 is deposited at the European Collection of Cell Cultures (ECACC) under number 03041601), which contains the heavy

and light chain constant domains for an IgG1 antibody. The resulting plasmid was designated pgG102-237. Due to the cloning strategy followed, the resulting N-terminus of the light chain of 02-237 as encoded by pgG102-237
5 differed slightly from the N-terminus of UBS54 and K53 as present by pUBS3000Neo, pCD46_3000(Neo), respectively (Fig. 3). Plasmid pgG102-237 was transiently produced in human 293(T) cells or stably in PER.C6 cells. It appeared that purified 02-237 IgG had a much higher affinity for
10 purified CD46 (Fig. 14) than K53 IgG, i.e. the affinity had increased from 9.1×10^{-7} M to 2.2×10^{-8} M for K53 and 02-237, respectively. Also, 02-237 bound much better to CD46 on human coloncarcinoma LS174T cells than K53 (Fig. 15).

15 Stable PER.C6TM derived cell lines expressing a combination of the plasmids pUBS3000Neo, pCD46_3000(Neo) and pgG102-237 encoding human IgG 02-237 were generated according to methods known as such to the person skilled
20 in the art (see e.g. WO 00/63403). Therefore, PER.C6TM cells were seeded in DMEM plus 10% FBS in tissue culture dishes (10 cm diameter) with approximately 2.5×10^6 cells per dish and kept overnight under their normal culture conditions (10% CO2 concentration and 37°C). The next day,
25 transfections were performed in separate dishes at 37°C using Lipofectamine (Invitrogen Life Technologies) according to standard protocols provided by the manufacturer, with 2 µg of an equimolar mixture of pUBS3000Neo, pCD46_3000(Neo) and pgG102-237. As negative
30 control for selection, a few dishes were not transfected. After 4 to 5 hours, cells were washed twice with DMEM and refed with fresh medium without selection. The next day,

medium was replaced with fresh medium containing 500
µg/ml G418. Cells were refreshed every 2 or 3 days with
medium containing the same concentrations of G418. About
20-22 days after seeding, a large number of colonies was
5 visible and about 300 were picked and grown via 96-well
and/or 24-well via 6-well plates to T25 flasks. During
sub-culturing, production levels of recombinant human IgG
antibody were determined in the supernatant using an
ELISA specific for human IgG1 (described in WO 00/63403).
10 About 25% of all colonies appeared to be positive in this
highly specific assay. The production levels measured at
this stage were comparable to the levels when a single
IgG is expressed in PER.C6TM cells (expression of a single
IgG described in Jones et al., 2003). It is important to
15 stress that these high expression levels were obtained
without any methods for amplification of the transgene
and that they occur at a low copy number of the
transgene.

The 30 best producing colonies were frozen down in vials
20 and the 19 highest producing clones were selected for
purification of the IgG (Table 1). They were sub-cultured
in T80 flasks and human IgG from each clone was
subsequently purified using Protein A affinity
chromatography. Therefore, 15-25 ml of conditioned medium
25 was loaded on a 5 ml Protein A FF Sepharose column
(Amersham Biosciences). The column was washed with 4 mM
phosphate buffered saline, pH 7.4 (PBS) before elution
with 0.1 M citrate pH 3.0. The eluted fraction was
subsequently desalted on a Sephadex G25 Fine HiPrep
30 Desalting column (Amersham Biotech) to PBS. The
concentration of the purified IgG fraction was determined

by absorbance measurement at 280 nm using a coefficient of 1.4 for a 0.1% (w/v) solution (Table 1).

The purified IgG samples were analysed on non-reduced and reduced SDS-PAGE and IEF. Non-reduced SDS-PAGE (Fig. 16A) showed that all IgG samples migrated comparable to the control K53 or 02-237, as an assembled, intact IgG molecule of approximately 150 kDa. On reduced SDS-PAGE (Fig. 16B), the IgG samples migrated as heavy and light chains of about 50 and 25 kDa, respectively, comparable to the heavy and light chain of the control K53 or 02-237.

On IEF, the purified IgG fractions were first compared to a mixture of equal amounts of K53, UBS54 and 02-237 (Fig. 17). Clearly, some of the samples contained isoforms with a unique pI profile, when compared to the mixture containing purified K53, UBS54 and 02-237. Some major unique isoforms have a pI in between the pI of K53 and 02-237 on one hand and UBS54 on the other hand. This is also anticipated on the basis of the theoretic pI when calculated with the ProtParam tool provided on the Expasy homepage (<http://www.expasy.ch>; Appel et al., 1994). K53, 02-237 and UBS54 have a theoretic pI of 8.24, 8.36 and 7.65, respectively, whereas an isoform representing a heterodimer of one UBS54 heavy chain and one K53 heavy chain has a theoretical pI of 8.01. Assembly of such a heterodimer can only occur when a single cell translates both the heavy chain of K53 and the heavy chain of UBS54 and assembles these into a full length IgG molecule together with the common light chain. Hence these results suggest that certain clones at least express two functional antibodies. To confirm the unique identity of some of the isoforms, samples of the most interesting

clones were run in parallel with K53, UBS54 and 02-237, either alone or in a mixture (Fig. 18). This furthermore showed that some clones expressed at least two antibodies (241, 282, 361). Moreover, it provided evidence that some clones express all three functional antibodies (280 and 402).

To confirm that the clones expressed IgG mixtures comprising all three heavy chains, peptide mapping (Garnick, 1992; Gelpí, 1995) was used to analyse the polyclonal IgG fraction. We previously employed peptide mapping to recover 99% of the protein sequence of K53. Based on the protein sequence provided in Fig. 12, the mass of the theoretical tryptic peptides of K53, UBS54 and 02-237 was calculated (Table II and III). A few unique peptides for each IgG, could be identified, i. e. for instance the CDR3 peptides for K53, 02-237 and UBS54 with a Mw of 2116.05, 2057.99 and 2307.15 Da, respectively. Next, a tryptic digest of Poly1-280 was prepared and this was analysed using LC-MS (Fig. 19). Peptides with Mw of 2116, 2057 and 2308 Da, representing the unique CDR3 peptides of K53, 02-237 and UBS54, respectively, were detected. The precise amino acid sequence of these peptides (as listed in Table III) was confirmed by MS-MS analysis (Tables IV, V and VI). We also confirmed the presence of the two unique N-terminal light chain peptides with Mw of 2580 and 2554 Da, respectively. The peptide mapping data unequivocally showed that a mixture of antibodies comprising a common light chain and three different heavy chains was expressed by PER.C6TM clone Poly1-280. Also clones 055, 241 and 402 were screened by peptide mapping. Clones 241 and 402 were confirmed positive for all three heavy chain

sequences, whereas clone 055 only showed expression of the heavy chains of K53 and 02-237, and not of UBS54. This confirms the IEF screening (Fig. 18), where no UBS54 related band was seen in sample 055.

5 Poly1-280 was analysed by BIACORE for binding to CD46 (Fig. 20). The affinity of poly1-280 for CD46 was 2.1×10^{-8} M, which shows that the IgG mixture contains CD46 binding molecules having the same affinity as 02-237 IgG alone.

10 Taken together, this experiment shows that it is possible to express a mixture of functional IgG molecules comprising three unique heavy chains in a single cell and that next to the homodimers, heterodimers consisting of two binding specificities are also formed. Furthermore,
15 the frequency of clones expressing three different heavy chains suggests that it will also be possible to obtain clones expressing at least 4, 5 or more heavy chains, using the same procedure. In case it would be difficult to obtain clones expressing higher numbers of heavy
20 chains, a clone expressing at least 3 heavy chains according to the invention can be used to introduce more heavy chains in a separate round of transfection, for instance by using a different selection marker.

25 Next, it was demonstrated that a single cell is able to produce a mixture of more than two functional human IgG's. Therefore, clones 241, 280 and 402, which were screened positive for the production of each of the three IgG's, both by IEF and MS, were subjected to limiting
30 dilution, i.e. seeded at 0.3 cells/well in 96-wells plate to guarantee clonal outgrowth.

Clonal cell populations, hereafter designated as sub-clones, were refreshed once a week with fresh medium. Sub-clones were grown and transferred from 96-wells via 24- and 6-wells plates, T25, T80 and T175 flasks. At the
5 T80 stage, sub-clones were frozen. Production levels of recombinant human IgG₁ antibody were determined in the supernatant using a human IgG₁ specific ELISA. For each parental clone, 3 sub-clones were chosen and cultured in a few T175 flasks to obtain sufficient conditioned medium
10 for purification using Protein A affinity chromatography as described above.

Purified human IgG₁ from the sub-clones was subsequently analyzed as described above for human IgG₁ obtained from the parental clone, by Iso-electric focusing (IEF). The
15 result is shown in Fig. 21. Subclones from clone poly 1-241 each have the same pattern, but differ from the parental clone in that they appear to miss certain bands. Subclones from clone poly 1-280 all appear to differ from each other and from the parental clone. Patterns obtained
20 by IEF for subclones from parental clone poly 1-402 are identical for all three subclones and the parent clone. From these data it can be concluded that clone 402 is stably producing a mixture of antibodies. This
25 demonstrates that it is feasible to produce a mixture of antibodies according to the invention from a single cell clone. The clones have undergone about 25 population doublings (cell divisions) from the transfection procedure up to the first analysis (shown in Fig. 18) under selection pressure, and from that point on further
30 have undergone about 30 population doublings during the sub-cloning procedure in the absence of selection pressure, before the material analysed in Fig. 21 was

harvested. Therefore, the production of a mixture of antibodies from a clone from a single cell can be stable over at least 30 generations.

Table I. Overview of the clones used for purification of IgG.

Clone Poly1-	Screening ELISA ($\mu\text{g/ml}$)	Purification	
		Conc. in feed ($\mu\text{g/ml}$)	Purified (mg)
209	6.1	98	1.37
233	10.0	53	0.75
234	8.0	51	0.71
241	6.6	91	1.42
250	12.5	117	2.10
280	6.3	36	0.80
282	8.5	67	1.48
289	8.2	33	0.64
304	7.2	161	3.91
320	6.3	43	0.83
322	15.2	168	3.27
340	6.0	109	2.64
361	10.4	71	1.73
379	9.5	78	1.75
402	39.9	135	3.14
022	16.2	83	1.69
040	7.8	67	1.43
048	6.5	43	0.94
055	11	55	1.04

Table II. Tryptic peptides of the variable domains of the light chain of K53/UBS54 and 02-237.

Peptide	First AA ¹⁾	Last AA	Monoiso- topic M _w (Da) K53/UBS54	Monoiso- topic M _w (Da) 02-237
L1	1	24	2580.31 ⁽²⁾	2554.28 ⁽²⁾
L2	25	59	4039.02	4039.02
L3	60	66	700.35	700.35
L4	67	79	1302.61	1302.61
L5	80	82	374.23	374.23
L6	83	107	2810.29 ⁽²⁾	2810.29 ⁽²⁾
L7	108	111	487.30	487.30
L8	112	112	174.11	174.11

5

¹⁾ AA, amino acid

²⁾ One Cysteine residue alkylated

Table III. Tryptic peptides of variable domains of heavy chains of K53, 02-237 and UBS54.

K53				02-237				UBS54			
A	B	C	D	A	B	C	D	A	B	C	D
H1	1	12	1267.68	H1	1	12	1267.68	H1	1	12	1267.68
H2	13	19	685.41	H2	13	19	685.41	H2	13	19	729.41
H3	20	23	492.24	H3	20	23	492.24	H3	20	23	492.24
H4	24	38	1693.81	H4	24	38	1693.81	H4	24	38	1587.77
H5	39	63	2783.28	H5	39	63	2783.28	H5	39	63	2646.33
H6	64	67	472.28	H6	64	67	472.28	H6	64	67	506.26
H7	68	84	1906.87	H7	68	84	1906.87	H7	68	87	2174.04
H8	85	87	374.23	H8	85	87	374.23	-	-	-	-
H9	88	98	1319.55	H9	88	98	1319.55	H8	88	98	1333.56
H10	99	102	493.21	H10	99	102	475.25	H9	99	119	2307.15
H11	103	122	2116.05	H11	103	122	2057.99	-	-	-	-

5

Key:

A: peptide

B: first amino acid

C: last amino acid

10 D: monoisotopic M_w (Da)

Remarks:

1) for H1, amino acid residue 1 is a pyroglutamic acid

2) peptides H3 and H9 from K53 and 02-237, and peptides H3 and H8 of UBS54 contain one alkylated cysteine residue

15 3) Unique peptides that can be used to confirm the presence of the respective IgG's are indicated in bold italics

Table IV. MS/MS-data of CDR3 peptide (H11) of K53, obtained by collision induced dissociation of doubly charged m/z 1059.06.

Ion	m/z	Ion	m/z
Y''_1	147.12	B_1	n.d.
Y''_2	248.18	B_2	157.10
Y''_3	<u>335.21</u> (1)	B_3	304.18
Y''_4	406.25	B_4	419.22
Y''_5	507.30	B_5	<u>582.31</u>
Y''_6	<u>594.33</u>	B_6	768.38
Y''_7	693.40	B_7	825.39
Y''_8	<u>794.46</u>	B_8	953.43
Y''_9	<u>893.54</u>	B_9	n.d.
Y''_{10}	1006.63	B_{10}	n.d.
Y''_{11}	1107.67	B_{11}	1224.65
Y''_{12}	<u>1164.68</u>	B_{12}	1323.68
Y''_{13}	1292.81	B_{13}	1424.79
Y''_{14}	<u>1349.77</u>	B_{14}	1523.86
Y''_{15}	<u>1535.85</u>	B_{15}	n.d.
Y''_{16}	1698.95	B_{16}	n.d.
Y''_{17}	1813.95	B_{17}	1782.96
Y''_{18}	1960.97	B_{18}	n.d.
Y''_{19}	n.d. (2)	B_{19}	n.d.

5 ¹ Underlined m/z -values are main peaks in the MS/MS-spectrum.

² n.d. is not detected.

Table V. MS/MS-data of CDR3 peptide (H11) of 02-237, obtained by collision induced dissociation of doubly charged m/z 1030.02.

5

Ion	m/z	Ion	m/z
Y''_1	147.12	B_1	n.d.
Y''_2	248.18	B_2	189.09
Y''_3	<u>335.20</u>	B_3	n.d.
Y''_4	406.24	B_4	451.22
Y''_5	493.30	B_5	n.d.
Y''_6	<u>580.32</u>	B_6	n.d.
Y''_7	679.40	B_7	n.d.
Y''_8	<u>780.44</u>	B_8	n.d.
Y''_9	<u>879.53</u>	B_9	n.d.
Y''_{10}	992.60	B_{10}	n.d.
Y''_{11}	1093.65	B_{11}	n.d.
Y''_{12}	<u>1150.67</u>	B_{12}	n.d.
Y''_{13}	1278.80	B_{13}	n.d.
Y''_{14}	<u>1335.80</u>	B_{14}	n.d.
Y''_{15}	1521.83	B_{15}	n.d.
Y''_{16}	1608.90	B_{16}	n.d.
Y''_{17}	1724.00	B_{17}	n.d.
Y''_{18}	n.d.	B_{18}	n.d.
Y''_{19}	n.d.	B_{19}	n.d.

¹ Underlined m/z -values are main peaks in the MS/MS-spectrum.

² n.d. is not detected.

Table VI. MS/MS-data of CDR3 peptide (H9) of UBS54, obtained by collision induced dissociation of triply charged m/z 770.09.

Ion	m/z	Ion	m/z
Y''_1	n.d.	B_1	n.d.
Y''_2	248.17	B_2	213.17
Y''_3	<u>335.20</u>	B_3	360.16
Y''_4	406.25	B_4	473.27
Y''_5	<u>507.30</u>	B_5	610.32
Y''_6	<u>594.33</u>	B_6	773.41
Y''_7	<u>693.42</u>	B_7	<u>959.48</u>
Y''_8	<u>794.45</u>	B_8	<u>1016.50</u>
Y''_9	<u>893.53</u>	B_9	<u>1144.57</u>
Y''_{10}	<u>1006.64</u>	B_{10}	<u>1201.59</u>
Y''_{11}	1107.67	B_{11}	<u>1302.68</u>
Y''_{12}	1164.68	B_{12}	<u>1415.72</u>
Y''_{13}	n.d.	B_{13}	1514.78
Y''_{14}	n.d.	B_{14}	n.d.
Y''_{15}	n.d.	B_{15}	n.d.
Y''_{16}	n.d.	B_{16}	n.d.
Y''_{17}	n.d.	B_{17}	n.d.
Y''_{18}	n.d.	B_{18}	n.d.
Y''_{19}	n.d.	B_{19}	n.d.
Y''_{20}	n.d.	B_{20}	n.d.

5 ¹ Underlined m/z -values are main peaks in the MS/MS-spectrum.

² n.d. is not detected.

References

- Appel RD, Bairoch A, Hochstrasser DF. 1994. A new generation of information retrieval tools for biologists: the example of the ExPASy WWW server. *Trends Biochem. Sci.* 19: 258-260.
- 5 Bendig MM. 1988. The production of foreign proteins in mammalian cells. *Genet Eng* 7: 91-127.
- Boel E, Verlaan S, Poppelier MJ, Westerdaal NA, Van Strijp JA, Logtenberg T. 2000. Functional human monoclonal antibodies of all isotypes constructed from phage display
- 10 library-derived single-chain Fv antibody fragments. *J Immunol Methods* 239:153-166.
- Brink MF, Bishop MD, Pieper FR. 2000. Developing efficient strategies for the generation of transgenic cattle which produce biopharmaceuticals in milk. *Theriogenology* 53:
- 15 139-148.
- Campbell KH, McWhir J, Ritchie WA, Wilmot I. 1996. Sheep cloned by nuclear transfer from a cultured cell line. *Nature* 380: 64-66.
- Casellas R, Shih TA, Kleinewietfeld M, Rakoniac J, Nemazee D, Rajewski K, Nussenzweig MC. 2001. Contribution of
- 20 receptor editing to the antibody repertoire. *Science* 291: 1541-1544.
- Cockett MI, Bebbington CR, Yarranton GT. 1990. High level expression of tissue inhibitor of metalloproteinases in
- 25 Chinese hamster ovary cells using glutamate synthetase gene amplification. *Bio/technology* 8: 662-667.
- De Kruif J, Terstappen L, Boel E and Logtenberg T (1995a) Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library.
- 30 *Proc Natl Acad Sci USA* 92:3938
- De Kruif J, Boel E and Logtenberg T (1995b) Selection and application of human single chain Fv antibody fragments from a

semi-synthetic phage antibody display library with designed CDR3 regions. *J Mol Biol* 248:97

Dinnyes A, De Sousa P, King T, Wilmot I. 2002. Somatic cell nuclear transfer: recent progress and challenges. *Cloning Stem Cells* 4: 81-90.

Flavell DJ, Noss A, Pulford KA, Ling N, Flavell SU. 1997. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. *Cancer Res* 57: 4824-4829.

Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, Jones D, Kay RM, Higgins KM, Schramm SR, Lonberg N. 1996. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. *Nat Biotechnol.* 14: 845-51.

Garnick RL. 1992. Peptide mapping for detecting variants in protein products. *Develop. Biol. Standard* 76: 117-130.

Gelpi E. 1995. Biomedical and biochemical applications of liquid chromatography-mass spectrometry. *J. Chromatography A* 703: 59-80.

Ghetie M-A, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta, ES. 1997. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. *Proc. Natl. Acad. Sci. USA* 94: 7509-7514.

Giddings G, Allison G, Brooks D, Carter A. 2000. Transgenic plants as factories for biopharmaceuticals. *Nat. Biotechnol.* 18: 1151-1155.

Gorman C, Bullock C. 2000. Site-specific gene targeting for gene expression in eukaryotes. *Curr Opin Biotechnol* 11: 455-460.

Hiatt A, Cafferkey R, Bowdish K (1989) Production of antibodies in transgenic plants. *Nature*. 342: 76-78.

Huls, G. A., Heijnen, I. A., Cuomo, M. E., Koningsberger, J. C., Wiegman, L., Boel, E., van der Vuurst de Vries, A. R.,
 5 Loyson, S. A., Helfrich, W., van Berge Henegouwen, G. P., van Meijer, M., de Kruif, J. & Logtenberg, T. 1999. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. *Nat Biotechnol* 17: 276-281.

10 Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. 1994. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. *Biotechnology (N Y)* 12: 899-903.

Jones, D., Kroos, N., Anema, R., Van Montfort, B., Vooys, A., Van Der Kraats, S., Van Der Helm, E., Smits, S., Schouten, J., Brouwer, K., Lagerwerf, F., Van Berkel, P., Opstelten, D-J., Logtenberg, T., Bout, A. (2003). High-level expression of recombinant IgG in the human cell line PER.C6TM. *Biotechnol Prog.* 19, 163-168.

20 Kim SJ, Kim Ns, Ryu CJ, Hong HJ, Lee GM. 1998. Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. *Biotechnol Bioeng* 58: 73-84.

25 Kohler G and Millstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 256: 495-497.

Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. 1994. Annexin V for flow cytometric
 30 detection of phosphatidylserine expression on B cells undergoing apoptosis. *Blood* 84: 1415-1420.

Larrick JW, Thomas DW. 2001. Producing proteins in transgenic plants and animals. *Curr. Opin. Biotechnol.* 12: 411-418.

Massengale WT, McBurney E, Gurtler J. 2002. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. *J. Am. Acad. Dermatol.* 46: 441-443.

Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM, Jakobovits A. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. *Nat Genet.* 15: 146-56.

Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. 1998. An efficient route to human bispecific IgG. *Nat. Biotech.* 16: 677-681.

Nemazee D. 2000. Receptor editing in B cells. *Adv. Immunol.* 74: 89-126.

Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, Winter G. 1994. Antibody fragments from a "single pot" phage display library as immunological reagents. *EMBO J.* 13: 692-698.

Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. *Proc. Natl. Acad. Sci. USA* 99: 11346-11350.

Patel AK, Boyd PN. 1995. An improved assay for antibody dependent cellular cytotoxicity based on time resolved fluorometry. *Journal of Immunological Methods* 184: 29-38.

Peeters K, De Wilde C, De Jaeger G, Angenon G, Depicker A. 2001. Production of antibodies and antibody fragments in plants. *Vaccine* 19: 2756-2761.

Pollock DP, Kutzko JP, Birck-Wilson E, Williams JL, Echelard Y, Meade HM. 1999. Transgenic milk as a method for the production of recombinant antibodies. *J Immunol Methods*. 231: 147-157.

Radic MC, Mascelli MA, Shan H, Weigert M. 1991. Ig H and L chain contributions to autoimmune specificities. *J. Immunol.* 146: 176-182.

Schnieke AE, Kind AJ, Ritchie WA, Mycock K, Scott AR, Ritchie M, Wilmut I, Colman A, Campbell KH. 1997. Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. *Science*. 278: 2130-2133.

Segal DM, Weiner GJ, Weiner LM. 2001. Introduction: bispecific antibodies. *J Immunol Methods*. 248:1-6.

Shields, RL, Namenuk AK, Hong K, Gloria Meng Y, Rae J, Biggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA and Presta LG. 2001. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcγR. *J Biol Chem* 276: 6591-6604.

Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES. 2002. Targeting multiple her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. *Clin. Cancer Res.* 8: 1720-1730.

Van der Vuurst de Vries A, Logtenberg T. 1999. Dissecting the human peripheral B-cell compartment with phage display-derived antibodies. *Immunology* 98: 55-62.

Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson

KS. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotech. 14: 309-314.

5 Wilmut I, Clark AJ. 1991. Basic techniques for transgenesis. J Reprod Fertil Suppl 43: 265-275.

Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. 1997. Viable offspring derived from fetal and adult mammalian cells. Nature 385: 810-813.

10 Wilson TJ, Kola I. 2001. The LoxP/CRE system and genome modification. Methods Mol Biol. 158:83-94.

Yelverton E, Norton S, Obijeski JF, Goeddel DV. 1983. Rabies virus glycoprotein analogs: biosynthesis in Escherichia coli. Science 219: 614-620.

15 Yoo EM, Coloma MJ, Trinh KR, Nguyen TQ, Vuong LU, Morrison SL, Chintalacharuvu KR. 1999. Structural requirements for polymeric immunoglobulin assembly and association with J chain. J Biol Chem. 274: 33771-33777.

Claims

1. A method for production of a mixture of antibodies in a recombinant host, the method comprising the step of:
expressing in a recombinant host cell a nucleic acid
sequence or nucleic acid sequences encoding at least one
light chain and at least three different heavy chains
that are capable of pairing with said at least one light
chain.
2. A method according to claim 1, wherein said recombinant host cell comprises a nucleic acid sequence encoding a common light chain that is capable of pairing with said at least three different heavy chains, such that the produced antibodies comprise common light chains.
3. A method according to claim 1 or 2, further comprising the step of:
recovering the antibodies from the host cell or the host cell culture.
4. A method according to any one of claims 1-3, wherein at least two antibodies comprising a heavy-light chain dimer in said mixture of antibodies have different specificities and/or affinities.
5. A method according to any one of claims 1-4, wherein said recombinant host cell is capable of high-level expression of recombinant proteins without the necessity of amplification of the nucleic acid encoding said proteins in said cell.

6. A method according to any one of claims 1-5, wherein said cell is derived from a human embryonic retina cell that has been immortalized or transformed by adenoviral E1 sequences.

5

7. A method according to claim 6, wherein said host cell is derived from a PER.C6 cell.

10

8. A mixture of antibodies that is obtainable by a method according to any one of claims 1-7.

15

9. A mixture according to claim 8, wherein antibodies present in said mixture bind to different epitopes of the same antigen and/or to different antigens present in one antigen comprising mixture.

20

10. A recombinant host cell comprising a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding at least three different heavy chains of an antibody, wherein said light and heavy chains are capable of pairing.

25

11. A composition comprising a mixture of recombinantly produced antibodies, wherein at least three different heavy chain sequences are represented in the mixture of recombinant antibodies.

30

12. A composition according to claim 11, wherein the light chains of said antibodies comprise a common sequence.

13. A composition according to claim 11 or 12, wherein said mixture comprises bispecific antibodies.
- 5 14. A composition according to any one of claims 11-13, wherein said mixture of antibodies has been produced by recombinant host cells according to claim 10.
- 10 15. A composition according to any one of claims 11-14, wherein at least two of said antibodies have different specificities.
- 15 16. A composition according to claim 15, wherein said different specificities are directed to different epitopes on the same antigen.
17. A composition according to claim 15, wherein said different specificities are directed to different antigens present in one antigen comprising mixture.
- 20 18. A composition according to any one of claims 11-14, wherein at least two of said antibodies have different affinities for the same epitope.
- 25 19. A composition according to any one of claims 11-18, wherein said composition has an effect that is greater than the effect of each individual antibody present in said composition, wherein said effect is measured in a functional assay.
- 30 20. A method for identifying at least one host cell clone that produces a mixture of antibodies, wherein said mixture of antibodies has a desired effect according to a

functional assay, the method comprising the steps of:

(i) providing a host cell with nucleic acid sequence encoding at least one light chain and nucleic acid sequences encoding at least two different heavy chains, wherein said heavy and light chains are capable of pairing with each other;

(ii) culturing at least one clone of said host cell under conditions conducive to expression of said nucleic acid sequences;

(iii) screening said at least one clone of the host cell for production of a mixture of antibodies having the desired effect by a functional assay; and

(iv) identifying at least one clone that produces a mixture of antibodies having the desired effect.

21. A method according to claim 20, wherein said host cell comprises a nucleic acid sequence encoding a common light chain that is capable of pairing with said at least two different heavy chains, such that the produced antibodies comprise common light chains.

22. A method according to claim 20 or 21, wherein said culturing in step ii) and said screening in step iii) is performed with at least two clones.

23. A method according to any one of claims 20-22, wherein said culturing of step ii) and/or said screening of step iii) is performed using high-throughput procedures.

24. A method according to any one of claims 20-23, wherein said host cell is capable of high-level expression of proteins without the necessity of amplification of the

nucleic acid encoding said proteins in said cell.

5 25. A method according to any one of claims 20-24, wherein said cell is derived from a human embryonic retinoblast that has been immortalized or transformed by adenoviral E1 sequences.

10 26. A method according to claim 25, wherein said host cell is derived from PER.C6.

15 27. A method according to any one of claims 20-26, wherein said mixture of antibodies comprises at least two antibodies having different specificities and/or affinities.

20 28. A method of producing a mixture of antibodies, comprising the step of:
(i) culturing a host cell clone identified by a method according to any one of claims 20-27 under conditions conducive to expression of the nucleic acids encoding the at least one light chain and the at least two different heavy chains.

25 29. A method according to claim 28, further comprising the step of:
(ii) recovering the antibodies from the host cell or the host cell culture.

30 30. A mixture of antibodies that is obtainable by a method according to claim 28 or 29.

31. A method for making a recombinant host cell for production of a mixture of antibodies, the method comprising the steps of:

introducing into said host cell a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding at least three different heavy chains that are capable of pairing with said light chain, wherein said nucleic acid sequences are introduced consecutively or concomitantly.

32. A method for making a recombinant host cell for production of a mixture of antibodies, the method comprising the step of:

introducing nucleic acid sequences encoding at least two different heavy chains into a recombinant host cell comprising a nucleic acid sequence encoding a light chain capable of pairing with at least two of said heavy chains.

33. A transgenic non-human animal or a transgenic plant comprising a nucleic acid sequence encoding a light chain and a nucleic acid sequence or sequences encoding at least two different heavy chains that are capable of pairing with said light chain, wherein said nucleic acid sequences encoding said light and heavy chains are under the control of a tissue-specific promoter.

34. A mixture of antibodies obtainable from a transgenic animal or transgenic plant according to claim 33.

35. A pharmaceutical composition comprising a mixture of recombinantly produced antibodies and a suitable carrier,

wherein at least two different heavy chains are represented in said mixture of recombinantly produced antibodies.

5 36. A pharmaceutical composition according to claim 35,
wherein said mixture comprises bispecific antibodies.

37. A mixture of antibodies wherein at least two different
heavy chains are represented, for use in the treatment or
10 diagnosis of a human or animal subject.

38. Use of a mixture of antibodies wherein at least two
different heavy chains are represented, for the
preparation of a medicament for use in the treatment or
15 diagnosis of a disease or disorder in a human or animal
subject.

39. A method for producing a mixture of antibodies
comprising different isotypes from a host cell, the
20 method comprising the step of:
expressing in a recombinant host cell a nucleic acid
sequence encoding a light chain and nucleic acid
sequences encoding at least two heavy chains of different
isotype that are capable of pairing with said light
25 chain.

40. A method according to claim 39, wherein said isotypes
comprise at least an IgG and an IgA.

30 41. A method for indentifying a mixture of antibodies having
a desired effect in a functional assay, comprising the
steps of

i) adding a mixture of antibodies in a functional assay,
and
ii) determining the effect of said mixture in said assay,
wherein the antibodies in said mixture comprise a common
light chain.

5

42. A method according to claim 41, wherein said mixture is
comprised in a composition according to any one of claims
11-19.

10

43. A method according to any one of claims 1-7, 20-29, 39
or 40, or a recombinant host cell according to claim 10,
or a method of making a recombinant host cell according
to claim 31 or 32, or a transgenic non-human animal or
transgenic plant according to claim 33, wherein the
nucleic acid sequence or sequences encoding at least one
of said light and/or heavy chains have been obtained by a
method comprising at least one antibody display selection
step.

15

20

44. A method for producing a mixture of antibodies that are
capable of binding to a target, the method comprising the
steps of: i) bringing an antibody display library
comprising antibodies into contact with material
comprising a target, ii) at least one step of selecting
antibodies binding to said target, iii) identifying at
least two antibodies binding to said target, wherein said
at least two antibodies comprise a common light chain,
iv) introducing a nucleic acid sequence encoding the
light chain and a nucleic acid sequence or nucleic acid
sequences encoding the heavy chains of said at least two
antibodies into a host cell, v) culturing a clone of said

25

30

host cell under conditions conducive to expression of said nucleic acid sequences.

- 5 45. A method for producing a mixture of antibodies in a recombinant host, the method including the step of: expressing in a recombinant host cell a nucleic acid sequence encoding a common light chain and nucleic acid sequences encoding at least two different heavy chains that differ in the variable region and that are capable of pairing with said common light chain, and wherein said heavy chains further differ in their constant regions sufficiently to reduce or prevent pairing between the different heavy chains.
- 10
- 15 46. A method according to claim 45, wherein said heavy chains are of different isotype.
47. A method according to claim 46, wherein said different isotypes include at least IgG1 and IgG3.
- 20
48. A method according to claim 46, wherein said different isotypes include at least an IgG and an IgA isotype.
- 25 49. A mixture of antibodies obtainable by a method according to any one of claims 45-48.
- 30 50. A method for producing a mixture of antibodies comprising dimeric IgA isotype $\{(IgA)_2\}$ antibodies in a recombinant host, wherein at least part of said dimeric IgA antibodies have different binding regions in each of the two IgA subunits, the method comprising the step of: expressing in a recombinant host cell a nucleic acid

sequence encoding a common light chain and nucleic acid sequences encoding at least two different heavy chains of IgA isotype capable of pairing to said common light chain.

5

51. A method for producing a mixture of antibodies comprising an IgM antibody having at least two different specificities, the method comprising the step of expressing in a recombinant host cell a nucleic acid sequence encoding a common light chain and nucleic acid sequences encoding at least two different heavy chains of IgM isotype, wherein said heavy chains are capable of pairing to said common light chain.

10

52. An IgA dimer, an IgM pentamer or an IgM hexamer having at least two different specificities.

15

53. A culture of cells producing a mixture of immunoglobulins from a single cell, said mixture comprising at least three different heavy chains.

20

54. A culture according to claim 53, further characterized in that said culture produces said mixture of immunoglobulins from a single cell for more than 20 population doublings.

25

30

Title: Recombinant production of mixtures of antibodies

Abstract

The invention provides methods for producing mixtures of
5 antibodies from a single host cell clone. Thereto a nucleic
acid sequence encoding a light chain, and nucleic acid
sequences encoding different heavy chains are expressed in a
recombinant host cell. The antibodies in the mixtures
according to the invention suitably comprise identical light
10 chains paired to different heavy chains capable of pairing to
the light chain, thereby forming functional antigen binding
domains. Mixtures of antibodies are also provided by the
invention. Such mixtures can be used in a variety of fields.

15

20

25

Fig. 1




Fig. 2




Fig. 3

UBS54-VL
K53-VL
02-237-VL

GAAATTGAGCTCACTCAGTCTCCTCCTGCCCCGTCACTCCCTGAGAGCCGGCC
GAAATTGAGCTCACTCAGTCTCCTCCTGCCCCGTCACTCCCTGAGAGCCGGCC
GAAATTGAGCTCACTCAGTCTCCTCCTGCCCCGTCACTCCCTGAGAGCCGGCC

UBS54-VL
K53-VL
02-237-VL

TCCATCTCCTGCAGGCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACATATTGGAT
TCCATCTCCTGCAGGCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACATATTGGAT
TCCATCTCCTGCAGGCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACATATTGGAT

UBS54-VL
K53-VL
02-237-VL

TGGTACCTGCAGAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTGGGTCTAATCGG
TGGTACCTGCAGAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTGGGTCTAATCGG
TGGTACCTGCAGAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTGGGTCTAATCGG

UBS54-VL
K53-VL
02-237-VL

GCCTCCGGGGTCCCTGACAGGTTTCAGTGGCAGTGGATCAGGCACAGATTTACACTGAAA
GCCTCCGGGGTCCCTGACAGGTTTCAGTGGCAGTGGATCAGGCACAGATTTACACTGAAA
GCCTCCGGGGTCCCTGACAGGTTTCAGTGGCAGTGGATCAGGCACAGATTTACACTGAAA

UBS54-VL
K53-VL
02-237-VL

ATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAACT
ATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAACT
ATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAACT

UBS54-VL
K53-VL
02-237-VL

TTCACTTTCGGCCCTGGGACCAAGGTGGAGATCAAA
TTCACTTTCGGCCCTGGGACCAAGGTGGAGATCAAA
TTCACTTTCGGCCCTGGGACCAAGGTGGAGATCAAA

Fig. 3, cont'd

K53-VH
02-237-VH
UBS54-VH
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTC
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTC
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCCTCGGTGAGGGTC

K53-VH
02-237-VH
UBS54-VH
TCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGCC
TCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGCC
TCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC

K53-VH
02-237-VH
UBS54-VH
CCTGGACAAGGCTTGAGTGGATGGGATGAGTCAGCGCTTACAATGGTAACACAACTAT
CCTGGACAAGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAACTAT
CCTGGACAAGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTAC


K53-VH
02-237-VH
UBS54-VH
GCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTAC
GCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTAC
GCACAGAAGTCCAGGGCAGAGTCACGATTACCGGGGACGAATCCACGAGCACAGCCTAC

K53-VH
02-237-VH
UBS54-VH
ATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCAAGGGGCATG
ATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCAAGGGGCTTT
ATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCTGTGTATTACTGTGCAAGAGACC--

K53-VH
02-237-VH
UBS54-VH
ATGAGGGGTGTGTTTACTACTGGGGCCCAAGGTACCCCTGGTCACCGTCTCGACA
CCGGCTACGTGCTGTTTACTCTCTGGGGCCAGGGCACCCCTGGTGACCGTCTCCTCA
-----CGTTTCTTCACTATTGGGGCCCAAGGTACCCCTGGTCACCGTCTCGACA
* * * * *
* * * * *

Fig. 4

pCD46_3000 (Neo)



pUBS3000Neo





Fig. 5

A.



—	K53	homodimer
—	UBS54/K53	heterodimer
—	UBS54	homodimer

B.




Fig. 6




Fig. 7

Anti-CD22 V_H fragment (Phage B28)

```

      M A E V Q L V E S G G G V V R P G G S L R L S C .
1  ATGCGCAGGTGCAGCTGGTGGAGTCTGGGGAGGTGTGTAACGGCTGGAGGTCCTGAGACTCTCCTG
    . A A S G F T F D D Y G M S W V R Q A P G K G L E .
72 TGCAGCCTCTGGATTACACCTTTGATGATTATGGCATGAGCTGGGTCCGCCAAGCTCCAGGGAAGGGCTGG
    . W V S G I N W N G G S T G Y A D S V K G R F T
143 AGTGGGTCTCTGGTATTAAATTGGAATGGTGTAGCACAGGTTATGCAGACTCTGTGAAGGCCGATTACAC
    I S R D N A K N S L Y L Q M N S L R A E D T A V .
214 ATCTCCAGAGACAACGCCAAGAACTCCCTGTATCTGCAATGAACAGTCTGAGAGCCGAGGACACGGCCGT
    . Y Y C A R G F L R F A S S W F D Y W G Q G T L V .
285 GTATTACTGTGCAAGAGGCTTTCTTCGTTTTGCTTCCTCCTGTTGACTATTGGGGCCAAGGTACCCCTGG
    . T V S R
356 TCACCGTCTCGAGA

```

Anti-CD72 V_H fragment (Phage II-2)

```

      M A Q V Q L V Q S G A E V K K P G A S V K V S C .
1  ATGCCCCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGTTTCCTG
    . K A S G Y T F T S Y Y M H W V R Q A P G Q G L E .
72 CAAGGCATCTGGATACACCTTCACCAGCTACTATATGCAGTGGGTGCGACAGGCCCTGGACAAGGGCTTG
    . W M G I I N P S G G G T S Y A Q K F Q G R V T
143 AGTGGATGGGAATAATCAACCCCTAGTGGTGGCACAAGCTACGCACAGAAGTTCAGGGGCAGAGTCACC
    M T R D T S T S T V Y M E L S S L R S E D T A V .
214 ATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGT
    . Y Y C A R D Y Y V T Y D S W F D S W G Q G T L V .
285 GTATTACTGTGCAAGAGACTACTATGTTACGTATGATTCTCCTGTTGACTCCTGGGGCCAAGGTACCCCTGG
    . T V S R
356 TCACCGTCTCGAGA

```

Fig. 7, cont'd

Anti-Class II V_H fragment (Phase I-2)

```

      M A E V Q L V E S G G L V Q P G R S L R L S C .
1  ATGGCCGAGGTGCAGCTGGTGGAGTCTGGGGAGGCTTGGTACAGCCTGGCAGGTCCTGAGACTCTCCTG
   . A A S G F T F D D Y A M H W V R Q A P G K G L E .
72 TGCAGCCTCTGGATTACCTTTGATGATTATGCCATGCACCTGGTCCGGCAAGCTCCAGGGAAGGCGCTGG
   . W V S G I S W N S G S I G Y A D S V K G R F T
143 AGTGGGTCTCAGGTATTAGTTGGAATAGTGGTAGCATAGGCTATGCGGACTCTGTGAAGGCCGATTACACC
   I S R D N A K N S L Y L Q M N S L R A E D T A V .
214 ATCTCCAGAGACAAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGCGCGT
   . Y Y C A R D L Y L A H F D Y W G Q G T L V T V S .
285 GTATTACTGTGCAAGGACCTTTATCTTGCGCATTTGACTACTGGGGCCAAGGTACCCCTGGTCACCGTCT
   . R
356 CGAGA

```

Shared V_L sequence of Phages I-2, II-2 and B28

```

      S S E L T Q D P A V S V A L G Q T V R I T C Q G .
1  TCGTCTGAGCTGACTCAGGACCCCTGCTGTGTCTGTGGCCTTGGGACAGACAGTCAGGATCACATGCCAAGG
   . D S L R S Y Y A S W Y Q Q K P G Q A P V L V I Y .
72 AGACAGCCTCAGAAGCTATTATGCAAGCTGGTACCAGCAGAAGCCAGGACAGGCCCTGTACTTGTCTATCT
   . G K N N R P S G I P D R F S G S S S G N T A S
143 ATGGTAAAACAACCGGCCCTCAGGGATCCCAGACCGATTCTCTGGCTCCAGCTCAGGAAACACAGCTTCC
   L T I T G A Q A E D E A D Y Y C N S R D S S G N .
214 TTGACCATCACTGGGGCTCAGGCGGAAGATGAGGCTGACTATTACTGTAACTCCCGGGACAGCAGTGGTAA
   . H V V F G G G T K L T V L G A A A
285 CCATGTGGTATTTCGGCGGAGGGACCAAGCTGACCGTCTCTAGGTGCGGGCGGCA

```

Fig. 8

pUBS54-IgA




Fig. 9




Fig. 10




Fig. 11




Fig. 12

V_H sequence of K53 IgG

1 Q V Q L V Q S G A E V K K P G A S V K V
 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTC

61 S C K A S G Y T F T S Y G I S W V R Q A
 TCCTGCAAGGCTTCTGGTTACACCTTTACCAAGCTATGGTATCAGCTGGGTGCGACAGGCC

121 P G Q G L E W M G W I S A Y N G N T N Y
 CCTGGACAAGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAACTAT

181 A Q K L Q G R V T M T T D T S T S T A Y
 GCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTAC

241 M E L R S L R S D D T A V Y Y C A R G M
 ATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGAAGGGGCATG

301 M R G V F D Y W G Q G T L V T V S
 ATGAGGGGTGTGTTTGACTACTGGGGCCAAAGGTACCCCTGGTCACCGTCTCG

Fig. 12, cont'd

V_H sequence of 02-237 IgG

```
1      Q V Q L V Q S G A E V K K P G A S V K V  
      CAGGTGCAGCTGGTGCAGTCTGGGGTGAGTGAAGAAGCCTGGGGCCTCAGTGAAGGTC  
61     S C K A S G Y T F T S Y G I S W V R Q A  
      TCCTGCAAGGCTTCTGGTTACACCTTACCAGCTATGGTATCAGCTGGGTGCGACAGGCC  
121    P G Q G L E W M G W I S A Y N G N T N Y  
      CCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAAACTAT  
181    A Q K L Q G R V T M T T D T S T S T A Y  
      GCACAGAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGCCTAC  
241    M E L R S L R S D D T A V Y Y C A R G F  
      ATGGAGCTGAGGAGCCTGAGATCTGACACACGGCCGTGTATTACTGTGCAAGGGGCTTT  
301    P R T S F D S W G Q G T L V T V S S  
      CCGGTACGTCGTTTGA CTCTCTGGGGCCAGGGCACCCCTGGTGACCGTCTCCTCA
```

Fig. 12, cont'd

V_H sequence of UBS54 IgG

```
1      Q V Q L V Q S G A E V K K P G S S V R V  
      CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCTCGGTGAGGGTC  
61     S C K A S G G T F S S Y A I S W V R Q A  
      TCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCC  
121    P G Q G L E W M G G I I P I F G T A N Y  
      CCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAACTAC  
181    A Q K F Q G R V T I T A D E S T S T A Y  
      GCACAGAAGTTCCAGGGCAGAGTCACGATTACCGGGACGAATCCACGAGCACAGCCTAC  
241    M E L S S L R S E D T A V Y Y C A R D P  
      ATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCTGTATTACTGTGCAAGAGACCCG  
301    F L H Y W G Q G T L V T V S T  
      TTTCTTCACTATTGGGGCCAAAGGTACCCTGGTACCGTCTCGACA
```

Fig. 12, cont'd

V_L sequence of K53 and UBS54 IgG

```
1      E I E L T Q S P L S L P V T P G E P A  
      GAAATTGAGCTCACTCAGTCTCCACTCTCCCTGCCGTCACCCCTGGAGAGCCGGCC  
58     S I S C R S S Q S L L H S N G Y N Y L D  
      TCCATCTCCTGCAGGCTAGTCAGAGCCTCCCTGCATAGTAATGGATACAACTATTGGAT  
118    W Y L Q K P G Q S P Q L L I Y L G S N R  
      TGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTGGGTTCTAATCGG  
178    A S G V P D R F S G S G S G T D F T L K  
      GCCTCCGGGGTCCCTGACAGGTTCAAGTGGCAGTGGATCAGGCACAGATTTACACTGAAA  
238    I S R V E A E D V G V Y Y C M Q A L Q T  
      ATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTATTACTGCATGCAAGCTCTACAAACT  
298    F T F G P G T K V E I K  
      TTCACITTCGGGCCCTGGGACCAAGGTGGAGATCAAA
```

Fig. 12, cont'd

V_L sequence of 02-237 IgG

1 D I V M T Q S P L S L P V T P G E P A
 GACATCGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCGGGCC

58 S I S C R S S Q S L L H S N G Y N Y L D
 TCCATCTCCTGCAGGTCTAGTCAGAGGCTCCTGCATAGTAATGGATACAACTATTGGAT

118 W Y L Q K P G Q S P Q L L I Y L G S N R
 TGGTACCTGCAGAGCCAGGCGAGTCTCCACAGCTCCTGATCTATTGGGTTCTAATCGG

178 A S G V P D R F S G S G S G T D F T L K
 GCCTCCGGGGTCCCTGACAGGTTCA GTGGCAGTGGATCAGGCACAGATTTACACTGAAA

238 I S R V E A E D V G V Y Y C M Q A L Q T
 ATCAGCAGAGTGGAGGCTGAGGATGTTGGGTTTATTACTGCATGCAAGCTCTACAACT

298 F T F G P G T K V E I K
 TTCACCTTTCGGCCCTGGGACCAAGGTGGAGATCAAA

FIG. 13

K53 VH
UBS54 VH
02-237

1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMG
1 QVQLVQSGAEVKKPGSSVRVSCKASGGTFSSYAISWVRQAPGQGLEWMG
1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMG

*****-**-*****-**-*****-*****

K53 VH
UBS54
02-237

50 WISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR
50 GIIPIFGNANYAQKFQGRVTITADESTSTAYMELSSLRSEDVAVYYCAR
50 WISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELSLRSDDTAVYYCAR

-*-***-**-*****-**-*****-*****-*****-*****

K53 VH
UBS54 VH
02-237

99 CDR3
99 GMMRGVFDYWGQGLVTVST
99 DPFLLH---YWGQGLVTVST
99 GFPRTSFDSWGQGLVTVSS

-----*****-

Fig. 14





Fig. 15




Fig. 16A





Fig. 16A, cont'd




Fig. 16B





Fig. 16B, cont'd




Fig. 17





Fig. 17, cont'd





Fig. 18




Fig. 19 Peptide mapping of Polyclonal Poly1-280




Fig. 20





Fig. 21

A.



B.

